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ABSTRACT 
Bacteria are a fruitful source of metabolites, many of which have been the scaffolds for 
the majority of approved antibiotic compounds. In this dissertation, I present the discovery and 
characterization of a bacterial natural product from Bacillus methylotrophicus FZB42, a Gram-
positive, rod-shaped bacterium that stimulates plant growth. A prolific producer of secondary 
metabolites, FZB42 excretes a compound bearing the molecular mass of 1335 Daltons called 
plantazolicin (PZN). I describe the genetic locus responsible for the biosynthesis of PZN, which 
is ribosomally synthesized via an amino acid precursor peptide and post-translationally modified 
to contain thiazoles and (methyl)oxazoles. This group of compounds, known as thiazole/oxazole-
modified microcins (TOMMs), exhibit disparate biological activities and complex chemical 
structures. Using high-resolution mass spectrometry, chemoselective modification, genetic 
interruptions, and various spectroscopic tools, I report the molecular structure of PZN. PZN 
contains two conjugated polyazole moieties and an N
α
,N
α
-dimethylarginine on the amino 
terminus. By altering oxygenation levels during fermentation, PZN analogs were produced that 
bear variability in their heterocycle content, which yielded insight into the order of biosynthetic 
events. Extensive tailoring of PZN endows it with not only a rigid, polyheterocyclic structure, but 
also antibacterial activity. After screening numerous microorganisms, PZN exhibited highly 
selective antibiotic activity against Bacillus anthracis. This remarkably discriminatory activity 
rivals a previously-described B. anthracis-specific gamma (γ) phage lysis assay in distinguishing 
B. anthracis from other members of the Bacillus cereus group. I evaluate this unusually selective 
activity by measuring the RNA expression profile of PZN-treated B. anthracis, which revealed 
significant upregulation of genes within the cell envelope stress response. Using fluorescence 
microscopy, PZN localizes to distinct ~200 nm wide foci within the envelope; furthermore, like 
other cell envelope-acting compounds, PZN depolarizes the B. anthracis membrane. Upon 
selection and whole-genome sequencing of PZN-resistant mutants of B. anthracis, I implicate a 
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relationship between the action of PZN and the phospholipid cardiolipin within the membrane. 
Exogenous cardiolipin increases the potency of PZN in wild type B. anthracis and promotes the 
incorporation of fluorescently tagged PZN in the cell envelope. I propose that PZN localizes to 
and exacerbates structurally compromised regions of the bacterial membrane, which ultimately 
results in cell lysis. 
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CHAPTER I: INTRODUCTION 
1.1 Bacteria as Abundance Sources of Natural Products 
Bacteria harbor extensive capabilities to synthesize structurally complex and useful 
natural products. Roughly two thirds of approved antibiotics are natural products or natural 
product derivatives/mimics (Newman and Cragg, 2012), with such notable examples as 
chloramphenicol (protein synthesis inhibitor) (Gottlieb et al., 1954) and rifampicin (RNA 
polymerase inhibitor) (Sensi et al., 1959). Past success with natural products as antimicrobial 
compounds warrants the exploration into uncharted biosynthetic territory to discover new natural 
products.  
Antibiotics have traditionally been discovered by large screening endeavors, examining 
the bioactivity of bacterial crude extracts for compounds harboring antibiotic activity (Figure 
1.1A). While this method has produced a number of useful compounds, the methodologies are 
tedious and limited.  Frequent compound rediscovery, the lack of laboratory culturable 
organisms, and extensive screening time limit the usefulness of the forward discovery approach 
(Baltz, 2006).  
 Low-cost next-generation DNA sequencing technology is responsible for the surge in 
genomic data mining. The availability of nearly 2,000 new microbial genomes has rekindled 
interest in the biosynthetic capabilities of bacteria (Bachmann et al., 2014; Challis, 2008; Gross, 
2009; Melby et al., 2011; Peric-Concha and Long, 2003; Van Lanen and Shen, 2006), reducing 
the need for timely screening procedures. Recent studies, making use of newly sequenced 
bacterial genomes, have demonstrated the enormous, largely untapped potential of microbes as a 
source of natural products (Bachmann et al., 2014; Bentley et al., 2002; Challis, 2008; Deane and 
Mitchell, 2014; Doroghazi et al., 2014; Doroghazi and Metcalf, 2013; Velasquez and van der 
Donk, 2011).  
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Reverse genetics approaches have demonstrated that Streptomyces coelicolor, one of the 
most studied organisms for natural product/antibiotic research, harbors the genetic capacity to 
produce many additional secondary metabolites of potential importance (Deane and Mitchell, 
2014). This phenomenon extends to the microbial population as a whole (Baltz, 2008; Bentley et 
al., 2002; Deane and Mitchell, 2014; Fischbach and Walsh, 2009; Jensen et al., 2014). 
Bioinformatic tools and databases help to organize the abundance of data that has emerged on 
these previously undescribed biosynthetic pathways (Blin et al., 2013; de Jong et al., 2006; Li et 
al., 2012; Mohimani et al., 2014). Reverse genetics reconciles some of the unfortunate downfalls 
of the forward genetic approach, e.g. a lack of culturable organisms, biosynthetic pathways that 
are silent under laboratory conditions, and compound rediscovery. By making use of the vast 
genomic sequence data available, researchers can enrich for a specific compound class, predict 
chemical structures, biological activities, and manipulate growth conditions to maximize natural 
product potential (Figure 1.1B).  
1.2 Ribosomally Synthesized and Post-Translationally Modified Peptide Natural Products 
 Natural product research and antibiotic discovery encompass numerous classes of 
bacterial compounds (of nonribosomal and ribosomal origin); of primary interest to this research 
is a relatively newly defined class of natural products referred to as the ribosomally synthesized 
and post-translationally modified natural products (RiPPs) (Arnison et al., 2013; Haft et al., 2010; 
Lee et al., 2008; Letzel et al., 2014; Maksimov and Link, 2014; Velasquez and van der Donk, 
2011). RiPPs comprise a diverse natural product landscape, encompassing lanthipeptides, linear 
azol(in)e-containing peptides, lasso peptides, and linaridins, among others. In all cases, a 
ribosomally produced precursor peptide undergoes modification including, but not limited to, 
cyclizations, dehydrations, methylations, and disulfide bond formations (Arnison et al., 2013; 
Dunbar and Mitchell, 2013b). The diverse modifications give rise to an expanse of chemical 
structures and numerous biological activities. The genomic sequence of the precursor peptide and 
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homology of the tailoring enzymes bring forth predictions of the chemical structure of the post-
translationally modified natural product. Furthermore, the microbial and scientific communities 
can “evolve” RiPPs by manipulating either the peptide precursor destined for tailoring or the 
tailoring enzymes themselves.  
1.3 Thiazole/Oxazole-Modified Microcins (TOMMs) 
 One region of largely uncharted biosynthetic RiPP natural product space is the 
thiazole/oxazole-modified microcin (TOMM) family, which is classified by conserved chemical 
modifications and genetic layout (Figure 1.2A) (Haft et al., 2010; Lee et al., 2008; Scholz et al., 
2011). Each TOMM precursor peptide harbors an N-terminal leader region that serves as the 
binding site for enzymes that post-translationally modify a C-terminal core region (Madison et 
al., 1997; Mitchell et al., 2009). The distinguishing chemical feature of a TOMM is the 
installation of heterocycles that are derived from Cys, Ser, and Thr residues, which are abundant 
in the core region of the precursor peptides. During processing by a genetically conserved 
cyclodehydratase, select Cys and Ser/Thr amino acids undergo peptide backbone cyclization to 
become thiazoline and (methyl)oxazoline heterocycles (Figure 1.2B) (Dunbar et al., 2014; 
Dunbar et al., 2012; Dunbar and Mitchell, 2013a). A subset of these are further subjected to a 
flavin mononucleotide (FMN)-dependent dehydrogenation, which yields the fully oxidized 
thiazole and (methyl)oxazole heterocycles (Melby et al., 2014). Together, the TOMM 
cyclodehydratase and dehydrogenase comprise a functional thiazole/oxazole synthetase. The 
genes encoding the synthetase are typically located as adjacent open reading frames in bacterial 
genomes, making such biosynthetic clusters relatively easy to identify using routine bioinformatic 
methods (Donia et al., 2008; Lee et al., 2008; Velasquez and van der Donk, 2011; Wieland 
Brown et al., 2009). TOMM biosynthetic clusters often contain ancillary tailoring enzymes that 
increase the chemical complexity of this natural product family, in addition to leader peptide 
proteolysis (Figure 1.2C) (Datta et al., 2005; Kelly et al., 2009; Liao et al., 2009; Morris et al., 
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2009; Wieland Brown et al., 2009). In many cases, the fully mature TOMM natural product is 
then actively exported from the cell through an ABC transport system.  
Although the unification of the TOMM family of natural products has only recently 
emerged, the molecular structure and biological function of some TOMMs have long been 
established. Examples include microcin B17 (DNA gyrase inhibitor) (Belshaw et al., 1998), the 
cyanobactins (eukaryotic cytotoxins) (Schmidt and Donia, 2009), streptolysin S (virulence-
promoting cytolysin) (Mitchell et al., 2009; Molloy et al., 2011), and the thiopeptides (ribosome 
inhibitors) (Just-Baringo et al., 2014; Melby et al., 2011).  
1.4 Natural Product Isolation and Structure Elucidation 
Genetic deletions and chemical investigation often prime natural product discovery. 
Armed with the genetic context of a natural product, the compound is subjected to isolation and 
purification from the crude bacterial cellular extract, which contains multiple metabolic 
compounds. Structure elucidation typically occurs on the purified compound, but can begin in 
crude form if the compound can be properly separated from the remaining bacterial metabolites.  
1.4.1 Natural product identification via genetic deletions and heterologous production 
 The reverse genetic approach to natural product discovery seeks to identify a connection 
between genes and metabolites. The most definitive method to link genes to molecules is through 
genetic deletion of the implicated genes. Then, by comparing the mutant to the parent strain, 
whether by mass spectrometry or activity screening, natural products can be identified and 
characterized. Heterologous expression of the target gene clusters can enhance this methodology, 
given the natural product remains expressed in the new, genetically amenable host (Ongley et al., 
2013). There are numerous examples of successful natural product identification that rely on both 
native producer and heterologous host expression. Native producer approaches typically involve 
improvement of the host strain to achieve greater natural product yields, including manipulation 
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of drug efflux pumps or deletion of undesired natural products that convolute compound 
identification (Ongley et al., 2013).  
1.4.2 Mass spectrometry-guided structure elucidation 
 Mass spectrometry (MS), alone or in conjunction with nuclear magnetic resonance 
(NMR), provides structural information and characterization of peptidic natural products. High 
resolution MS provides an accurate compound mass, which is then used to determine a chemical 
formula within the error of the MS instrument. Tandem MS results in fragmentation of the 
molecule of interest, breaking the compound into segments from which the structure of the full 
peptide can be deduced (Kind and Fiehn, 2010). Competing chemical formulas can often be 
eliminated by integrating knowledge of the chemical modification potentially encoded within the 
gene cluster. In 2011, a MS method was created specifically for linking biosynthetic genes to 
molecules (Kersten et al., 2011). MS data from an organism of interest is subjected to tandem 
MS, and the fragmentation pattern of peptidic compounds is assembled into a sequence tag, 
providing information on the amino acid sequence of the compound. The genome of the 
producing organism can then be searched for loci corresponding to that particular amino acid 
sequence. The assembled fragmentation database includes common post-translational 
modifications, expanding the method’s utility for natural product discovery. In 2013, this method 
was extended to tandem MS networks, relating all metabolites of an organism to their 
fragmentation spectra (Nguyen et al., 2013). This method can even be extrapolated to include 
unsequenced organisms by comparing fragmentation of chemical standards or sequenced 
organisms.  
1.5 Determining the Mode of Action of Antibiotics 
Determining the mode of action (MOA) (or molecular target) of bioactive compounds 
can be challenging, especially if the compound does not have activity similar to other known 
compounds. There exist some typical methodologies for the mechanistic evaluation of antibiotics.  
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1.5.1 MOA determination bolstered by genomic sequencing 
After establishing a compound as an antibiotic, MOA research is typically initiated by 
treating a susceptible strain with the compound of interest and isolating resistant mutants (Arias et 
al., 2011; Friedman et al., 2006; Hachmann et al., 2009; Palmer et al., 2011). Resistant mutants 
can be generated in a variety of ways, whether it be spontaneous adaptation or via mutagenesis 
(Price et al., 2003; Vogler et al., 2002). The resistant strains are then bioinformatically mined for 
the genomic polymorphisms endowing them with resistance; oftentimes, the genetic mutations 
provide evidence suggestive of a certain MOA. Validation via engineering genetic deletions or 
overexpression of the suspected target supports the involvement of the genes of interest. 
An orthogonal approach to MOA determination is analyzing the changes in gene 
expression upon exposure to the antibiotic of interest. Transcriptional profiling via RNA-Seq or 
microarray can reveal the metabolic adjustments an affected organism must make in order to 
tolerate the harmful compound (Dengler et al., 2011; Muthaiyan et al., 2008; Shaw and Morrow, 
2003; Wecke et al., 2009). Transcriptome studies provide essential information on how the entire 
bacterium responds to the compound of interest. Sub-inhibitory antibiotic treatment stimulates 
rapid transcriptional responses in bacteria (Goh et al., 2002) and the induced/repressed genes are 
oftentimes indicative of MOA (Brazas and Hancock, 2005; Freiberg et al., 2005; Hutter et al., 
2004).  
1.5.2 Macromolecular synthesis 
Often, antibiotic classes are known to target major pathways within primary metabolism. 
Utilizing radioactive precursors to RNA, DNA, protein, peptidoglycan, and fatty acids, 
researchers can assess the biosynthesis of cellular macromolecules in the presence of the 
compound of interest (Cotsonas King and Wu, 2009; Silver, 2011). Bacteria are grown in the 
presence of the radioactive macromolecular precursors (e.g. nucleotides or amino acids), and 
treated with the tested antibiotic. As the cells grow, radiolabelled precursors are incorporated into 
7 
their respective macromolecules. Inhibition of radioactive incorporation in cells treated with the 
compound of interest, relative to untreated cells, can thereby inform about the MOA of the 
antibiotic. This protocol can be adapted for high throughput use, providing a way to measure the 
effect of a compound over time and in different concentrations. 
1.5.3 Cytological profiling 
A more recently-described method of analyzing MOA is cytological profiling. 
Cytological profiling uses fluorescence microscopy to reveal how fluorescently tagged 
compounds influence cellular morphology (Nonejuie et al., 2013). The authors use bioinformatics 
to compare numerous morphological characteristics. This method not only distinguishes between 
compounds acting on different cellular pathways, but it can even separate inhibitors that target 
different points along the same pathway. Compounds can be classified by their molecular target 
or provide evidence for a new MOA, based on their fluorescence patterns. 
1.5.4 Difficulties of mode of action determination 
The methodologies described above are not always fruitful, especially for compounds 
with unique MOAs, like daptomycin and nisin. Based on current research, in a calcium-dependent 
manner, daptomycin oligomerizes and displaces phospholipids in the bacterial membrane. 
Daptomycin oligomers assemble into a pore structure that depolarizes the membrane, disrupting 
cell integrity (Pogliano et al., 2012; Silverman et al., 2003; Straus and Hancock, 2006; Zhang et 
al., 2014). However, despite over two decades of research, the exact MOA and stoichiometry of 
daptomycin oligomerization is still debated, illustrating the difficulty in characterizing antibiotics 
that do not target the major biosynthetic pathways. Nisin, on the other hand, exhibits at least two 
MOAs, targeting lipid II, as well as forming pores across the cytoplasmic membrane (Brotz and 
Sahl, 2000). Never-before-seen MOAs can easily convolute target determination of unique 
compounds, and require further experimentation. 
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1.6 Model Organisms 
TOMM natural products are common among bacterial and archaeal species. Here we 
introduce one TOMM producer, Bacillus methylotrophicus FZB42. Chapter 2 will describe the 
genetic context for the TOMM biosynthetic cluster in FZB42, and Chapter 4 will discuss the 
bacterium of most relevance to the determination of its MOA, Bacillus anthracis. 
1.6.1 Bacillus methylotrophicus FZB42 
Bacillus methylotrophicus* FZB42 [previously named Bacillus amyloliquefaciens FZB42 
(Dunlap et al., 2015)] is a Gram-positive, plant growth-promoting bacterium with an impressive 
capacity to produce secondary metabolites with antimicrobial activity (Chen et al., 2007). The 
nonribosomal synthesis of polyketides (bacillaene, difficidin, and macrolactin), lipopeptides 
(surfactin, fengycin, and bacillomycin D), and siderophores (bacillibactin and the product of the 
nrs cluster) are carried out by large gene clusters distributed over the entire genome of FZB42. In 
total, 8.5% of the entire genomic capacity of FZB42 is devoted to the nonribosomal synthesis of 
secondary metabolites, exceeding that of the model Gram-positive bacterium Bacillus subtilis 168 
by more than 2-fold (Chen et al., 2009). Prophage sequences that often harbor RiPP biosynthetic 
gene clusters, of which are common in B. subtilis strains, were not previously detected within the 
FZB42 genome. This finding underscores the diversity of biosynthetic strategies employed by 
FZB42 and offers new possibilities for discovering novel natural products with biomedically 
relevant activities. Specifically, studying the metabolites of soil-dwelling bacteria like FZB42 can 
reveal a number of products that may be useful for combating infectious disease. While most of 
the described natural products from FZB42 are classified as non-ribosomal peptides and 
polyketides, this strain has been recently demonstrated to produce a TOMM which is now 
referred to as plantazolicin (PZN) (Scholz et al., 2011).  
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1.6.2 Bacillus anthracis: disease and differentiation 
Bacillus anthracis is the causative agent of anthrax. Of clear interest to bioterrorism, the 
bacterial spores responsible for the disease can also be encountered by the consumption of 
contaminated meat of grazing livestock or direct contact with infected animals. Preventative 
measures include a variety of bacterial vaccines. Currently, the vaccines used are only 
administered to those with routine exposure (military, veterinarians, researchers), as safety 
concerns and production/storage costs are high (Beierlein and Anderson, 2011; Spencer, 2003). 
The components of the vaccines differ from lot to lot, which may cause complications and 
reactivity after dosage. Furthermore, the vaccines in present circulation are not approved for post-
exposure; therefore, anthrax infections are treated with intense, prolonged antibiotic regimens. A 
60-day course of penicillin, doxycycline, and/or ciprofloxacin is the chosen treatment for the 
most serious manifestation; inhalational anthrax (Inglesby et al., 1999). Antibiotic resistance is a 
logical concern after such prolonged periods of antibiotic treatment, and resistance has been 
documented for the above-mentioned compounds (Brook et al., 2001; Pomerantsev et al., 1992; 
Price et al., 2003). Further, secondary infections like Clostridium difficile-associated diarrhea are 
not uncommon after treatment with quinolones such as ciprofloxacin (Yip et al., 2001). 
Antibiotics, while extremely useful in fighting infections, can actually be harmful to our 
wellbeing due to misuse and overprescribed practices in medical facilities today. We must 
continue to develop and implement new treatment options if we plan to combat these diseases 
while minimizing drug resistance in future generations 
B. anthracis is a Gram-positive bacterium and is a member of the B. cereus sensu lato 
group, which includes B. cereus, B. anthracis, B. thuringiensis, and B. mycoides (Jensen et al., 
2003; Rasko et al., 2005). Microbiologists have debated whether these organisms should be 
considered as one species, given that they can be greater than 99% identical at the DNA level. 
Despite being grouped with other Bacillus species, B. anthracis harbors a number of features that 
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set it apart from other members of the B. cereus group. As the causative agent of anthrax and a 
category A priority pathogen, fully virulent B. anthracis contains two conserved plasmids, pXO1 
and pXO2. The genes responsible for producing the anthrax toxin and poly-D-glutamic acid 
capsule are encoded on pXO1 and pXO2, respectively. Importantly though, plasmid content 
cannot be relied upon as a definitive indicator for B. anthracis, as a growing number of B. cereus 
and B. thuringiensis strains are known to carry homologous plasmids (Kolsto et al., 2009; Wright 
et al., 2011). Beyond characteristic plasmid content, B. anthracis, unlike other members of the B. 
cereus group, harbors a nonsense mutation in plcR (phospholipase C regulator), which yields a 
truncated and inactive protein. B. anthracis is therefore devoid of phospholipase C activity, but 
also, owing to the pleiotropic regulation of several other virulence factor genes, plcR dysfunction 
renders B. anthracis non-motile and non-hemolytic (Agaisse et al., 1999).   
Exterior to the cell wall, B. anthracis displays a two-dimensional protein lattice that 
encompasses the entire cell surface. This surface layer (S-layer) is non-covalently attached to the 
cell by lectin-like interactions with a secondary cell wall polysaccharide (SCWP) (Wang et al., 
2013; Zheng et al., 2013), which is covalently tethered to the peptidoglycan and radiates 
outwards. The S-layer is decorated with surface associated proteins in a csaB (cell surface 
attachment)-dependent manner (Mesnage et al., 2000). The B. anthracis SCWP is species-
specific (Choudhury et al., 2006; Weidenmaier and Peschel, 2008) and serves as the binding site 
for gamma (γ) phage (Ganguly et al., 2013; Schuch et al., 2013) and previously described B. 
anthracis typing antibodies (Ezzell et al., 1990). γ phage produces a peptidoglycan hydrolase, 
PlyG, which specifically recognizes the terminal galactoses of the B. anthracis SCWP and 
subsequently hydrolyzes the cell wall (Ganguly et al., 2013). The vast majority of non-B. 
anthracis members within the B. cereus sensu lato group bear terminal glucose moieties in their 
SCWP and thus are resistant to γ phage lysis. However, there exist atypical B. anthracis strains 
which lack the galatose-forming UDP-glucose 4-epimerase. Such B. anthracis strains are resistant 
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to γ phage lysis and would constitute false-negatives in any diagnostic assay based on γ phage 
(Abshire et al., 2005). Additionally, atypical strains of B. cereus exist that encode the galatose-
forming UDP-glucose 4-epimerase, rendering the strain susceptible to γ phage (a false-positive in 
the diagnostic assay) (Hoffmaster et al., 2006). Wip1, another B. anthracis-specific phage, is 
even more selective than γ phage, but yet certain B. cereus strains remain sensitive (Kan et al., 
2013). Similarly taking advantage of differences in the SCWP, the above-mentioned typing 
method uses monoclonal antibodies to the galactose-bearing SCWP. As expected, this assay 
suffers from the same selectivity issues as the γ phage lysis assay (Ezzell et al., 1990).  
1.7 Summary and Outlook 
For more than a century, natural product researchers have extracted thousands of 
structurally complex compounds from living organisms, most of them bacteria. Many of these 
natural products have clinical utility and form the foundation of our modern chemotherapeutic 
arsenal. The most prolific producers of such compounds are soil-dwelling, Gram-positive 
bacteria. Today, antibiotic resistance is on the rise, and the need for antibiotics with novel MOA 
is pressing (Clatworthy et al., 2007).  
TOMMs are a large and expanding category of peptide natural products that are post-
translationally modified to contain heterocycles. A variety of structural scaffolds and chemical 
modifications, installed by conserved tailoring enzymes, endow TOMMs with disparate 
biological activities. A growing number of TOMM natural products have been structurally and 
functionally assessed, but the majority are unknown compounds that have yet to reveal their 
potential utility. In 2008, a predicted TOMM precursor peptide was discovered in Bacillus 
methylotrophicus FZB42. In Chapter 2, we introduce a novel natural compound, a TOMM 
produced by FZB42, referred to as plantazolicin (PZN) and report the initial findings on PZN 
purification and production. We investigate the biosynthetic cluster responsible for the production 
of PZN, and engineer genetic deletions in the native producer to confirm the genes required for 
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biosynthesis, export, and potential self-immunity. In Chapter 2, we begin to explore the 
bioactivity of PZN, screening a panel of Gram-positive and Gram-negative strains for 
antibacterial activity. 
TOMM natural products are characterized by their short unstructured leader peptide that 
undergoes post-translational modification. This endows the peptide with structural rigidity 
(conferred by heterocycle incorporation) and a resultant biological function. At the end of 
Chapter 2, we divulge the precursor peptide sequence of PZN and establish the initial biological 
activity. In Chapter 3, we present the high resolution mass of PZN which, in conjunction with 
tandem MS, NMR, and chemoselective modification, reveals the chemical structure of PZN. 
Bioinformatic analysis of the PZN gene cluster establishes a small family of PZN or PZN-like 
bacterial natural products, demonstrating the potential for compound evolution and chemical 
modification. We further assess the biological activity of PZN, validating the limited spectrum of 
its biological activity. 
Until now, the biological activity of PZN has been only minimally described. In Chapter 
4, we examine the unique specificity of PZN for B. anthracis, the causative agent of anthrax. We 
present a large panel of PZN-treated strains that establish PZN as a B. anthracis specific 
compound at clinically relevant concentrations (1 μg/mL). We investigate the molecular target of 
PZN by assessing the gene expression of B. anthracis upon PZN treatment, as well as analyzing 
the genomic sequences of PZN-resistant B. anthracis mutants. These studies, along with confocal 
localization and synergistic activity with cell envelope-acting antibiotics, provide evidence that 
PZN targets the B. anthracis membrane. 
The current rate of antibiotic discovery is one of many factors hindering our fight in the 
arms race against bacteria. Natural products, which comprise the overwhelming majority of 
antibiotics, are a plentiful source for new medicinal compounds. The reverse genetics discovery 
method has provided a way to tap into this resource by accelerating the identification of new 
13 
compound classes and inspiring ingenious chemical engineering of our existing arsenal. The 
discovery of PZN provides a chemical and biological scaffold to advance natural product research 
as a whole.  
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1.9 Figures 
 
Figure 1.1 | Forward/reverse genetic approaches to natural product discovery. (A) Forward 
natural product discovery begins with bacterial isolation and growth in laboratory culture. 
Bacterial extracts undergo large screens for biological activity, and compounds of interest are 
analyzed for genetic characterization. (B) Reverse natural product discovery utilizes the vast 
genomic sequencing databases in search for specific natural product classes. Compound 
production via the native or heterologous host is followed by compound characterization. The 
genomic sequence alludes to predicted structural scaffolds, simplifying mass spectrometry and 
activity screens. 
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Figure 1.2 | Thiazole/oxazole-modified microcins (TOMMs). (A) Here we depict an example 
of a TOMM biosynthetic gene cluster. (B) An inactive precursor peptide is ribosomally 
synthesized and undergoes chemical installation of heterocycles. First, a cyclodehydratase 
catalyzes the formation of thiazoline/(methyl)oxazoline rings from Cys/Ser/Thr residues in the C-
terminal core region (loss of 18 Daltons). Second, a flavin-dependent dehydrogenase oxidizes the 
heterocycle to afford the thiazole/(methyl)oxazole (additional loss of 2 Daltons, resulting in total 
loss of 20 Daltons). (C) If encoded, ancillary modifications may be incorporated. A protease 
cleaves the N-terminal leader region from the core, resulting in an active compound that is then 
transported to perform its biological activity. 
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CHAPTER II: PLANTAZOLICIN, A NOVEL MICROCIN B17/STREPTOLYSIN S-LIKE 
NATURAL PRODUCT FROM BACILLUS METHYLOTROPHICUS FZB42 
 
This chapter was adapted from Scholz, R., Molohon, K.J., Nachtigall, J., Vater, J., Markley, A.L., 
Sussmuth, R.D., Mitchell, D.A., and Borriss, R. (2011). Copyright © American Society for 
Microbiology, J. Bacteriology, Vol 193, 2011, pp 215-224, doi:10.1128/JB.00784-10. 
 
For this publication, I critically revised the manuscript, figures, and performed the reverse 
transcriptase PCR (RT-PCR, Figure 2.6). 
2.1 Abstract 
Here we report on a novel thiazole/oxazole-modified microcin (TOMM) from Bacillus 
methylotrophicus FZB42, a Gram-positive soil bacterium. This organism is well known for 
stimulating plant growth and biosynthesizing complex small molecules that suppress the growth 
of bacterial and fungal plant pathogens. Similar to microcin B17 and streptolysin S, the TOMM 
from B. methylotrophicus FZB42 undergoes extensive posttranslational modification to become a 
bioactive natural product. Our data show that the modified peptide bears a molecular mass of 
1335 Da and displays antibacterial activity towards closely related Gram-positive bacteria. A 
cluster of twelve genes that covers ~10 kb is essential for the production, modification, export, 
and self immunity of this natural product. We have named this compound plantazolicin (PZN), 
based on the association of several producing organisms with plants and the incorporation of 
azole heterocycles, which derive from Cys, Ser, and Thr residues of the precursor peptide.  
2.2 Introduction 
Bacillus methylotrophicus FZB42 [previously named Bacillus amyloliquefaciens FZB42 
(Dunlap et al., 2015)] is a Gram-positive, plant-growth promoting bacterium with an impressive 
capacity to produce secondary metabolites with antimicrobial activity (Chen et al., 2007). The 
nonribosomal syntheses of polyketides (bacillaene, difficidin, and macrolactin), lipopeptides 
(surfactin, fengycin, and bacillomycin D), and siderophores (bacillibactin and the product of the 
nrs-cluster) are carried out by large gene clusters distributed over the entire genome of B. 
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methylotrophicus FZB42. While these compounds are biosynthesized in a 4’-phosphopantetheine 
transferase (Sfp)-dependent fashion, the production of the antibacterial dipeptide, bacilysin, is 
independent of Sfp (Chen et al., 2009b; Chen et al., 2009c). In total, 8.5% of its entire genomic 
capacity is devoted to the non-ribosomal synthesis of secondary metabolites, exceeding that of the 
model Gram-positive bacterium Bacillus subtilis 168 by more than two-fold (Chen et al., 2009a). 
Prophage sequences that often harbor biosynthetic gene clusters of ribosomally synthesized 
peptides (microcins, lantibiotics/lantipeptides), which are common in B. subtilis strains, were not 
previously detected within the FZB42 genome. However, the presence of antimicrobial 
compound(s) active against sigW mutant strain HB0042 of B. subtilis has been reported. SigW is 
an extracytoplasmic sigma factor that provides intrinsic resistance to antimicrobial compounds 
produced by other Bacilli (Butcher and Helmann, 2006).  
The driving force for the current report was the finding that FZB42 mutant RS6, which is 
deficient in the Sfp-dependent synthesis of lipopeptides, polyketides, and in Sfp-independent 
bacilysin production (Chen et al., 2009c), still produced an antibacterial substance active against 
Bacillus subtilis HB0042. This finding underscores the diversity of biosynthetic strategies 
employed by FZB42 and offers new possibilities to discover novel natural products with 
biomedically relevant activities. Recent genomic analysis of FZB42 revealed a ribosomally 
encoded biosynthetic gene cluster that is conserved among many species across two domains of 
life (Lee et al., 2008). This cluster encodes a small precursor peptide that is posttranslationally 
modified to contain thiazole and (methyl)oxazole heterocycles (Figure 2.1). These rings are 
derived from Cys and Ser/Thr through the action of a trimeric ‘BCD’ synthetase complex, which 
consists of a cyclodehydratase complex (CD) and dehydrogenase (B) (Dunbar et al., 2014; 
Dunbar et al., 2012; Dunbar and Mitchell, 2013; Lee et al., 2008). This mechanism of 
modification is utilized in the biosynthetic pathway for streptolysin S (SLS, Streptococcus 
pyogenes) (Datta et al., 2005), microcin B17 (Li et al., 1996), the patellamides (Schmidt et al., 
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2005), and the thiopeptides (Kelly et al., 2009; Liao et al., 2009; Morris et al., 2009; Wieland 
Brown, 2009). The products of these clusters have been collectively classified as 
thiazole/oxazole-modified microcins (TOMMs) due to their genetic and chemical structure 
conservation (Haft et al., 2010).   
During TOMM biosynthesis, the precursor peptide is bound by the BCD synthetase 
complex through specific motifs within the N-terminal leader sequence (Mitchell et al., 2009; 
Roy et al., 1999). After substrate recognition, heterocycles are synthesized on the C-terminal core 
peptide over two enzymatic steps. The first is carried out by a cyclodehydratase, which converts 
Cys and Ser/Thr residues into the corresponding thiazolines and (methyl)oxazolines. A 
dehydrogenase then oxidizes the ‘azoline’ rings to yield ‘azole’ rings [thiazoles and 
(methyl)oxazoles], resulting in a net loss of 20 Da. The completion of TOMM biosynthesis 
includes the incorporation of ancillary modifications (e.g. dehydrations, methylations, 
macrocyclization, etc.) and leader peptide proteolysis (Datta et al., 2005), (Kelly et al., 2009; 
Liao et al., 2009; Morris et al., 2009; Wieland Brown, 2009). In many cases, the fully mature 
TOMM natural product is then actively exported from the cell through the use of an ABC 
transport system. In this work, we describe the discovery, production, isolation, and initial genetic 
and chemical characterization of a novel TOMM from B. methylotrophicus FZB42. This natural 
product compound has a molecular mass of 1335 Da (cpd1335) and has been named plantazolicin 
(PZN).  
2.3 Results 
2.3.1 MALDI TOF-MS detection of a new metabolite from FZB42 
B. methylotrophicus FZB42 is a prolific producer of antibacterial and antifungal natural 
products. To date, nonribosomally produced peptides, including three antimicrobial lipopeptides 
(surfactin, bacillomycin D, and fengycin), three polyketide antibiotics (bacillaene, difficidin, and 
macrolactin), the antibacterial dipeptide bacilysin, and two siderophores (bacillibactin and the 
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putative product of the nrs- gene cluster) have been identified (Chen et al., 2007). In addition to 
these compounds, small molecule metabolite screening of FZB42 by MALDI-TOF-MS revealed 
a metabolite with a molecular mass of [M+H]
+
 = 1336 Da (Figure 2.2A, cpd1335). The visible 
species at m/z = 1354 Da indicates that this compound also appears in a hydrated form (Figure 
2.2A, +18 Da). This may be attributed to a hydrolysis product given that the +18 Da signal 
progressively dominates after extensive sample manipulation (data not shown). Similar to the 
lipopeptide products, mass spectrometric signals from this compound were detected in surface 
extracts and in the culture filtrate. Based on our previous work on small molecule metabolites 
from FZB42 (Chen et al., 2009a), we surmise that after biosynthesis, cpd1335 is actively 
transported out of the cell. After export, the product presumably accumulates in the peptidoglycan 
layer of FZB42, with a portion being spontaneously released into the culture medium. Thus, we 
set out to determine the biosynthetic origin of cpd1335. 
Previously, we generated a strain of FZB42, dubbed RS6, that is deficient in the 
production of all Sfp-dependent lipopeptides, polyketides, and the Sfp-independent synthesis of 
bacilysin (sfp::ermAM, bac::cm, Table 2.1) (Chen et al., 2009c). We were initially surprised when 
strain RS6 was still capable of producing cpd1335, as assessed by MALDI-TOF-MS (Figure 
2.2B). Clearly, this natural product is not being assembled by typical non-ribosomal machinery, 
such as the non-ribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) biosynthetic 
pathways. This suggested that FZB42 was either assembling cpd1335 using an unrecognized Sfp 
or that cpd1336 was of ribosomal origin (i.e. a bacteriocin). Despite the absence of all known, 
non-ribosomally synthesized secondary metabolites (Chen et al., 2009c), supernatants of the RS6 
mutant strain retained antagonistic activity towards closely related Bacilli, such as B. megaterium, 
B. subtilis 168 (trpC2), and a sigW mutant of B. subtilis designated as strain HB0042 (Table 2.2). 
Butcher and Helmann have reported that the growth of B. subtilis HB0042 was inhibited by an 
unknown substance, a potential bacteriocin, produced by FZB42 (Butcher and Helmann, 2006). 
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Further, BLAST searching returns only one copy of Sfp in the FZB42 genome (Altschul et al., 
1997). These findings led us to favor the hypothesis that cpd1335 was a ribosomally synthesized 
antibacterial substance, which heretofore have not been reported in FZB42. 
2.3.2 Preliminary characterization of cpd1335 
The non-concentrated, cell surface extract of RSpMarA2, the strain which bears a 
mariner transposon insertion in the degU global transcriptional regulator gene (Koumoutsi et al., 
2007), contains significantly higher levels of cpd1335 relative to wild type and the RS6 mutant 
strain (Table 2.1, Figure 2.3A). Due to the elevated production level of cpd1335, strain 
RSpMarA2 was employed for further characterization. The dialyzed surface extract of 
RSpMarA2 was separated by tris-tricine-SDS-PAGE and stained with Coomassie Blue (Figure 
2.4A). While the Coomassie stain was relatively weak, we were able to achieve an improved 
visualization of the peptide-sized band (1-2 kDa) by double staining with Schiff’s reagent after 
oxidation with periodic acid (Figure 2.4B). Periodic acid oxidizes alcohols to aldehydes, which 
then react with Schiff’s reagent (Hardonk and Van, 1964). The band, which presumably contained 
cpd1335 based on electrophoretic migration, was excised for further characterization. After 
extraction from the gel, MALDI-TOF-MS identified m/z = 1354 Da as the most intense ion in the 
monitored mass window (Figure 2.4C), corresponding to the hydrated form [M+H2O+H]
+
 of 
cpd1335. Given that this apparent hydrated product was detected earlier (Figure 2.2), it was not 
surprising that after extensive sample preparation (gel electrophoresis and extraction), the 
hydrated product was the major species. Cpd1335 was found to be growth inhibitory towards 
closely related Gram-positive Bacilli, but no activity was observed towards Gram-negative 
bacteria, such as E. coli K12, Klebsiella terrigena, Erwinia carotovora, and Pseudomonas sp. 
(Table 2.2). 
Solubility profiling of purified cpd1335 revealed that this natural product is extractable 
with chloroform, separable by reverse-phase HPLC-chromatography, and insoluble in water at 
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high concentrations (Figure 2.3). Taken together, our solubility data and production from strain 
RS6 suggest that cpd1335 is a relatively hydrophobic, extensively modified peptide of ribosomal 
origin. 
2.3.3 Bioinformatic assessment of the cpd1335 biosynthetic genes  
Supported by the above preliminary characterization of cpd1335, we performed a 
literature search for small, hydrophobic, modified, antibacterial peptides produced by Gram-
positive bacteria. Research on thiopeptides revealed similar characteristics to cpd1335 (Kelly et 
al., 2009; Liao et al., 2009; Morris et al., 2009; Wieland Brown, 2009). Interestingly, several 
orthologs to the genes involved in thiopeptide biosynthesis can be found clustered in FZB42, 
suggesting that cpd1335 may be synthesized by a related route. Introduction of a spectinomycin 
antibiotic cassette within one of these orthologous genes (RBAM_007480, a putative flavin 
mononucleotide-dependent dehydrogenase) resulted in mutant RS26, which was unable to 
produce cpd1335, as assessed by mass spectrometry (Figure 2.3A). This result strongly suggested 
that cpd1335 was a thiazole/oxazole-modified microcin (TOMM). 
In addition to their similarity to proteins involved in thiopeptide biosynthesis, protein 
BLAST (Altschul et al., 1997) and ClustalW (Thompson, 1994) sequence alignment have 
demonstrated that the FZB42 TOMM biosynthetic proteins also exhibit modest similarity to a 
previously characterized TOMM from Streptococcus pyogenes (Lee et al., 2008). The TOMM 
biosynthetic locus from S. pyogenes is referred to as the sag cluster, for SLS-associated genes. 
SagB (dehydrogenase), SagC and SagD(cyclodehydratase), are homologous to RBAM_007480 
(20% identical, 53% similar) RBAM_007460 (13% identical, 50% similar), and RBAM_007470 
(19% identical, 58% similar), respectively. Also bearing similarity to the SLS biosynthetic cluster 
are RBAM_007490 (SagE, Caax protease; 16% identical, 54% similar), RBAM_007420 (SagG, 
ABC transporter; 15% identical, 53% similar) and RBAM_007430 (SagH, ABC transporter; 22% 
identical, 63% similar) (Datta et al., 2005; Lee et al., 2008). Due to this similarity, we have 
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adopted the sag lettering nomenclature for this biosynthetic cluster (Figure 2.5). Despite the 
genetic similarities between SLS and cpd1335, there is no difference in the hemolytic activity of 
RSpMarA2 (cpd1335 overproducer) and mutant RS26 (devoid of cpd1335 production) on blood 
agar plates using the concentrated, dialysed cell surface extract (Figure 2.3B). This demonstrates 
that cpd1335 is not required for the hemolytic activity of FZB42 and suggests cpd1335 exhibits 
other biological activity. 
2.3.4 Preliminary biological activity for cpd1335  
 It is important to note that although there is remarkable similarity in the genetic 
organization of the TOMM biosynthetic clusters, the chemical structure and biological targets of 
the resultant natural products vary widely (e.g. SLS, cellular membrane; microcin B17, DNA 
gyrase; thiostrepton/thiocillin, 50S ribosome; cyanobactins, anticancer activity). Previous data 
have shown that the specific biological activity of the TOMM product is encoded by the sequence 
of the precursor peptide and that the cyclodehydratase and dehydrogenase are functionally 
redundant (Lee et al., 2008). Although this study has not elucidated the molecular target of 
cpd1335, we have determined that the purified compound is growth inhibitory towards most of 
the Gram-positive Bacilli surveyed, especially B. megaterium and B. subtilis HB0042 (Figure 
2.3C, Table 2.2). Interestingly, extracts of mutant RS26, which do not contain cpd1335, were still 
capable of suppressing the growth of B. subtilis HB0042. This shows that cpd1335 was not solely 
responsible for the specific antibiotic activity previously observed in FZB42 culture fluid 
(Butcher and Helmann, 2006). These results demonstrate that FZB42 biosynthesizes at least one 
additional narrow-spectrum antibiotic, which like cpd1335, is likely synthesized by ribosomes. 
As demonstrated by our mass spectrometry studies (Figure 2.2), cpd1335 requires a 
TOMM-type dehydrogenase for production (Figures 2.1 and 2.5). RBAM_007480 is a sagB-like 
gene, embedded within a cluster of 12 genes involved in the biosynthesis, export, and immunity 
of a posttranslationally modified, hydrophobic natural product (Figure 2.5). The defining feature 
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of all TOMM natural products is the incorporation of Cys- and Ser/Thr-derived heterocycles onto 
a ribosomally synthesized, peptidic backbone. To highlight these suspected modifications, we 
hereafter refer to cpd1335 as plantazolicin (PZN). The PZN biosynthetic 12-gene cluster spans 
nearly 10 kb of the FZB42 chromosome (Figure 2.5). Akin to SLS and microcin B17 production, 
a trimeric thiazole/oxazole BCD synthetase complex is present. Based on similarity to these 
systems, all three genes (pznBCD) will be required for heterocycle formation (pznC, 
RBAM_007460; pznD, RBAM_007470) (Figure 2.5). 
2.3.5 Reverse Transcriptase-PCR 
Transcription of all 12 pzn genes in M9 minimal media was confirmed by RT-PCR 
(Figure 2.6). All amplicons migrated with their expected sizes (Table 2.3). In addition to 
confirming transcription, we also assessed the intergenic regions of the PZN biosynthetic cluster 
to determine if the mRNA was polycistronic. Using the appropriate primers from adjacent genes, 
we determined that the biosynthetic genes are transcribed into two polycistronic mRNAs 
(pznFKGHI and pznJCDBEL) and a monocistronic mRNA for pznA (Figure 2.6). Amplification 
of the region between pznE and pznL resulted in a band that was visible only under extreme 
contrast (data not shown). Numerous attempts to amplify the pznIJ junction were unsuccessful. 
2.3.6 Functional analysis of the PZN gene cluster by gene targeted mutagenesis 
Precursor peptide gene. Like many TOMM clusters, the gene encoding the precursor 
peptide is not annotated as an open reading frame (ORF) in the FZB42 genome (gb CP000560.1) 
(Lee et al., 2008). This gene was identified by a manual ORF search and found to be encoded 
between pznI (RBAM_007440) and pznJ (RBAM_007450) in the opposite direction. Although 
unannotated, this ORF (pznA) bears a robust Shine-Dalgarno sequence, AGGAGG, which is 
found 8 bp upstream of an AUG start codon. pznA is predicted to encode for only 41 amino acids 
(Figure 2.5A), which is 6 shorter than previously reported (Lee et al., 2008). The C-terminal 
region, also known as the core peptide (Oman and van der Donk, 2009), is rich in residues that 
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can be enzymatically cyclized to thiazoles and (methyl)oxazoles (2 Cys, 4 Thr, and 4 Ser). This 
feature is a clear indicator of TOMM precursor peptides (Haft et al., 2010; Lee et al., 2008; 
Wieland Brown, 2009) (Figure 2.1). As expected, the pznA mutant RS32, was also deficient in 
synthesis of PZN (Figure 2.3A, 2.5).  
Operon structure and transcriptional regulation. The pzn biosynthetic gene cluster is 
partitioned into three sections. The first operon (pznFKGHI) consists of genes predicted to be 
involved in immunity, regulation, and transport (Figure 2.5). The product of pznK 
(RBAM_007410) is related to homodimeric repressor proteins of the ArsR family (Busenlehner et 
al., 2003). This protein possibly regulates the expression of other pzn genes through an 
unexplored mechanism. The second operon (pznJCDBEL) harbors the genes encoding for the 
enzymes responsible for converting the inactive PznA precursor peptide into the mature, bioactive 
natural product. A summary of the putative function of the members of the pzn gene cluster in B. 
methylotrophicus FZB42 is given in Figure 2.5B. 
Enzymatic processing of PznA. The enzymes dedicated to the modification and 
processing of the PznA precursor peptide are encoded by the second operon of the PZN 
biosynthetic cluster (pznJCDBEL) (Figure 2.5). The function of the first gene, pznJ, is not known; 
however, uncharacterized orthologs can also be found in two plant-associated, Gram-positive 
organisms, Bacillus pumilus and Clavibacter michiganensis. In the latter organism, pznJ is 
annotated as a putative hydroxylase. Sequence analysis and literature searching fail to 
substantiate this designation. As with the creation of other mutant strains, we applied the splicing 
by overlapping extension (SOE) method (Horton et al., 1990) to replace pznJ with a 
spectinomycin resistance gene. The resulting mutant, RS28, did not produce PZN (Figures 2.3A 
and 2.5), demonstrating that PznJ plays a vital biosynthetic role.  
Based on sequence alignment, PznC is related to the TOMM cyclodehydratase present in 
S. pyogenes, SagC. Previous research on SagC revealed its importance in substrate (SagA) 
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recognition, in addition to its ability to catalyze the peptide backbone cyclization of Cys, Ser, and 
Thr residues (Mitchell et al., 2009). Based on this information, we generated a mutant interrupted 
in pznC, RS31 (Table 2.1). As expected, this mutant does not produce PZN (Figure 2.3A). We did 
not prepare a deletion mutant of pznD (RBAM_007470) or pznE (RBAM_007490). PznD is 
highly similar to SagD from the SLS biosynthetic cluster and contains the ATP binding domain 
necessary for heterocycle formation (Dunbar et al., 2014; Dunbar et al., 2012; Dunbar and 
Mitchell, 2013). Therefore, PznD is expected to be of significant importance in the maturation 
process of PznA. PznE belongs to the type II Caax protease family (Pei and Grishin, 2001). As 
predicted by OCTOPUS (Viklund and Elofsson, 2008), PznE contains 4 transmembrane domains, 
similar to the type II Caax proteases from S. pyogenes, C. botulinum, S. aureus, and L. 
monocytogenes (Lee et al., 2008). We hypothesize that this protein will function as a leader 
peptidase, proteolytically processing the PznA peptide at PMAA/R (Figure 2.5A). Two arguments 
supporting this site as the putative leader peptide processing site are: i. cleavage between or 
before the Ala residues is unlikely given the molecular mass of the resultant peptide and the 
number of modifiable residues, and ii. bacteriocin leader peptides are most often processed after a 
Gly-Gly sequence, but other small residues, such as Ser and Ala, can be found directly N-terminal 
to the scissile bond (Dirix et al., 2004; Oman and van der Donk, 2009; van Belkum et al., 1997).  
The product of the last gene within the cluster, PznL (RBAM_007500), was identified by 
sequence analysis to be a S-adenosylmethionine (SAM)-dependent methyltransferase (Figure 
2.5). Mutant RS33, devoid in pznL (Table 2.1), produced a compound with m/z = 1308.5 Da, 
indicating a loss of 28 Da relative to wild type. Based on this data, PznL is responsible for the 
transfer of two methyl groups to PZN [CH3 = 15 Da; (2 x 15) – 2H = 28 Da] (Figure 2.3A, right 
inset). 
Natural product export and immunity. As mentioned above, pznG (RBAM_007420) and 
pznH (RBAM_007430) are homologous to ABC transporters, with PznG being responsible for 
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binding ATP and PznH carrying out the permease activity. ABC transporters are common 
constituents of TOMM biosynthetic gene clusters and are present across many taxa of bacteria 
and archaea (Lee et al., 2008). The function of the pznF (RBAM_007400) and pznI 
(RBAM_007440) gene products are more convoluted. It has previously been hypothesized that 
one or both of these gene products could be involved in self-immunity of FZB42 against PZN 
(Lee et al., 2008). While a protein BLAST database search on PznF yields homology to putative 
membrane proteins, PznI is annotated as a pentapeptide repeat protein. Research on other proteins 
of the pentapeptide repeat family has revealed that they play important signaling roles via 
coordinating protein-protein interactions (Vetting et al., 2006) and also can confer resistance to 
quinolone antibiotics (Rodriguez-Martinez et al., 2009). To address their potential role in PZN 
production/immunity, the pznI and pznF genes were individually replaced with the spectinomycin 
resistance gene. Although both of these mutants were still able to produce PZN (Figure 2.3A), 
they displayed different growth characteristics. Neither mutant exhibited visible growth defects 
during growth on LB agar plates. In liquid LB media, the pznI mutant (RS27) growth curve was 
indistinguishable from the background strain (RS6). However, the pznF mutant (RS29) displayed 
markedly different growth behavior. Upon reaching a maximum culture density, which was equal 
to that of RS6, RS29 appeared to undergo lysis instead of maintaining a high culture density 
(Figure 2.3D). Mature PZN is present at sufficient quantity to be detected by MALDI mass 
spectrometry during the early stationary growth phase (Figure 2.2), but not at earlier time points 
(data not shown). This suggests that the pznF mutant is more susceptible to the actions of an 
antimicrobial compound produced in higher abundance during later growth phases. Upon treating 
RS6 and RS29 with purified PZN, a larger zone of inhibition was visible for the RS29 strain, 
confirming that the above growth phenotype was indeed PZN-dependent (data not shown). Given 
the observation that FZB42 requires an immunity gene (pznF) for fully competent growth, and  
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that PZN exhibits activity against only select Gram-positive bacteria (Table 2.2), we conclude 
that PZN acts as a narrow spectrum antibacterial compound.  
2.4 Summary and Outlook 
A novel, antibacterial, microcin B17/streptolysin-like compound with a molecular mass 
[M+H]
+
 of 1336 Da (plantazolicin, PZN) was identified in culture supernatant and cell surface 
extract from B. methylotrophicus FZB42. We postulate that the core peptide consists of 14 amino 
acids (RCTCTTIISSSSTF), 10 of which potentially serve as a site of heterocycle formation (Cys, 
Ser/Thr). Although we have not yet ascertained the precise chemical structure of PZN, supportive 
evidence is available that demonstrates this natural product undergoes extensive posttranslational 
modification (Figures 2.2-2.4). Numerous attempts to elucidate the structure of PZN by LC ESI-
MS/MS (tandem) analysis showed an unusually incomplete fragmentation pattern (data not 
shown). Such tandem MS analysis (i.e. collision-induced dissociation) tends to fragment parent 
ions at the amide bond, leading to a series of ions containing the N-terminus (b ion series) and the 
C-terminus (y ion series). If contiguous heterocycles were indeed formed on adjacent residues of 
PznA, an incomplete tandem spectrum would be the expected outcome. A full structural 
elucidation of PZN by other spectroscopic methods is currently underway and will be the subject 
of a future publication. 
A previous bioinformatics survey revealed modest similarity of a putative biosynthetic 
locus from FZB42 with the streptolysin S (SLS) biosynthetic operon from Streptococcus 
pyogenes (Lee et al., 2008). Genes from this operon are designated as SLS-associated genes 
(sag), of which there are a total of 9 (sagA-I). Related gene clusters have been widely 
disseminated among bacteria and archaea. The genetic and biochemical conservation within this 
particular natural product family has led to a new classification of small, highly modified 
bacteriocins, the thiazole/oxazole-modified microcins (TOMMs) (Haft et al., 2010; Lee et al., 
2008). Genetic ablation of RBAM_007480, a gene homologous to sagB, resulted in the inability 
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of FZB42 to synthesize PZN (Figure 2.3). Thus, the FZB42 TOMM cluster appeared to be 
responsible for the synthesis of PZN. Analysis of the local genomic context of RBAM_007480 
identified a 12-gene biosynthetic cluster, encoding hypothetical genes involved in the TOMM 
biosynthesis, immunity, and export (Figure 2.5). The TOMM precursor gene, pznA, encodes a 
small peptide consisting of 41 amino acids. Like pznB (the sagB ortholog), deletion of pznA, 
among other essential genes (e.g. pznC), abolishes the production of PZN. After PznBCD-
dependent heterocycle formation, dimethylation (PznL), and N-terminal processing by a protease, 
(possibly PznE), the core peptide of modified PznA is secreted into the exterior environment via 
the ABC transporters, PznG and PznH. In addition to establishing the order and location of all 
posttranslational events, the biosynthetic role of the requisite PznJ protein is also under 
investigation in our laboratory. 
Several gene clusters encoding TOMMs have been detected in the genomes of plant-
associated bacteria, such as Bradyrhizobium japonicum, Pseudomonas putida, and Clavibacter 
michiganensis (Lee et al., 2008). Performing a protein BLAST search using each PZN gene 
product as the query sequence returns orthologous protein matches from Bacillus pumilus ATCC 
7061 as the top hit after FZB42 itself. The thiazole/oxazole synthetase proteins (PznBCD) from 
B. pumilis (protein IDs: EDW22765.1, EDW22903.1, and EDW23125.1, respectively) 
demonstrated a remarkable degree of amino acid identity to those from FZB42 (PznB, 77%; 
PznC, 63%, and PznD, 82%). Moreover, the pzn genes from B. pumilis are found clustered and in 
identical order to that found in FZB42. Also like FZB42, B. pumilis is a plant saprophyte that 
produces an array of antibacterial and antifungal natural products (Choudhary and Johri, 2009). 
Further, the PznA core peptide sequences from FZB42 and B. pumilis (unannotated, located 
between EDW23486.1 and EDW22932.1) are 100% identical. Taken together, we predict that B. 
pumilis is also a PZN producer.  
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Interestingly, the pzn gene cluster was absent from the genome of B. amyloliquefaciens 
type strain DSM7
T 
(EMBL identifier FN597644), a non-plant-associated bacterium. It is plausible 
that the pzn gene cluster in FZB42 has been horizontally transferred between members of the 
plant rhizosphere. To bolster this possibility, we performed a protein BLAST search of three draft 
genomes of plant-associated B. methylotrophicus strains, which became recently available 
(Borriss et al., 2010). Within the B. methylotrophicus CAU-B946 genome, we found the complete 
12-gene PZN biosynthetic cluster, displaying 95-100% amino acid identity with that of FZB42. 
The genomes of strains B. methylotrophicus YAU-Y2 and NAU-B3 did not possess the complete 
set of genes for the PZN cluster, but did harbor a portion of the immunity/transport operon, 
pznFKGH. These genes displayed 95-100% identity with the corresponding genes from FZB42. 
Although the YAU-Y2 and NAU-B3 genomes lack an intact PZN biosynthetic cluster, the genetic 
composition of these strains implies that the plant-associated members of the B. methylotrophicus 
(plantarum) taxon are at least immune towards, and/or capable of de novo synthesis of PZN.  
A detailed biological function for PZN has yet to be established. Unlike some TOMMs, a 
functional prediction cannot reliably be made based on the sequence of pznA due to its lack of 
homology to other TOMM precursors with known functions. In other words, TOMM precursor 
peptides similar in sequence to SagA are cytolysins (Cotter et al., 2008; Mitchell et al., 2009), 
while unrelated sequences do not encode cytolytic activity (i.e. the precursors for microcin B17, 
patellamides, thiostrepton, etc.). Our preliminary results demonstrate that PZN functions as a 
narrow-spectrum, antibacterial compound. Presumably, this natural product is meant to suppress 
the growth of taxonomically related competitors within the plant rhizosphere. Independent of 
function, PZN should be highly protected from degradation by peptidases within the plant 
rhizosphere due to an extensive degree of modification. 
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2.5 Experimental 
2.5.1 Strain construction 
The B. methylotrophicus strains and plasmids used in this study are summarized in Table 
2.1. Bacillus and indicator strains were cultivated routinely on Luria-Bertani broth (LB) medium 
solidified with 1.5% agar. For production of PZN, a medium containing: 40 g soy peptone, 40 g 
dextrin 10, 1.8 g KH2PO4, 4.5 g K2HPO4, 0.3 g MgSO4 x 7 H2O, and 0.2 ml KellyT trace metal 
solution per L was used. KellyT trace metal solution: 25 mg EDTA disodium salt dihydrate, 0.5 g 
ZnSO4 x 7 H2O, 3.67 g CaCl2 x 2 H2O, 1.25 g MnCl2 x 4 H2O, 0.25 g CoCl2 x 6 H2O, 0.25 g 
ammonium molybdate, 2.5 g FeSO4 x 7H2O, 0.1 g CuSO4 x 5 H2O; adjust to pH 6 with NaOH, 
500 ml H2O. 
The media and buffers used for DNA transformation of Bacillus cells were prepared 
according to Kunst and Rapoport (Kunst, 1995). Competent cells were prepared as previously 
described (Koumoutsi et al., 2004). Mutants were obtained after transformation of the FZB42 
derivatives with linearized, integrative plasmids containing resistance cassettes flanked by DNA 
regions homologous to the FZB42 chromosome. The oligonucleotides used for strain construction 
are listed in Table 2.3. Spectinomycin (90 µg/ml) was used for selecting transformants. Gene 
interruption strains were obtained as follows: PznB RS26: A 2.7 kb PCR fragment was amplified 
from FZB42 chromosomal DNA using primers pznB-fw and pznB-rv. The fragment was then 
cloned into pGEM-T, yielding plasmid pRS26a. Plasmid pRS26b was obtained by insertion of a 
spectinomycin resistance cassette, which was subcloned by PCR using the spc-fw and spc-rv 
primers and the pIC333 plasmid as a template. The cassette was placed into the central region of 
the insert and digested with BglII and BamHI. PznC RS31: With primers pznC-fw and pznC-rv, a 
2.6 kb fragment containing pznC was amplified by PCR and cloned into vector pGEM-T-Easy 
yielding plasmid pRS31a. A central fragment of the insert was removed by digestion with 
Eco105I and replaced with the spectinomycin resistance cassette, yielding pRS31b. PznA RS32: 
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With primers 007400cst-fw and 007400cst-rv, a 2.3 kb fragment encoding the unannotated 
precursor peptide, pznA, was amplified by PCR and cloned into vector pGEM-T-Easy, yielding 
plasmid pRS32a. The precursor peptide gene was cleaved by Bsp1407I and interrupted by 
insertion of a spectinomycin resistance cassette, yielding pRS32b.  
The mutants RS27, RS28, RS29 and RS33 were generated by gene splicing using the 
overlapping extension (SOE) method (Horton et al., 1990). This method assists in avoiding 
possible polar effects caused by interrupted reading frames. SOE PCR fusion products were 
generated using the primers listed in Table 2.3 and the spectinomycin gene of pIC333. A-tailing 
of the Pfu-PCR product was performed according to the Promega pGEM-T protocol and ligated 
into pGEM-T yielding pRS27, pRS28 and pRS29. For mutant RS33, the PCR product was used 
directly for transformation. 
Mutant RSpMarA2 was isolated from a mariner-based (pMarA) transposon library 
prepared in strain CH5 according to Breton et al. (Le Breton et al., 2006). In this transposon 
mutant, pMarA was integrated into the degU gene, which is a global transcriptional regulator that 
activates the bacillomycin D promoter (Koumoutsi et al., 2007). Coincidentally, we observed by 
HPLC-ESI-MS that PZN is overproduced by this strain (Figure 2.3A). 
2.5.2 Bioassay 
LB-Agar (20 ml) was mixed with 0.5 ml of the indicator strain (OD600 ~1.0). 10 µl of 
purified PZN suspended in water was spotted on the agar and incubated for 16 h at 22 °C. The 
growth suppression activity of PZN was observed as clear zone. 
2.5.3 Cell surface extract 
The extract was prepared in the following way: Cells of strain RSpMarA2 and RS26 were 
grown using production media containing 1.5% agar for 24 h at 37 °C. Cells were removed from 
the plates and treated with 50 ml of 70% acetonitrile : 30% water with 0.1% formic acid. After 
centrifugation (7000 rpm, 20 min, 22 °C), the extract was passed through a 0.45 µm filter and 
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concentrated to 2 ml using a rotary evaporator. The extract was dialyzed overnight against 5 L 
distilled water using a 1 kDa membrane (Zellutrans V, Roth).  
2.5.4 HPLC-ESI-MS 
 Bacterial strains were grown for 24 h at 37 °C on solid production media containing 1.5% 
agar. One square centimeter of the bacterial lawn culture was extracted with 50 µl of 70% 
acetonitrile : 30% water with 0.1% formic acid for 30 s with vortexing. After centrifugation 
(14,000 rpm, 5 min) the solution was analyzed by an online HPLC (1100 series HPLC system, 
Agilent Technologies) coupled to a QTRAP 2000 mass spectrometer (Applied Biosystems). A 
sample of extract (4 µl) was separated by HPLC using a Luna C18 100Å 50 x 1 mm column 
(Phenomenex) at a flow rate of 60 µl/min and a linear gradient of 5% to 100% acetonitrile with 
0.1% formic acid in 10 min. MS analysis was performed in positive ion mode. MS settings: mass 
window was from 500 - 1400 Da, ion spray voltage was 4500, and ion source temperature was 
300 °C. 
2.5.5 Purification of cpd1335 
A cell surface extract from a 250 ml culture of strain RSpMarA2 was collected using the 
previous method. During concentration under reduced pressure, cpd1335 precipitated. The 
precipitate was washed 3 times with deionized water, resulting in crude, desalted cpd1335. Pure 
cpd1335 was obtained using RP-HPLC (Grom-Sil ODS-5 ST, 20 x 250 mm, Alltech-Grom, 
Rottenburg-Hailfingen) with a linear gradient elution of 40 - 70% aqueous acetonitrile with 0.1% 
v/v formic acid over 40 min at a flow rate of 15 ml/min. 
2.5.6 MALDI-TOF mass spectrometric analysis 
Strains were grown for 16 h at 37 °C on production media solidified with 1.5% agar. For 
preparation of surface extracts, colonies were picked from the agar plates and extracted by 
vortexing for 30 sec with 50 µl 70% acetonitrile : 30% water with 0.1% formic acid. MALDI-
TOF mass spectra were recorded using a Bruker Autoflex MALDI-TOF instrument containing a 
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337 nm nitrogen laser for desorption and ionization. 2 µl samples were mixed with the same 
volume of matrix solution (a saturated solution of -cyano-4-hydroxycinnamic acid in 50% 
aqueous acetonitrile containing 0.1% v/v trifluoroacetic acid), spotted on the target, air-dried, and 
measured as described previously (Vater et al., 2002). Spectra were obtained by positive ion 
detection and reflector mode MS. 
2.5.7 RT-PCR 
Total RNA was isolated with the Qiagen RNeasy Mini Kit. Cells (1.0 OD600) were 
harvested from M9 minimal media supplemented with BME vitamin mix (Cat. No. B6891) and 
ATCC trace mineral solution (Cat. No. MD-TMS) and treated with the Qiagen RNAprotect 
Bacteria Reagent. Harvested cells were resuspended in 250 μl of 10 mM tris (pH 8.5) with 15 
mg/ml lysozyme and 5 μl proteinase K (20 mg/ml) and digested for 1 h at 22 °C with gentle 
agitation. A DNase I digestion was performed for pznE and pznL using the Qiagen RNase Free 
DNase set. DNase I (7 µl) and RDD DNA digest buffer (7 µl) were used to hydrolyze 
contaminating DNA for 20 min at 22 °C. The RNA isolation protocol was then followed to 
manufacturer’s instructions.  To minimize background, a DNase I digestion (5 µl) was executed 
to the RNA samples and placed at 37 °C for 20 min. Note that this was the second DNase I digest 
for pznE and pznL. Samples were column purified using the RNA cleanup protocol in the RNeasy 
Mini Handbook (Qiagen). Digestion and cleanup were repeated for all RNA samples, excluding 
those used to analyze pznE and pznL. cDNA was prepared with commercially available RT-PCR 
kits using 1 µg of RNA and the primers listed in Table 2.3. 
2.5.8 Tris-Tricine SDS-PAGE 
Gels (18%) were prepared according to Schägger and Jagow (Schägger and von Jagow, 
1987)  with water instead of glycerol and without a spacer gel. Cellular extracts (100 µl) were 
mixed with 5x SDS sample buffer  (20 µl) and then heated at 100 °C for 5 min prior to gel 
loading, along with a Ultra-low Range Molecular Weight Marker (Sigma). The peptides were 
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separated by low current (30 mA) electrophoresis. The gel was subsequently washed with 
destaining solution (10 ml ethanol, 10 ml acetic acid, 50 ml water) for 20 min (x3), and in 
deionized water for 20 min (x3). The gel was stained with Coomassie (EZBlue, Sigma) and/or 
Schiff’s reagent (Sigma) after 1 h oxidation with 0.7% v/v periodic acid. The Coomassie stained 
band was excised from the gel and extracted with 50 µl 70% acetonitrile:30% water with 0.1% 
v/v formic acid for 24 h. The supernatant was used for MALDI-TOF MS measurement. 
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2.7 Figures 
 
Figure 2.1 | Thiazole/oxazole-modified microcin (TOMM) biosynthesis. Through the action of 
a trimeric “BCD” complex, consisting of a cyclodehydratase (CD, green/blue), dehydrogenase 
(B, yellow), thiazoles and (methyl)oxazoles are incorporated onto a peptidic scaffold (black). 
These heterocycles are synthesized from serine/threonine (X = O; R = H/CH3) and cysteine (X = 
S; R = H) residues of the inactive precursor peptide and yield a bioactive natural product. The 
chemical transformations carried out by the cyclodehydratase and the dehydrogenase are shown, 
along with the corresponding mass change from the parent peptide in Daltons. 
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Figure 2.2 | MALDI-TOF mass spectra of B. methylotrophicus surface extracts. The samples 
were prepared from FZB42 (A) and RS6 (B) cells. Surface extracts were prepared and measured 
as described in the Material and Methods section. Peaks at 1336.8 [M+H]
+
, 1354.8 [M+H2O+H]
+
, 
1358.8 [M+Na]
+
, and 1374.8 [M+K]
+
 Da indicate the presence of PZN in the wild type strain, and 
in the Δsfp/ Δbac mutant strain, RS6.  
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Figure 2.3 | Effect of mutations in the pzn gene cluster on biological activity. (A) Extracted 
ion chromatogram of PZN ([M+H]
+
 1336 Da) of FZB42 and mutant strains. This compound (m/z 
= 1336.6 Da, left inset) is synthesized by wild-type FZB42, and by the mutant strains RS6 (Δsfp/ 
Δbac), RS27, and RS29. RSpMarA2 (ΔdegU) overproduces PZN. Strains RS26, RS28, RS31, 
and RS32 were deficient in PZN production. Strain RS33 (right inset) produced a compound with 
m/z = 1308.5 Da, suggesting the loss of two methyl groups (-H2 + C2H6, -28 Da). (B) Hemolytic 
activity of 100 µl extract from RSpMarA2 and RS26 on blood-agar plates. (C) Antibacterial 
activity of PZN. Left: HPLC purified PZN (10 µl of 100 µg/µl suspended in water) was spotted 
onto an agar plate of B. subtilis HB0042 (sigW null) and incubated for 16 h to assess growth 
inhibition. Right: 10 µl of water (negative control). (D) Growth curves of strains RS6 and pznF 
mutant RS29. After approximately 20 h of growth, the RS29 culture density is 9 log units lower 
than RS6. 
 
  
46 
 
Figure 2.4 | Characterization of cell surface extract. Samples were prepared from RSpMarA2 
and separated by 18% tris-tricine SDS-PAGE stained with either Coomassie EZBlue (A) or 
double-stained with Coomassie EZBlue and Schiff’s reagent (B). M: size marker; 1-5: 1 µL, 2 
µL, 5 µL, 10µL and 20 µL surface extract. (C) MALDI-TOF mass spectrum of the hydrated form 
of PZN (m/z: 1336 + 18 = 1354 Da) obtained by excising the peptide band from the tris-tricine 
SDS-PAGE gel.  
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Figure 2.5 | Plantazolicin gene cluster. (A) FZB42 PZN gene cluster (9892 bp) and amino acid 
sequence of the precursor peptide. (-) putative leader peptide processing site. (B) Proposed 
function of individual PZN genes. Upon deletion of pznF and pznI, cpd1336 (PZN) was detected 
by mass spectrometry. Deletion of pznL resulted in desmethyl PZN (m/z = 1308 Da) while 
individual inactivation of all other tested genes (pznABCJ) did not produce PZN. The functions of 
pznF, pznI, and pznJ require further exploration, but preliminary data suggests that pznF plays a 
role in immunity, pznI encodes a pentapeptide repeat protein, and pznJ is required for PZN 
maturation. 
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Figure 2.6 | RT-PCR reveals polycistronic mRNAs. Reverse transcriptase PCR was performed 
using 1 μg of FZB42 RNA isolated from stationary phase using a commercially available kit. 
PCR products were analyzed in comparison to a negative control lacking reverse transcriptase (-
RT). (A) All genes in the putative PZN cluster are transcribed under the culturing conditions 
employed.  Cells (1.0 OD600) were removed from a stationary culture growing at 37 °C 24 h after 
inoculation. Total RNA was isolated and converted to cDNA by RT-PCR.  cDNA (500 ng) was 
added to each reaction, excluding pznE and pznL (750 ng each). Gene fragments were then 
amplified using specific primers and PCR. Amplicons were assessed by separation on 1.1% 
agarose gels containing ethidium bromide and visualized by UV illumination. (B) Amplification 
of adjacent pzn genes reveals polycistronic mRNA. Not shown: junction A-J did not reveal a 
significant band; junction E-L was visible under extreme contrast. All amplicons migrate with 
their expected sizes. 
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2.8 Tables 
Table 2.1 | Bacterial strains and plasmids used in this study 
Strains  Description Source / reference 
Bacillus subtilis  
DSM10
T
 168, trpC2, type strain  DSMZ 
Braunschweig 
CU1065 168, trpC2 attSPβ (Butcher and 
Helmann, 2006) 
(Butcher and 
Helmann, 2006) 
HB0042 168, trpC2 attSPβ sigW::kan 
Bacillus megaterium 
7A/1 Indicator strain for polyketides Laboratory stock 
Bacillus methylotrophicus  
FZB42 Wild type (Idriss et al., 2002) 
CH5 FZB42 sfp::ermAM yczE::cm (Chen, 2009) 
RSpMarA2 Insertion of pMarA in CH5: degU::kan this work 
RS6 sfp::ermAM, bac::cmR, deficient in 
lipopeptides, polyketides and bacilysin 
(Chen et al., 2009c) 
RS26 (ΔpznB) RS6 ΔRBAM_007480::spc does not produce 
PZN 
this work 
RS27 (ΔpznI) RS6 ΔRBAM_007440::spc produces PZN this work 
RS28 (ΔpznJ) RS6 ΔRBAM_007450::spc does not produce 
PZN 
this work 
RS29 (ΔpznF) RS6 ΔRBAM_007400::spc produces PZN this work 
RS31 (ΔpznC) RS6 ΔRBAM_007460::spc does not produce 
PZN 
this work 
RS32 (ΔpznA) RS6 ΔpznA::spc does not produce PZN this work 
RS33 (ΔpznL) RS6 ΔRBAM_007500::spc produces 
desmethyl-PZN, 1308 Da 
this work 
Plasmids  
pGEM-T Ap
r
, lacZ` Promega 
pMarA plasmid containing mariner transposon 
TnYLB-1 
(Le Breton et al., 
2006) 
pIC333 plasmid with spc cassette  T. Msadek, Institute 
Pasteur, Paris, 
France 
pRS26a pGEM-T with 2700bp pznB this work 
pRS26b pGEM-T with pznB::spc this work 
pRS27 
 
pRS28 
 
pRS29 
 
pRS31a 
pGEM-T with SOE fusion-product 
RBAM_007440/spc 
pGEM-T with SOE fusion-product 
RBAM_007450/spc 
pGEM-T with SOE fusion-product 
RBAM_007400/spc 
pGEM-T with 2600 bp pznC 
this work 
 
this work 
 
this work 
 
this work 
pRS31b pGEM-T with pznC::spc this work 
pRS32a pGEM-T with 2300 bp flanking region pznA this work 
pRS32b pGEM-T with pznA::spc this work 
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Table 2.2 | Activity spectrum of plantazolicin 
Indicator strain Result
a
 Source or reference
b
 
Bacillus brevis ATCC8246 + ATCC 
Bacillus subtilis 168 + (Butcher and Helmann, 
2006) 
Bacillus cereus ATCC14579 + ATCC 
Bacillus licheniformis ATCC9789 + ATCC 
Micrococcus luteus + Laboratory collection 
Bacillus pumilus - Laboratory collection 
Bacillus subtilis CU1065 + (Butcher and Helmann, 
2006) 
Bacillus subtilis HB0042 ++ (Butcher and Helmann, 
2006) 
Bacillus sphaericus + Laboratory collection 
Paenibacillus polymyxa - Laboratory collection 
Paenibacillus granivorans + Laboratory collection 
Bacillus megaterium  7A1 ++ Laboratory collection 
Arthrobacter sp. - Laboratory collection 
Staphylococcus aureus - Laboratory collection 
E. coli K12 - Laboratory collection 
Klebsiella terrigena - Laboratory collection 
Pseudomonas sp. - Laboratory collection 
Erwinia caratovora - Laboratory collection 
a
 Degree of inhibition in a bioassay: ++: inhibition; +: weak inhibition; -: no inhibition 
b
 ATCC: 
American Type Culture Collection 
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Table 2.3 | Oligonucleotides used for gene replacement and SOE PCR 
Oligonucleotide Sequence (5’ to  3’) 
Spectinomycin resistance cassette 
Spc-fw CTCAGTGGAACGAAAACTCACG 
Spc-rv TAAGGTGGATACACATCTTGTC 
pRS26a/b 
 
pznB-fw ATCCATATCGCCAATCATACGG 
pznB-rv GGAATCAATACCTGTCAGTTCG 
pRS31a/b 
 
pznD-fw ATTGACTAGGAGGTATTGGACG 
pznD-rv TTCTATTGAATAGGAGGAGGCG 
pRS32a/b 
 
007400cst-fw TGGAATGCTCTTTCCGCAGTAC 
007400cst-rv GTAACTCTGTTTCCACGTAACC 
SOE PCR 
 
7400 rv TCTTCATCACGCAAATCAGTGC 
7400 fw CCGCATAAACGGGAATTGGAAG 
Spc in 7410  
TCTATAGAAACTTCTCTCAATTAGAA
AAGAAAAGGGCAAGGAAATGAG 
7410 in spc  
ACTCATTTCCTTGCCCTTTTCTTTTCT
AATTGAGAGAAGTTTCTATAG 
Start in spc  
CTTTGTAAAAAGAGGAGCCTGTCTTA
TGAGCAATTTGATTAACGG 
Spc in start  
TTTTTCCGTTAATCAAATTGCTCATA
AGACAGGCTCCTCTTTTTACAAAG 
7430 in spc  
GCTGGGACTAAAAGGAGAGCGGGAA
ATGAGCAATTTGATTAACGG 
Spc in ORF2  
TTCTATAGAAACTTCTCTCAATTAGA
TTTAATATAAAGAAGCATAGACC 
Spc in 7430  
TTTTTCCGTTAATCAAATTGCTCATTT
CCCGCTCTCCTTTTAGTCCCAGC 
ORF2 in spc  
TGGTCTATGCTTCTTTATATTAAATCT
AATTGAGAGAAGTTTCTATAG 
7440 rv TCACGTCCAATACCTCCTAGTC 
7440 fw ATCGACAGAGGGCAGATTATCG 
ORF2 in spc for 7450 fw 
GATTATTGACTAGGAGGTATTGGACA
TGAGCAATTTGATTAACGG 
7460 in spc for 7450 rv 
GTTTGTTGAGACATCTGTATTCCTCC
CTAATTGAGAGAAGTTTCTATAG 
7450 rv TAATGTCGTCCATTTACTCACC 
7450 fw TTGGCTCGAATAAATGTTGACC 
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Table 2.3 (continued) 
Spc in ORF2 for 7450 rv 
TTTTTCCGTTAATCAAATTGCTCATGT
CCAATACCTCCTAGTCAATAATC 
Spc in 7460 for 7450 fw 
TTCTATAGAAACTTCTCTCAATTAGG
GAGGAATACAGATGTCTCAACAAAC 
End in spc for 7500 rv 
CGCTTAGACCCTAAAGATATACTTTC
TCTAATTGAGAGAAGTTTCTATAG 
7490 in spc for 7500 fw 
AACTCTTTGGAGGTGTCACAGTTATA
TGAGCAATTTGATTAACGG 
7500 fw AAGGTCCTAGACGCCCTATTCC 
7500 rv GATGTGTAGTTTTCAACGCTCG 
Spc in end for 7500 fw 
CTATAGAAACTTCTCTCAATTAGAGA
AAGTATATCTTTAGGGTCTAAGCG 
Spc in 7490 for 7500 rv 
CCGTTAATCAAATTGCTCATATAACT
GTGACACCTCCAAAGAGTTTACC 
RT-PCR 
 
pznF-fw GGATTATTGCGTACTCCGTTTC 
pznF-rv CTGCCTCCGCCAATAAATG 
pznK-fw ATGCCAAAGTACGGTTGGG 
pznK-rv CTCCTTGTAGGCTGCTTTCC 
pznG-fw CCACAGGATATCAGCCTTGAAG 
pznG-rv CGATAATCTGCCCTCTGTCG 
pznH-fw CGCTCGCTCAAATTGAAACG 
pznH-rv ACAACAACCCACAGATACGC 
pznI-fw TAGCCTGGAAGCAGAGGGTA 
pznI-rv ACTTTTGGCAGGTGACAACC 
pznA-fw GGAGGAGGTAACAATTATGACTCAA 
pznA-rv GGTACAGGTACAGCGTGCAG 
pznJ-fw TTGGATATCGGAATCGAGTTG 
pznJ-rv CGGATGCCCAATTATCTGTT 
pznC-fw TCATGTCCCTTGGTTGTGTG 
pznC-rv GCCGTGATACCATACTTGAGG 
pznD-fw CGCGATGTAGATGACGTTTG 
pznD-rv GATTGGCGATATGGATTAGTTG 
pznB-fw AAGGCATGCCACTAATTTGG 
pznB-rv GATAAAGAGCTCCGCCAGAA 
pznE-fw CATAGCAATAATGCGTACGGTG 
pznE-rv GAGACATTGTCGGCGAAGA 
pznL-fw GATGAGAGGGAAACCTCATCC 
pznL-rv CTCCCAAACTGTTCCTGTCC 
 
53 
2.9 References 
1. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. 
(1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. 
Nucleic Acids Res: 25, 3389-3402. 
2. Borriss, R., Chen, X., Rueckert, C., Blom, J., Becker, A., Baumgarth, B., Fan, B., Pukall, R., 
Schumann, P., Sproer, C., et al. (2010) Relationship of Bacillus amyloliquefaciens clades 
associated with strains DSM7T and FZB42: a proposal for Bacillus amyloliquefaciens subsp. 
amyloliquefaciens subsp. nov. and Bacillus amyloliquefaciens subsp. plantarum subsp. nov. based 
on their discriminating complete genome sequences. Int J Syst Evol Microbiol: 61, 1786-1801. 
3. Busenlehner, L.S., Pennella, M.A., and Giedroc, D.P. (2003) The SmtB/ArsR family of 
metalloregulatory transcriptional repressors: Structural insights into prokaryotic metal resistance. 
FEMS Microbiol Rev: 27, 131-143. 
4. Butcher, B.G., and Helmann, J.D. (2006) Identification of Bacillus subtilis sigma-dependent 
genes that provide intrinsic resistance to antimicrobial compounds produced by Bacilli. Mol 
Microbiol: 60, 765-782. 
5. Chen, X. (2009) Whole genome analysis of the plant growth-promoting Rhizobacteria 
Bacilllus amyloliquefaciens FZB42 with focus on its secondary metabolites. Dissertation: HU-
Berlin. 
6. Chen, X.H., Koumoutsi, A., Scholz, R., and Borriss, R. (2009a) More than anticipated - 
production of antibiotics and other secondary metabolites by Bacillus amyloliquefaciens FZB42. 
J Mol Microbiol Biotechnol: 16, 14-24. 
7. Chen, X.H., Koumoutsi, A., Scholz, R., Eisenreich, A., Schneider, K., Heinemeyer, I., 
Morgenstern, B., Voss, B., Hess, W.R., Reva, O., et al. (2007) Comparative analysis of the 
complete genome sequence of the plant growth-promoting bacterium Bacillus amyloliquefaciens 
FZB42. Nat Biotechnol: 25, 1007-1014. 
8. Chen, X.H., Koumoutsi, A., Scholz, R., Schneider, K., Vater, J., Sussmuth, R., Piel, J., and 
Borriss, R. (2009b) Genome analysis of Bacillus amyloliquefaciens FZB42 reveals its potential 
for biocontrol of plant pathogens. J Biotechnol: 140, 27-37. 
9. Chen, X.H., Scholz, R., Borriss, M., Junge, H., Mogel, G., Kunz, S., and Borriss, R. (2009c) 
Difficidin and bacilysin produced by plant-associated Bacillus amyloliquefaciens are efficient in 
controlling fire blight disease. J Biotechnol: 140, 38-44. 
  
54 
10. Choudhary, D.K., and Johri, B.N. (2009) Interactions of Bacillus spp. and plants--with special 
reference to induced systemic resistance (ISR). Microbiol Res: 164, 493-513. 
11. Cotter, P.D., Draper, L.A., Lawton, E.M., Daly, K.M., Groeger, D.S., Casey, P.G., Ross, R.P., 
and Hill, C. (2008) Listeriolysin S, a novel peptide haemolysin associated with a subset of lineage 
I Listeria monocytogenes. PLoS Pathog: 4, e1000144. 
12. Datta, V., Myskowski, S.M., Kwinn, L.A., Chiem, D.N., Varki, N., Kansal, R.G., Kotb, M., 
and Nizet, V. (2005) Mutational analysis of the group A Streptococcal operon encoding 
streptolysin S and its virulence role in invasive infection. Mol Microbiol: 56, 681-695. 
13. Dirix, G., Monsieurs, P., Marchal, K., Vanderleyden, J., and Michiels, J. (2004) Screening 
genomes of Gram-positive bacteria for double-glycine-motif-containing peptides. Microbiology: 
150, 1121-1126. 
14. Dunbar, K.L., Chekan, J.R., Cox, C.L., Burkhart, B.J., Nair, S.K., and Mitchell, D.A. (2014) 
Discovery of a new ATP-binding motif involved in peptidic azoline biosynthesis. Nat Chem Biol: 
10, 823-829. 
15. Dunbar, K.L., Melby, J.O., and Mitchell, D.A. (2012) YcaO domains use ATP to activate 
amide backbones during peptide cyclodehydrations. Nat Chem Biol: 8, 569-575. 
16. Dunbar, K.L., and Mitchell, D.A. (2013) Insights into the mechanism of peptide 
cyclodehydrations achieved through the chemoenzymatic generation of amide derivatives. J Am 
Chem Soc: 135, 8692-8701. 
17. Dunlap, C.A., Kim, S.J., Kwon, S.W., and Rooney, A.P. (2015) Phylogenomic analysis shows 
that Bacillus amyloliquefaciens subsp. plantarum is a later heterotypic synonym of Bacillus 
methylotrophicus. Int J Syst Evol Microbiol: 65, 2104-2109. 
18. Haft, D.H., Basu, M.K., and Mitchell, D.A. (2010) Expansion of ribosomally produced 
natural products: a nitrile hydratase- and Nif11-related precursor family. BMC Biol: 8, 70. 
19. Hardonk, M.J., and Van, D. (1964) The mechanism of the Schiff reaction as studied with 
histochemical model systems. J Histochem Cytochem: 12, 748-751. 
20. Horton, R.M., Cai, Z.L., Ho, S.N., and Pease, L.R. (1990) Gene splicing by overlap 
extension: tailor-made genes using the polymerase chain reaction. Biotechniques: 8, 528-535. 
21. Idriss, E.E., Makarewicz, O., Farouk, A., Rosner, K., Greiner, R., Bochow, H., Richter, T., and 
Borriss, R. (2002) Extracellular phytase activity of Bacillus amyloliquefaciens FZB45 contributes 
to its plant-growth-promoting effect. Microbiology: 148, 2097-2109. 
55 
22. Kelly, W.L., Pan, L., and Li, C. (2009) Thiostrepton biosynthesis: prototype for a new family 
of bacteriocins. J Am Chem Soc: 131, 4327-4334. 
23. Koumoutsi, A., Chen, X.H., Henne, A., Liesegang, H., Hitzeroth, G., Franke, P., Vater, J., and 
Borriss, R. (2004) Structural and functional characterization of gene clusters directing 
nonribosomal synthesis of bioactive cyclic lipopeptides in Bacillus amyloliquefaciens strain 
FZB42. J Bacteriol: 186, 1084-1096. 
24. Koumoutsi, A., Chen, X.H., Vater, J., and Borriss, R. (2007) DegU and YczE positively 
regulate the synthesis of bacillomycin D by Bacillus amyloliquefaciens strain FZB42. Appl 
Environ Microbiol: 73, 6953-6964. 
25. Kunst, F., and G. Rapoport. (1995) Salt stress is an environmental signal affecting degradative 
enzyme synthesis in Bacillus subtilis. J Bacteriol: 177, 2403–2407. 
26. Le Breton, Y., Mohapatra, N.P., and Haldenwang, W.G. (2006) In vivo random mutagenesis of 
Bacillus subtilis by use of TnYLB-1, a mariner-based transposon. Appl Environ Microbiol: 72, 
327-333. 
27. Lee, S.W., Mitchell, D.A., Markley, A.L., Hensler, M.E., Gonzalez, D., Wohlrab, A., 
Dorrestein, P.C., Nizet, V., and Dixon, J.E. (2008) Discovery of a widely distributed toxin 
biosynthetic gene cluster. Proc Natl Acad Sci U S A: 105, 5879-5884. 
28. Li, Y.M., Milne, J.C., Madison, L.L., Kolter, R., and Walsh, C.T. (1996) From peptide 
precursors to oxazole and thiazole-containing peptide antibiotics: microcin B17 synthase. 
Science: 274, 1188-1193. 
29. Liao, R., Duan, L., Lei, C., Pan, H., Ding, Y., Zhang, Q., Chen, D., Shen, B., Yu, Y., and Liu, 
W. (2009) Thiopeptide biosynthesis featuring ribosomally synthesized precursor peptides and 
conserved posttranslational modifications. Chem Biol: 16, 141-147. 
30. Mitchell, D.A., Lee, S.W., Pence, M.A., Markley, A.L., Limm, J.D., Nizet, V., and Dixon, J.E. 
(2009) Structural and functional dissection of the heterocyclic peptide cytotoxin streptolysin S. J 
Biol Chem: 284, 13004-13012. 
31. Morris, R.P., Leeds, J.A., Naegeli, H.U., Oberer, L., Memmert, K., Weber, E., LaMarche, 
M.J., Parker, C.N., Burrer, N., Esterow, S., et al. (2009) Ribosomally synthesized thiopeptide 
antibiotics targeting elongation factor Tu. J Am Chem Soc: 131, 5946-5955. 
32. Oman, T.J., and van der Donk, W.A. (2009) Insights into the mode of action of the two-
peptide lantibiotic haloduracin. ACS Chem Biol: 4, 865-874. 
  
56 
33. Pei, J., and Grishin, N.V. (2001) Type II CAAX prenyl endopeptidases belong to a novel 
superfamily of putative membrane-bound metalloproteases. Trends Biochem Sci: 26, 275-277. 
34. Rodriguez-Martinez, J.M., Briales, A., Velasco, C., Conejo, M.C., Martinez-Martinez, L., and 
Pascual, A. (2009) Mutational analysis of quinolone resistance in the plasmid-encoded 
pentapeptide repeat proteins QnrA, QnrB and QnrS. J Antimicrob Chemother: 63, 1128-1134. 
35. Roy, R.S., Gehring, A.M., Milne, J.C., Belshaw, P.J., and Walsh, C.T. (1999) Thiazole and 
oxazole peptides: biosynthesis and molecular machinery. Nat Prod Rep: 16, 249-263. 
36. Schägger, H., and von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem: 166, 
368-379. 
37. Schmidt, E.W., Nelson, J.T., Rasko, D.A., Sudek, S., Eisen, J.A., Haygood, M.G., and Ravel, 
J. (2005) Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, 
the cyanobacterial symbiont of Lissoclinum patella. Proc Natl Acad Sci U S A: 102, 7315-7320. 
38. Thompson, J.D., D.G. Higgins, and T.J. Gibson. (1994) CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence weighting, position-
specific gap penalties and weight matrix choice. Nucleic Acids Res: 22, 4673-4680. 
39. van Belkum, M.J., Worobo, R.W., and Stiles, M.E. (1997) Double-glycine-type leader 
peptides direct secretion of bacteriocins by ABC transporters: colicin V secretion in Lactococcus 
lactis. Mol Microbiol: 23, 1293-1301. 
40. Vater, J., Kablitz, B., Wilde, C., Franke, P., Mehta, N., and Cameotra, S.S. (2002) Matrix-
assisted laser desorption ionization-time of flight mass spectrometry of lipopeptide biosurfactants 
in whole cells and culture filtrates of Bacillus subtilis C-1 isolated from petroleum sludge. Appl 
Environ Microbiol: 68, 6210-6219. 
41. Vetting, M.W., Hegde, S.S., Fajardo, J.E., Fiser, A., Roderick, S.L., Takiff, H.E., and 
Blanchard, J.S. (2006) Pentapeptide repeat proteins. Biochemistry: 45, 1-10. 
42. Viklund, H., and Elofsson, A. (2008) OCTOPUS: improving topology prediction by two-track 
ANN-based preference scores and an extended topological grammar. Bioinformatics: 24, 1662-
1668. 
43. Wieland Brown, L.C., et al. (2009) Thirteen posttranslational modifications convert a 14-
residue peptide into the antibiotic thiocillin. Proc Natl Acad Sci U S A: 106, 2549-2553. 
 
 
57 
CHAPTER III: STRUCTURE DETERMINATION AND INTERCEPTION OF 
BIOSYNTHETIC INTERMEDIATES FOR THE PLANTAZOLICIN CLASS OF 
HIGHLY DISCRIMINATING ANTIBIOTICS 
 
This chapter was adapted with permission from Molohon, K.J., Melby, J.O., Lee, J., Evans, B.S., 
Dunbar, K.L., Bumpus, S.B., Kelleher, N.L., and Mitchell, D.A. (2011) ACS Chem Biol: 6, 1307-
1313. doi: 10.1021/cb200339d. Copyright © (2011) American Chemical Society. 
3.1 Abstract   
The soil dwelling, plant-growth promoting bacterium, Bacillus methylotrophicus FZB42, 
is a prolific producer of complex natural products.  Recently, a new FZB42 metabolite, 
plantazolicin (PZN), has been described as a member of the growing thiazole/oxazole-modified 
microcin (TOMM) family. TOMMs are biosynthesized from inactive, ribosomal peptides and 
undergo a series of cyclodehydrations, dehydrogenations, and other modifications to become 
bioactive natural products. Using high-resolution mass spectrometry, chemoselective 
modification, genetic interruptions, and other spectroscopic tools, we have determined the 
molecular structure of PZN. In addition to two conjugated polyazole moieties, the amino-
terminus of PZN has been modified to N
α
,N
α
-dimethylarginine. PZN exhibited a highly selective 
antibiotic activity towards Bacillus anthracis, but no other tested human pathogen. By altering 
oxygenation levels during fermentation, PZN analogs were produced that bear variability in their 
heterocycle content, which yielded insight into the order of biosynthetic events. Lastly, genome-
mining has revealed the existence of four additional PZN-like biosynthetic gene clusters. Given 
their structural uniqueness and intriguing antimicrobial specificity, the PZN class of antibiotics 
may hold pharmacological value.  
3.2 Introduction 
With facile access to low-cost next-generation DNA sequencing technology, there has 
been a recent surge in genome sequencing. The availability of nearly 2,000 microbial genomes 
has rekindled interest in the biosynthetic capabilities of bacteria (Challis, 2008; Gross, 2009; 
Melby et al., 2011; Peric-Concha and Long, 2003). Given the status of natural products and their 
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derivatives as the largest source of all medicines, exploring uncharted biosynthetic territory holds 
vast potential (Newman and Cragg, 2007). One such region of natural product space includes the 
thiazole/oxazole-modified microcin (TOMM) family (Haft et al., 2010; Lee et al., 2008; Scholz 
et al., 2011). Unlike the well-known non-ribosomal peptides and polyketides, TOMMs are 
derived from inactive, ribosomally synthesized precursor peptides. Each TOMM precursor 
peptide harbors an N-terminal leader region that serves as the binding site for enzymes that 
posttranslationally modify a C-terminal core region (Madison et al., 1997; Mitchell et al., 2009). 
The distinguishing chemical features of a TOMM are heterocycles that derive from Cys, Ser, and 
Thr residues, which are abundant in the core region of the precursor peptide. During processing 
by a genetically conserved cyclodehydratase, select Cys and Ser/Thr amino acids undergo peptide 
backbone cyclization to become thiazoline and (methyl)oxazoline heterocycles (Dunbar et al., 
2014; Dunbar et al., 2012; Dunbar and Mitchell, 2013). A subset of these are further subjected to 
a flavin mononucleotide (FMN)-dependent dehydrogenation, which yields the aromatic thiazole 
and (methyl)oxazole heterocycles. Together, the TOMM cyclodehydratase (CD) and 
dehydrogenase (B) comprise a functional, heterotrimeric thiazole/oxazole synthetase. The genes 
encoding for this synthetase are typically located as adjacent open reading frames in bacterial 
genomes, making such biosynthetic clusters relatively easy to identify using routine bioinformatic 
methods (Donia et al., 2008; Lee et al., 2008; Wieland Brown et al., 2009). TOMM biosynthetic 
clusters often contain ancillary tailoring enzymes that increase the chemical complexity of this 
natural product family. 
Although the unification of the TOMM family of natural products has only recently 
emerged, the molecular structure and biological function of some TOMMs have long been 
established. Examples include microcin B17 (DNA gyrase inhibitor), the cyanobactins 
(eukaryotic cytotoxins), streptolysin S (disease-promoting cytolysin), and the thiopeptides 
(ribosome inhibitors) (Melby et al., 2011). As reported in early 2011, a plant-growth promoting 
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bacterium, Bacillus methylotrophicus FZB42 [previously named Bacillus amyloliquefaciens 
FZB42 (Dunlap et al., 2015)], produces a TOMM with antimicrobial activity towards select 
Gram-positive bacteria (Scholz et al., 2011). In this work, we report the structure and 
antimicrobial specificity of a TOMM natural product from FZB42. In addition to the natural 
production of PZN variants by FZB42, we discovered that other Gram-positive bacteria also 
contain PZN biosynthetic clusters. We further demonstrate the in vivo biosynthesis of PZN in one 
of these newly identified producers.  
3.3 Results 
3.3.1 High resolution mass spectrometry of PZN 
Very recently, the structure of PZN from FZB42 was reported by Süssmuth and co-
workers, primarily using 2D-NMR (Kalyon et al., 2011). Independently, we employed mass 
spectrometry (MS) as our principle spectroscopic tool and arrived at the same structure. Through 
the use of high-resolution, linear ion trap Fourier Transform hybrid MS (LTQ-FT) operating at 11 
tesla, we measured the mass of the protonated form of PZN to be 1336.4783 Da (Figures. 3.1a 
and 3.2). Due to the high mass accuracy of FT-MS and the known sequence of the core region of 
the precursor peptide (1RCTCTTIISSSSTF14) (Lee et al., 2008; Scholz et al., 2011), the 
molecular formula of [PZN+H]
+
 can be deduced (C63H70N17O13S2; theoretical monoisotopic mass 
= 1336.4780 Da; error, 0.22 ppm). This formula required that 9 out of 10 heterocyclizable 
residues (Cys, Ser, Thr) in the core region of the precursor peptide were converted to the azole 
heterocycle (Figure 3.1a). Due to their adjacent positions, these processed residues form a 
contiguous polyazole, which was supported by spectrophotometric analysis. PZN gave absorption 
bands at 260 nm (λmax), 310 nm (minor shoulder), and 370 nm (weak), indicating the presence of 
a complex chromophore (Figure 3.3). The remaining heterocyclizable residue was left at the 
azoline (thiazoline, oxazoline, or methyloxazoline) oxidation state. Also, this formula required 
leader peptide cleavage after Ala-Ala and two methylation events, consistent with earlier deletion 
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studies (Scholz et al., 2011). Collision induced dissociation (CID) was then used to localize the 
site(s) of dimethylation and the azoline heterocycle. Analysis of the doubly charged PZN ion 
using in-line HPLC-FTMS resulted in a spectrum that was featureless from m/z ~700-1100 as a 
result of contiguous heterocycle formation (Figure 3.2). Nonetheless, we noted the production of 
several diagnostic fragment ions, including peptide bond cleavage at Ile-Ile. The masses of these 
resultant ions demonstrated that the N-terminal (b
+
 ion) fragment contained both posttranslational 
methyl groups and that the C-terminal (y
+
 ion) fragment contained the azoline (now restricted to 
oxazoline or methyloxazoline due to the absence of Cys on this fragment). Other informative 
fragment ions were derived from cleavage between Arg1-Cys2(thiazole) and 
Thr13(methyloxazoline)-Phe14. The former cleavage event demonstrated that both 
posttranslational methyl groups were localized to Arg1. Cleavage between Thr13-Phe14 led to 
the formation of several decomposition products that permitted the localization of the 
(methyl)oxazoline to Thr13. From the apparently unstable parent ion, we routinely observed 
formal loss of allene from methyloxazoline (C3H4, 40.0313 Da) to yield a C-terminal amide 
(Figure 3.2). Further support for the location of the azoline heterocycle comes from hydrolysis 
studies, as discussed below. Proposed structures for all assignable ions are given (Figures. 3.4 and 
3.5). 
3.3.2 Localization of the dimethylation site 
Upon in-depth FTMS analysis of singly charged PZN introduced by direct infusion, we 
observed larger ions relative to doubly charged PZN parent ions, including ones consistent with 
the loss of guanidine (-59.0483 Da, m/z 1277.4299; error, 0.63 ppm) (Figure 3.1b). This indicated 
that the site of dimethylation was restricted to either the N-terminal amine or the alkyl sidechain 
of Arg1. The latter is exceedingly improbable since the enzyme known to catalyze this reaction 
(PznL) is predicted by sequence alignment to be a S-adenosylmethionine (SAM)-dependent 
methyltransferase. The only SAM-dependent enzymes capable of engaging in C-H bond 
61 
activation are the radical SAM enzymes, which are identifiable by numerous conserved Cys 
lacking in PznL (Frey et al., 2008; Lee et al., 2008; Scholz et al., 2011). Higher order CID was 
performed on the deguanidinated form of PZN (m/z 1277), providing corroborating evidence for 
N-terminal dimethylation (Figure 3.6). Further support for the N-terminus being the site of 
dimethylation in PZN comes from chemoselective labeling. We reacted HPLC-purified PZN and 
desmethylPZN (from the pznL deletion strain) with the amine-specific reagent, N-
hydroxysuccinimide (NHS)-biotin (Scholz et al., 2011). As observed by MALDI-MS, labeling 
was only successful in the desmethylPZN reaction, indicating the presence of a free amine in this 
compound, but not in PZN (Figure 3.7). From these studies, we conclude that leader peptide 
cleavage occurs before methylation and that the ABC transport system does not distinguish 
between PZN and desmethylPZN. The nucleophilic N-terminus of desmethylPZN will likely be a 
convenient derivatization point for future structure-activity relationship (SAR) studies.  
From the apparent hydrolysis of PZN following SDS-PAGE (Scholz et al., 2011), we 
were not surprised to find that PZN contained an azoline. Such heterocycles are prone to both 
acid- and base-catalyzed hydrolysis (Frump, 1971; Martin and Parcell, 1961). Mild acid treatment 
of PZN yields m/z 1354 (+18), which was shown by CID studies to be from the reconstitution of 
the Thr13 residue of the precursor peptide (Figure 3.1b). Higher order tandem MS experiments 
further confirmed the location of the PZN methyloxazoline moiety (Figures. 3.5 and 3.6). Since 
the Thr13(methyloxazoline) is the only heterocycle not processed by the dehydrogenase, PznB 
displays a high level of regiospecificity.. While our PZN structure is identical to that just 
published, note that Thr13 has been converted to a methyloxazoline, not a methyloxazolidine as 
reported (Kalyon et al., 2011).  
During our extensive MS analysis of PZN, we noticed that fragmentation of the 
methyloxazoline moiety gave rise to a characteristic mass loss. CID fragmentation of PZN 
yielded an intense daughter ion of m/z 1292.4519 (Figure 3.1b). The mass difference from the 
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PZN parent ion is 44.0261 Da, which is consistent with the neutral loss of acetaldehyde (C2H4O, 
exact mass = 44.0262). Loss of acetaldehyde is conceivable from cycloelimination of 
methyloxazoline to yield a nitrile ylide, which can re-cyclize to form an azirine. The microscopic 
reverse of this reaction pathway is well known in the chemical literature where azirines are 
reacted with aldehydes to form oxazolines via 1,3-dipolar cycloaddition (Frump, 1971; Giezenda 
et al., 1973; Sa and Kascheres, 1996). Importantly, the loss of acetaldehyde was observed only 
when methyloxazoline was present on the parent ion (compare Figure 3.1b-c and Figures. 3.4-
3.6). This observation could potentially be capitalized upon in future studies as a means of 
screening complex mixtures for the presence of azoline-bearing natural products. (Melby et al., 
2011) 
3.3.3 Nuclear magnetic resonance (NMR) of PZN 
To corroborate the proposed structure elucidated by MS, we performed a series of two-
dimensional NMR experiments including 
1
H-
1
H-gCOSY, 
1
H-
1
H-TOCSY, and 
1
H-
13
C-gHMBC on 
a 600 MHz instrument (Figures. 3.8-3.10). The results of these experiments are compiled in Table 
3.1. Briefly, the gCOSY and TOCSY spectra confirmed the following: i. Due to the absence of 
NH and CαH correlations, all Cys, Ser, and Thr must be heterocyclized. The NH and CαH 
correlations were readily visible for all internal residues with an intact amide bond (Ile, Ile, Phe). 
ii. The carbon framework of the Arg1, Ile7, Ile8, and Phe14 side chains were not modified and, 
iii. The sole azoline moiety of PZN occurs on a Thr. The 
1
H-
13
C-gHMBC spectrum further 
validated findings from the 
1
H-
1
H experiments, in addition to proving the methylation sites as 
N
α
,N
α
-dimethylArg (Figure 3.10). N-terminal methylation of ribosomally produced peptides in 
bacteria is an exceedingly rare posttranslational modification. While N-terminal dimethylation 
has been described on Ala (e.g. cypemycin) (Claesen and Bibb, 2010) N
α
,N
α
-dimethylArg appears 
to be a novel posttranslational modification (Garavelli, 2004). The structure of PZN provides yet 
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another example of the complex natural product repertoire of B. methylotrophicus FZB42 (Chen 
et al., 2007).  
3.3.4 Production of PZN analogs 
During the course of optimizing the production of PZN for detailed spectroscopic 
analysis, we noticed that the level of culture oxygenation had a substantial impact on the 
production of PZN and derivative metabolites. Under low oxygen fermentation, PZN (m/z 1336) 
was the majority species present after a non-lytic, cell surface extraction procedure, as 
demonstrated by the UV trace, total ion chromatogram (TIC), and the extracted ion 
chromatogram (EIC, Figure 3.11a-c). The product of methyloxazoline ring opening (i.e. 
hydrolyzed PZN, m/z 1354) was also monitored (Figure 3.11c-d). The m/z 1338 species that 
“coelutes” with 1336 at 19.9 min is actually the second isotope peak of m/z 1336 (Figure 3.12). 
Under oxygen saturated cultivation, UV and TIC monitoring revealed an additional, highly 
abundant species at 14.7 min (Figure 3.11a-b). MS analysis demonstrated this species was m/z 
1338, suggestive of a reduced PZN species (dihydroPZN) containing two azolines (Figures. 3.11d 
and 3.13). The earlier elution time on reverse-phase chromatography suggested that this species 
was more polar than PZN, which is consistent with the replacement of an aromatic azole with a 
protonated azoline (expected in 0.1% formic acid). After treatment of m/z 1338 with mild 
aqueous acid, two additions of water were observed (m/z 1356 and 1374). Tandem MS was then 
used to demonstrate that the second azoline was located on the N-terminal half of PZN (Figure 
3.14). Higher order CID analysis prompted the neutral loss of acetaldehyde, indicating the 
heterocycle was derived from Thr, likely the residue directly preceding Ile (Thr6, data not 
shown). To an approximation, this position is sterically and electronically equivalent to the 
previously discussed methyloxazoline (Thr13) since both lie between an N-terminal tetra-azole 
and a C-terminal unmodified, hydrophobic residue (Figure 3.1a). The corresponding 
desmethylPZN species was observed when oxygenation levels were increased during cultivation 
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of the methyltransferase deletion strain (Figures. 3.15 and 3.16). It is possible that azoline 
oxidation is the rate-determining step in PZN biosynthesis. With increased aeration (faster 
metabolism), partially processed PZN products may be more rapidly produced and accepted as 
substrates by proteins acting downstream of the dehydrogenase. The biosynthetic implication of 
observing PZN oxidation intermediates is that the rate of methyloxazoline oxidation at “Thr6” 
(putative) and Thr13 (Figure 3.1a) must be slower than the dissociation rate from the 
heterotrimeric synthetase complex and subsequent maturation steps. An additional ramification of 
intercepting this PZN oxidation intermediate is that cyclodehydration must precede 
dehydrogenation, as has been previously supported by in vitro reconstitution experiments but 
never before demonstrated in vivo (McIntosh and Schmidt, 2010; Milne et al., 1999). While the 
oxygen-dependency of secondary metabolism is well known (Clark et al., 1995), the precise 
mechanism accounting for the production of a more reduced PZN species during increased 
culture aeration is not clear at the present time. 
3.3.5 Bioactivity of PZN and PZN analogs 
In early 2011, the activity of PZN towards 16 distinct bacterial species (18 strains) was 
reported (Scholz et al., 2011). It was determined that PZN was growth-suppressive primarily 
towards Bacillus sp., including B. subtilis. PZN exhibited no activity against any tested Gram-
negative organisms. To further define the selectivity within the Gram-positives, we evaluated the 
scope of PZN activity towards a panel of ubiquitous human pathogens, including methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), 
Listeria monocytogenes, Streptococcus pyogenes, and Bacillus anthracis strain Sterne. Using a 
microbroth dilution bioassay, we observed potent growth inhibition of B. anthracis (Figure 
3.17a). All other species were unaffected by PZN, with the exception of S. pyogenes, which was 
only inhibited by very high concentrations of PZN. The specificity for PZN against B. anthracis 
was recapitulated in an agar diffusion bioassay (Figure 3.17a), as inhibition zones were not 
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observed for any other tested bacterium (data not shown). The action of PZN upon B. anthracis 
was decidedly bactericidal, as reculturing of treated cells in the absence of PZN led to no 
bacterial growth. Live cell imaging by differential interference contrast (DIC) microscopy 
revealed that B. anthracis treated with PZN at 4 µg mL
-1
 underwent massive lysis, as evidenced 
by an abundance of cellular debris (data not shown). Of the few remaining non-lysed cells, we 
observed marked changes in the appearance of the cell surface (Figure 3.17c-d). While the 
biological target of PZN has yet to be established, the “sidewall spot” phenotype suggests PZN 
has either directly or indirectly compromised the integrity of the cell wall (Tiyanont et al., 2006). 
Due to the selective, biomedically relevant bactericidal activity exhibited by PZN, elucidation of 
the precise mode of action for PZN is ongoing in our laboratory. 
Dimethylation of the α-amino group was apparently critical for PZN’s antibiotic activity, 
as desmethylPZN was devoid of activity against B. anthracis in both bioassays (Figure 3.17a). 
While the molecular basis for this effect is not currently known, dimethylation increases amine 
basicity, increases lipophilicity, and removes two potential H-bond donors. Also tested were the 
effects of hydrolyzing the methyloxazoline moiety of PZN (hydrolyzed PZN, m/z 1354) and the 
variant with two azolines (dihydroPZN, m/z 1338). While hydrolyzed PZN retained measurable 
activity towards B. anthracis, dihydroPZN was devoid of activity. Due to difficulty in separating 
dihydroPZN from the mono- and dihydrolyzed forms (m/z 1356 and 1374), these bioassays were 
performed using a 1:2:2 mixture (non:mono:di). The lack of activity with this mixture of 
hydrolyzed, dihydroPZN compounds might be attributable to the fact that hydrolyzed PZN is 
roughly 8-fold less active than PZN (Figure 3.17a). Although the production of dihydroPZN 
under oxygen-saturated conditions may be artifactual, it nonetheless raises interesting questions 
regarding the regiospecificity of azoline oxidation and the substrate tolerance of the downstream 
tailoring enzymes and export apparatus. 
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3.3.6 Identification of PZN-like gene clusters across phyla 
A targeted bioinformatics survey using the thiazole/oxazole synthetase proteins 
(cyclodehydratase and dehydrogenase) of PZN yielded four highly related biosynthetic gene 
clusters (Figure 3.18). The cluster found in Bacillus pumilus ATCC 7061 (also a plant-growth 
promoting saprophyte) is of identical gene order and direction as the cluster from B. 
methylotrophicus FZB42 (Scholz et al., 2011). The remaining three PZN-like biosynthetic 
clusters were found in the Actinobacteria phylum including Clavibacter michiganensis subsp. 
sepedonicus (potato pathogen) (Bentley et al., 2008), Corynebacterium urealyticum DSM 7109 
(human skin-associated bacterium, causative agent of some urinary tract infections) and 
Brevibacterium linens BL2 (human skin-associated bacterium). The PZN clusters from C. 
urealyticum and B. linens have amino acid similarity values much higher with each other than the 
other PZN producers, which is interesting given their overlapping niche and the absence of 
TOMM genes in sequenced relatives (Figure 3.19). In each of the five species, the PZN 
biosynthetic cluster contained the canonical TOMM genes: a precursor peptide, dehydrogenase, 
and cyclodehydratase complex. Beyond this, all five clusters also include a putative membrane-
spanning leader peptidase from the type II CAAX superfamily (Pei et al., 2011), SAM-dependent 
methyltransferase, and a required protein of unknown function (Scholz et al., 2011). Conversely, 
homologs of the PznF immunity protein and PznGH transporters were not found in the local 
genomic context for the PZN biosynthetic gene clusters for C. urealyticum and B. linens (Figure 
3.18a). This suggests a distinct mechanism of immunity and chromosomally distant transporters 
for these PZN variants. Alternatively, the PZNs from C. urealyticum and B. linens could act 
intracellularly or the biosynthetic gene cluster might always be silent (non-product forming).  
Based on the identical amino acid sequence of the core regions of the precursor peptides 
from FZB42 and B. pumilus, it would be expected that these species produce identical compounds 
(Figure 3.18b). To test if B. pumilus was indeed producing PZN, stationary phase B. pumilus 
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ATCC 7061 cultures were cell surface extracted in an identical manner as with FZB42. MALDI-
TOF-MS of HPLC-purified fractions revealed the presence of m/z 1336, and in an earlier fraction, 
m/z 1354 (+H2O), supporting the production of PZN and hydrolyzed PZN (Figure 3.20a-b). The 
identity of this species as PZN was confirmed by high accuracy mass measurement (LTQ-FT-
MS) and CID analysis (Figure 3.20c-e). As anticipated, B. amylo. FZB42 and B. pumilus were not 
susceptible to the action of PZN (MIC > 128 µg mL
-1
). A non-plant associated strain of B. amylo. 
(NRRL B-14393), which does not produce PZN, was also completely resistant (data not shown). 
Resistance within the Bacillus genus to PZN is clearly complex, with a few strains being bona 
fide PZN producers and others simply harboring the immunity gene [e.g. B. amylo. strains YAU-
Y2 and NAU-B3 (Scholz et al., 2011) and B. atrophaeus 1942, BATR1942_01200, 94% identical 
to FZB42]. Early attempts to isolate a PZN-type natural product from the Actinobacteria family 
members have not yet been successful. The lack of a signal by MALDI-MS and reverse 
transcriptase-PCR suggested that the biosynthetic genes were not transcribed under our 
cultivation conditions (data not shown). As with many “silent” gene clusters, highly precise 
environmental conditions are often necessary for the bacterium to produce particular natural 
products.  
With several PZN-like biosynthetic gene clusters identified in this work, these natural 
products comprise an entirely new class of antibiotic.  Sequence alignment of all five PZN 
precursor peptides showed that there has been evolutionary pressure to maintain a nearly 
invariant chemotype giving rise to the PZN structure (from N- to C-terminus): leader peptide 
cleavage site and N-terminal Arg (FEPxAA*R), five cyclizable residues with position 2 and 4 
always Cys and position 6 always Thr, two hydrophobic residues, five cyclizable residues, and a 
more variable C-terminus that ends with Phe, Trp-Gly, or Gly-Gly (Figure 3.18b). It is probable 
that more PZN producers will emerge with on-going efforts in genome sequencing. Future work 
will establish the contribution of these conserved functionalities on the bioactivity of PZN.  
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3.4 Summary and Outlook 
Here we have reported on the structural uniqueness of PZN, production of oxygen-
dependent derivatives, distribution of producing species, and a striking human pathogen 
selectivity for Bacillus anthracis. Elucidation of the structure, in conjunction with the interception 
of dehydrogenase and methyltransferase intermediates, has provided a glimpse into the 
biosynthetic strategy employed by nature (Figure 3.21). With respect to the bioactivity of PZN, it 
is noteworthy that strains of B. anthracis have been reported to be increasingly resistant to the 
quinolone, beta-lactam, tetracycline, and macrolide classes of antibiotics, thus new strategies to 
overcome this NIAID-designated Category A priority pathogen are needed (Athamna et al., 2004; 
Bryskier, 2002). With improved diagnostic technology, we anticipate that highly discriminating 
antibiotics will play a large role in our future antibiotic repertoire. The ideal drugs will be capable 
of distinguishing between pathogenic bacteria and those that live in commensal and/or symbiotic 
relationships with humans. Selection theory predicts that such drugs will delay the rise of 
antibiotic resistance, as non-targeted species have no evolutionary benefit to develop/obtain a 
resistance mechanism. Faced with the never-ending arms race with multiple drug resistant 
bacteria, novel structural classes of antimicrobials with unique modes of action must continually 
be discovered and clinically implemented to treat bacterial infections. However, more work is 
necessary to determine if PZN-like compounds exhibit desirable in vivo properties. 
3.5 Experimental 
3.5.1 Production and purification of PZN 
Overnight cultures (4 x 20 mL) of B. methylotrophicus FZB42 strain RSpMarA2 (sfp, 
yczE, degU) (Scholz et al., 2011) were used to inoculate 4 x 6 L flasks with 2 L of Luria Burtani 
(LB) broth supplemented with chloramphenicol (7 µg mL
-1
) and kanamycin (7 µg mL
-1
). Cultures 
were grown with shaking for 48 h at 37 °C. Cells were harvested by centrifugation (4,000 x g), 
washed with Tris-buffered saline (pH 8.0), and harvested a second time. Crude PZN was obtained 
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by a non-lytic, methanolic extraction of the cellular surface. Cells were resuspended in MeOH 
(10% culture volume) and anhydrous Na2SO4 (5 g/L culture). The cell mixture was agitated by 
vortex (45 s) and equilibrated for 15 min at 22 °C. The supernatant was retained after 
centrifugation (4,000 x g), vacuum filtered with Whatman filter paper, and rotary evaporated to 
dryness to yield about 100 mg/L of a yellowish-brown solid. This crude material was dissolved in 
80% aqueous MeCN (10 mL for 8 L culture), where the sample separated into two layers. The top 
organic layer was retained and concentrated for injection onto an Agilent 1200 series liquid 
chromatograph that was fitted inline to an Agilent 6100 Series Quadrupole LC/MS. For 
preparative purposes, PZN was reverse phase purified using a Thermo BETASIL C18 column 
(250 mm x 10 mm; pore size: 100 Å; particle size: 5 μm) at a flow rate of 4 mL min-1. A gradient 
of 65-85% MeOH with 0.1% formic acid over 32 min was used. The fractions containing PZN (as 
monitored by A266 and MS) were collected into 20 mL borosilicate vials and the solvent removed 
in vacuo. The isolated yield for PZN following this procedure was routinely 150-200 µg L
-1
 
culture. Mutant RS33 (Δsfp, bac, pznL) was prepared similarly, with the only exceptions being a 
24 h fermentation, substitution of spectinomycin (90 µg mL
-1
) for kanamycin, and elimination of 
the TBS wash.  
3.5.2 Production of PZN (elevated oxygen) 
Increased aeration of B. methylotrophicus FZB42 strains RSpMarA2 and RS33 were 
achieved using a New Brunswick Scientific BioFlo 110 Fermenter system. RSpMarA2 and RS33 
(9 L) were cultured at 37 °C with 250 rpm stirring for 24 h. Air was supplied at 5 L/min 
(saturated in oxygen, ~1 L min
-1
).  
3.5.3 On-line RPLC-FTMS 
All reverse phase liquid chromatography (RPLC)-Fourier-transform mass spectrometry 
(FTMS) was conducted using an Agilent 1200 high performance LC (HPLC) system with an 
autosampler coupled directly to a ThermoFisher Scientific LTQ-FT hybrid linear ion trap-FTMS 
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system operating at 11 tesla.  The MS was calibrated weekly using the calibration mixture and 
instructions specified by the manufacturer.  All instrument parameters were tuned according to 
the manufacturer’s instructions (employing bovine ubiquitin for tuning purposes). For all analyses 
of PZN, a 1 mm x 150 mm Jupiter C18 column (Phenomenex, 300 Å, 5 µm) was connected in-
line with the electrospray ionization source (operated at ~5 kV with a capillary temperature of 
200-250 °C) for the MS system.  A typical sample was loaded onto the column using the 
autosampler and separated using a linear gradient of H2O/MeCN and 0.1% formic acid with the 
analytes eluted directly into the MS. All ionized species were subjected to an MS method with 
five MS and MS/MS events:  1) full scan measurement of all intact peptides (all ions detected in 
the FTMS in profile mode; resolution: 100,000; m/z range detected: 400-2000), 2-5) data-
dependent MS/MS on the first, second, third, and fourth most abundant ions from scan (1) using 
collision induced dissociation (CID) (all ions detected in the FTMS in profile mode; minimum 
target signal counts: 5,000; resolution: 50,000; m/z range detected:  dependent on target m/z, 
default charge state: 2, isolation width: 5 m/z, normalized collision energy: 35; activation q value: 
0.40; activation time: 30 ms).  During all analyses, dynamic exclusion was enabled with the 
following settings: repeat count – 2, repeat duration – 30 s, exclusion list size – 300, exclusion 
duration – 60 s.  
3.5.4 Direct infusion FTMS 
After lyophilization for at least 24 h, HPLC purified samples were dissolved in 80% 
MeOH (to ~0.5 mg mL
-1
) and then further diluted 10-fold into 50% MeOH supplemented with 
0.1% (v/v) formic acid. The diluted samples were directly infused using an Advion Nanomate 
100. The singly charged ions were targeted for CID using identical settings as above, except that 
the resolution was set to 100,000. 
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3.5.5 N-terminal labeling 
Purified PZN and desmethylPZN were dissolved in 80% MeCN, 10 mM MOPS (pH 8.0) 
to a final concentration of 1.5 mM. An aliquot (5 µL) was transferred to a microfuge tube 
containing 5 µL of 80% MeCN, 10 mM MOPS (pH 8.0) supplemented with 20 mM EZ-
Link
®
 sulfo-NHS-biotin. Control reactions lacked the NHS-biotin reagent. The samples were 
allowed to react for 3 h at 23 °C prior to analysis on an Applied Biosystems Voyager DE-STR 
MALDI-TOF-MS. 
3.5.6 NMR 
PZN was produced from low oxygenation cultures and purified as described in the main 
text methods. PZN (700 µg) was dissolved in 200 µL of DMSO-d6 and placed into an Advanced 
Shigemi 5 mm NMR tube matched to DMSO-d6. NMR experiments were conducted on a Varian 
Unity Inova 500 NB (
1
H-
1
H-gCOSY) and a Varian Unity Inova 600 spectrometer (
1
H, 
1
H-
1
H-
TOCSY and 
1
H-
13
C-gHMBC) using a 5 mm Varian 
1
H{
13
C/
15
N} PFG Z probe and 5 mm Varian 
1
H{
13
C/
15
N} XYZ PFG triple resonance probe, respectively. The 
1
H-NMR, TOCSY and gHMBC 
experiments were conducted at 25 °C and utilized water suppression. A mixing time of 150 ms 
was used for the TOCSY. For the gHMBC, 
1
J and 
n
J were set to 140 and 8 Hz, respectively. 
Chemical shifts were referenced using DMSO (δH=2.50 and δC=39.51), and the spectra were 
processed and analyzed using MestReC. Stereochemical configuration was assumed to be 
identical to the ribosomally produced precursor peptide. 
3.5.7 Determination of MIC 
B. anthracis strain Sterne was grown to stationary phase in a 10 mL LB culture at 37 °C. 
The culture was adjusted to OD600 of 0.01 in LB broth and added to 96-well plates. 2-fold 
dilutions of PZN (5 mg mL
-1
 in 80% MeCN) were added to the cultures (0.5 – 128 µg mL-1). 
Kanamycin was added similarly to control samples, with dilutions from 1 – 32 µg mL-1. Covered 
plates were incubated at 37 °C for 12 h. The minimum inhibitory concentration that suppressed 
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the growth of at least 99% of the bacteria (MIC99) was established based on culture turbidity. 
Additional pathogens were grown and prepared similarly as above, with the exception of 
optimizing the growth media to match an organism’s nutritional requirements (Streptococcus 
pyogenes, Todd Hewitt broth; Listeria monocytogenes, Enterococcus faecalis st. U503 [VRE], 
and Staphylococcus aureus st. NRS384/USA300 [MRSA], brain heart infusion). Positive 
controls: S. pyogenes and L. monocytogenes, kanamycin; E. faecalis, tetracycline; S. aureus, 
vancomycin. Bactericidal activity was determined by diluting 1 µL of B. anthracis strain Sterne 
grown with 8 µg mL
-1
 PZN into 99 µL of media. The sample was then streaked onto LB agar 
plates and incubated for 24 h for counting colony-forming units. 
3.5.8 Agar diffusion bioassay 
B. anthracis strain Sterne was grown as described previously and diluted to OD600 of 
0.13. The diluted culture (100 µL) was inoculated onto an LB plate and allowed to dry. HPLC-
purified PZN (50-200 µg) was added to a paper disk, dried, and added to the plate. Culture were 
then incubated at 37 °C for 12 h. Kanamycin (8-25 µg) was used as a positive control, and 80% 
MeCN was the negative (solvent) control.  
 3.5.9 Microscopy 
Differential interference contrast (DIC) microscopy images were obtained by preparing 
live cell images of B. anthracis cultures. Samples were pretreated with or without PZN at 4 µg 
mL
-1
 (MIC99) and morphology was assessed using a Zeiss LSM 700 microscope. The objective 
used was a Plan-Apochromat 63x/1.40 Oil DIC M27. The analysis software used was Program 
Zen 2009 Light Edition. 
3.5.10 Production of PZN from Bacillus pumilus ATCC 7061 
Cultures were prepared as described above, but with the exception no antibiotics were 
added. The method employed for metabolite extraction and HPLC purification were identical to 
samples from B. methylotrophicus. Purified fractions were analyzed on a Bruker Daltonics 
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ultrafleXtreme MALDI-TOF/TOF instrument operating in reflector/positive mode. Sinapic acid 
was used as the matrix. 
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3.7 Figures and Tables 
Figure 3.1 
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Figure 3.1 (continued)| Mass spectrometry-based structural elucidation of PZN. (a) After 
biosynthetic processing, the chemical structure of PZN features N
α
,N
α
-dimethylArg (green), two 
thiazoles (red), seven (methyl)oxazoles (blue), and one methyloxazoline (brown). The numbering 
scheme used for each original residue is given at the top of the figure. After treatment with mild 
acid, azolines undergo hydrolytic ring opening to the original amino acid (in this case, Thr). (b) 
CID spectrum of the singly charged PZN ion (m/z 1336) acquired by LTQ-FT-MS. (c) Same as 
(b) except the parental ion analyzed was hydrolyzed PZN (m/z 1354). *Denotes ions resulting 
from the loss of guanidine localize the site of dimethylation to the α-amine of Arg. Localization 
to Arg is further supported by loss of N
α
,N
α
-dimethylArg (m/z 1180). **Denotes ions indicating 
that the sole azoline moiety of PZN is derived from the most C-terminal Thr residue. All masses 
are given in Da and represent the singly-charged ion. For proposed structures of the daughter 
ions, see Fig 3.4 and 3.5. 
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Figure 3.2 | FTICR-MS of PZN (m/z 1336, broadband and CID spectrum of 2+ charge 
state). (a) Broadband spectrum of HPLC-purified PZN on a linear ion trap MS (11 Tesla LTQ-
FT). Visible are the singly and doubly charged positive ions of PZN. Due to the high mass 
accuracy of FT-MS (<5 ppm error) and the known sequence of the precursor peptide (Lee et al., 
2008; Scholz et al., 2011), the molecular formula of PZN was deduced from this mass 
measurement. This formula required that 9 out of the 10 heterocyclizable residues were converted 
to the azole heterocycle and the remaining residue was left at the azoline oxidation state. Also, 
this formula required two methylation events (consistent with earlier deletion studies) and leader 
peptide cleavage after Ala-Ala (see Figure 3.18b). (b) Collision induced dissociation (CID) 
spectrum of m/z 668.7 (PZN
2+
). The fragmentation pattern of PZN in the doubly charged state is 
markedly different than that of the singly charged species shown in Figure 3.1b of the main text. 
The amino acid sequence for the PZN precursor peptide from B. methylotrophicus FZB42 
(BamA) is color-coded by posttranslational modification as follows: N

,N

-dimethylarginine 
(green), thiazoles (red), methyloxazoles and oxazoles (blue), and methyloxazoline (brown). 
Identified fragment ions are also plotted onto the BamA precursor sequence. The most diagnostic 
peaks for localizing posttranslational modifications resulted from Ile-Ile cleavage (green and 
brown mass peaks). These ions demonstrate that both methylation events are on the N-terminal 
fragment and that the sole azoline moiety is on the C-terminal fragment. *Fragment ions with the 
azoline as the most C-terminal moiety spontaneously decompose, supporting the assignment of 
the C-terminal Thr as being converted to methyloxazoline in PZN (assigned in Figure 3.4).  
Under the CID conditions employed, most peptides will fragment at the amide bond. The first 
step in TOMM biosynthesis, cyclodehydration, removes an amide bond from the peptide 
backbone. **Contiguous heterocycles thus preclude the formation of a complete series of y
+
 and 
b
+
 ions and results in a CID spectrum that is featureless from m/z ~710-1100. One non-amide 
cleavage is noted between arginine and cysteine (highest mass ion in the spectrum), which 
permits the methyl groups to both be localized to arginine. ^Internal fragments (assigned in 
Figure 3.4).  
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Figure 3.3 | UV-Vis spectrum of HPLC-purified PZN in DMSO acquired on a Nanodrop 
2000. The instrument was blanked on DMSO, which has a UV cut-off of approximately 245 nm. 
The extinction coefficient for PZN in DMSO is 260 = 560 M
-1
cm
-1
. The max in 80% 
acetonitrile/water is 266 nm. 
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Figure 3.4 | Observed fragments during MS/MS of PZN (m/z 1336). Cleavage sites are shown 
with their corresponding theoretical monoisotopic fragment masses. Some of the observed 
fragments are derived from multiple bond cleavages, denoted by superscripts (these are not 
intended to suggest a pathway of fragmentation). In the lower part of the figure, structures with 
more complex fragmentation pathways are shown with their corresponding masses. The m/z 1277 
structure permits the localization of both methyl groups to the N-terminus of PZN. The m/z 1145 
structure results from the loss of the C-terminal Phe residue and CO. In conjunction with selective 
hydrolysis studies, m/z 1145 and the subsequent azoline decomposition ions (1117 and 1105) 
localize the sole azoline as the C-terminal Thr residue. Further, we note many examples of neutral 
loss of acetaldehyde (C2H4O, exact mass = 44.0262; not to be confused with loss of CO2, exact 
mass = 43.9898; >800 ppm difference). See the main text for an explanation of the formation of 
these ions. 
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Figure 3.5 | Observed fragments during MS/MS of hydrolyzed PZN (m/z 1354). Unlike their 
aromatic azole counterparts, azoline heterocycles are hydrolytically unstable in mild acid and 
mild base (Frump, 1971). Selective acidic hydrolysis of PZN was performed to convert the sole 
azoline heterocycle back to the original amino acid. This reinstates an amide bond that can be 
located by subsequent MS
n
 analysis. Observed cleavage sites are shown with their corresponding 
theoretical monoisotopic fragment masses. Some of the observed fragments are derived from 
multiple bond cleavages, denoted by superscripts (these are not intended to suggest multiple 
fragmentation events or a pathway of fragmentation). Note that upon methyloxazoline hydrolysis 
to threonine, in no cases can neutral loss of acetaldehyde be found. This implies that loss of 
acetaldehyde (formation of azirine) is specific to methyloxazolines under the CID conditions we 
employed. Note that loss of C2H4O is possible from hydrolyzed (Thr-containing) PZN, but only 
via dehydration and subsequent loss of acetylene. Other fragment ions of interest in this map 
confirm the site of dimethylation to be the N-terminal amine. 
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Figure 3.6 | CID spectra for deguanidinated PZN (m/z 1277) and deguanidinated hydrolyzed 
PZN (m/z 1295). MS
3
 collision induced dissociation (CID) spectra for (a) deguanidinated PZN 
(m/z 1277) and (b) deguanidinated hydrolyzed PZN (m/z 1295). **Indicates loss of acetaldehyde 
(44.0262 Da) from methyloxazoline (1277 – 44 = 1233; 1194 – 44 = 1150). Note that this is only 
possible in (a) where an intact heterocycle is found. The ions at m/z 575, 1150, and 1194 
demonstrate that the Arg was dimethylated on the amino terminus. Structural assignments are 
given for the fragments of deguanidinated PZN and deguanidinated hydrolyzed PZN in Figure 3.4 
and 3.5, respectively. 
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Figure 3.7 | N-terminal labeling of PZN and desmethylPZN using NHS-biotin. MALDI-TOF-
MS results of NHS-biotin labeling for (a) PZN (m/z 1336) and hydrolyzed PZN (m/z 1354) and 
(b) desmethylPZN (m/z 1308) and hydrolyzed desmethylPZN (m/z 1326). Abbreviation: 
desmethylPZN, dmPZN. Red traces are samples that included the NHS-biotin reagent while black 
traces are from control reactions that lacked NHS-biotin. Labeling was only observed with 
desmethylPZN, as indicated by the new species at m/z 1534 and 1552. Addition of biotin gives a 
net mass increase of 226 Da (C10H14N2O2S). Specific labeling reactions are given in the methods 
section. 
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Table 3.1 | Complilation of NMR results. Abbreviations: Tz, thiazole; Oz, oxazole; Ozn, 
oxazoline 
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Figure 3.8 | 
1
H-
1
H-gCOSY of PZN. Assigned correlations are drawn on the structure of PZN as 
thickened bonds. The brown circles indicate correlations deriving from the methyloxazoline 
protons (shown as brown bonds in structure). The red asterisk indicates that in the 1D-
1
H-
spectrum, the signal from water was suppressed. This signal was not suppressed for the 2D 
experiment.  
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Figure 3.9 | 
1
H-
1
H-TOCSY of PZN. Assigned correlations are drawn on the structure of PZN as 
thickened bonds. The brown circles indicate correlations deriving from the methyloxazoline 
protons (shown as brown bonds in structure). The red asterisks on the 1D spectra indicate the 
signal from water suppression. This signal was also suppressed for the 2D experiment.  
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Figure 3.10 | 
1
H-
13
C-gHMBC of PZN. Assigned correlations are drawn on the structure of PZN 
as red arrows. The green arrows/circles indicate correlations that localize the posttranslational 
methyl groups to the N-terminus. The brown arrows/circles indicate correlations that demonstrate 
the azoline is methyloxazoline. 
  
 
8
6
 
 
 
Figure 3.11 | Effect of fermentation oxygenation on PZN production. High and low oxygenation cultures were extracted and subjected to 
chromatography using an identical procedure. In all panels, vertical lines were drawn at 14.7, 19.9, and 20.5 min. (a) UV chromatogram (Abs 
266 nm) of FZB42 strain RSpMarA2 extract from high and low oxygen fermentation. (b) Same as (a) except the trace is the total ion 
chromatogram (TIC). (c) Extracted ion chromatogram (EIC) of m/z 1336, 1338, and 1354 from a low oxygen fermentation. (d) Same as C 
except under high oxygenation conditions.  
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Figure 3.12 | Predicted isotope pattern for PZN (m/z 1336). Note that the average mass is 
slightly heavier than the first isotope mass. This figure was generated using iMass version 1.1 
(freeware written by Urs Roethlisberger). 
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Figure 3.13 
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Figure 3.13 (continued) | Effect of oxygen levels during fermentation on the production of 
PZN. ESI-MS at selected time points from LCMS analysis (UV, TIC, EIC) shown in Figure 3.11. 
(a) Under low oxygen conditions, PZN (m/z 1336) is the only species present in the 19.9 min 
elution. (b) Under an oxygen saturated fermentation, PZN is found in the 20.5 min elution. (c) As 
expected from the EIC’s shown in Figure 3.11, high oxygen fermentation yields an additional 
compound eluting at 14.7 min consistent with dihydroPZN (dhPZN, m/z 1338). The earlier 
elution of dhPZN relative to PZN is in agreement with azolines being more hydrophilic and basic 
than azoles (azoles are not protonated with 0.1% formic acid). Right insets for all panels show a 
zoomed in spectrum to highlight the isotopic pattern of the singly charged PZN species.  
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Figure 3.14 | Partial localization of the second azoline in dihydroPZN (dhPZN). (a) CID 
spectrum of dhPZN (m/z 1338) acquired using LTQ-FT-MS. The heavier fragment ions are 
identical to those shown in Figure 3.1, with the exception of each fragment being 2 Da heavier. 
The gray box depicts a zoomed in region shown in (b). Brown boxes highlight two ions 
demonstrating that an azoline heterocycle exists on each side of the Ile-Ile. The location of the C-
terminal azoline was localized to the most C-terminal Thr. The location of the N-terminal azoline 
is likely to be the Thr adjacent to Ile due to similar sterics/electronics. However, the precise 
position cannot be concluded from this spectrum. (b) Zoomed in region from (a) (gray box). 
Diagnostic ions are boxed in gray and their respective (predicted) structures drawn in the right 
margin.  
  
 91 
 
 
Figure 3.15 | Effect of oxygen levels during fermentation on the production of 
desmethylPZN. In each case presented, the low oxygen samples were prepared by shake flask 
fermentation of B. methylotrophicus strain RS33 (pznL deletion, desmethylPZN producer) in 2 L 
of LB in 6 L flasks. High oxygen samples were prepared using a biofermentor with 5 L/min air 
input. Both cultures were grown for 24 h at 37 °C. All samples were extracted in an identical 
fashion and subjected to identical chromatographic procedures (analytical C18-HPLC) as 
described in the methods. In all panels, vertical lines are drawn at 14, 17, and 21 min. (a) UV 
chromatogram (Abs 272 nm) of RS33 extract from high and low oxygen fermentation. This trace 
shows that more chromophores absorbing light at 272 nm are produced under high oxygen 
conditions. (b) Same as (a) except the trace is the total ion chromatogram (TIC). (c) Extracted ion 
chromatogram (EIC) of m/z 1308, 1310, and 1326 from low oxygen fermentation. Under these 
conditions, the majority species is desmethylPZN (1308) with trace amounts of hydrolyzed 
desmethylPZN (1326). The 1310 trace that appears to “coelute” with 1308 at 17 min is the 
actually the second isotope peak of 1308, not dihydrodesmethylPZN (see Figure 3.12). (d) Same 
as C except under high oxygenation conditions. The peaks at 14 and 16 min contain primarily 
dihydrodesmethylPZN (m/z 1310) while the peaks at 17 and 21 min contain primarily 
desmethylPZN (m/z 1308). The species eluting at 14 and 16 min are suspected to be regioisomers, 
as are the species eluting at 17 and 21 min. ESI-MS at these selected time points are shown in 
Figure 3.16. 
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Figure 3.16 | Effect of oxygen levels during fermentation on the production of 
desmethylPZN. ESI-MS at selected time points from LCMS analysis (UV, TIC, EIC) shown in 
Figure 3.15. (a) Under low oxygen conditions, hydrolyzed desmethylPZN (m/z 1326) is visible in 
the 14 min elution. (b) As expected from the EIC’s shown in Figure 3.15, the 14 min elution is 
dominated by dihydrodesmethylPZN (m/z 1310) at the 14 min elution. (c) Low oxygen 
fermentation and an elution of 17 min yields exclusively desmethylPZN (m/z 1308). As indicated 
by the ion purity and signal to noise ratio in this spectrum, relative to the other panels, 
desmethylPZN was a majority product and easily separated under the conditions employed. (d) 
Same as C but high oxygen conditions led to the production of a mixture of desmethylPZN and 
dihydrodesmethylPZN (ratio ~60:40, respectively). (e) At 16 min under high oxygen conditions, 
1310 is the majority species produced, consistent with azolines being more hydrophilic than 
azoles. Right insets for panels c-e show a zoomed in spectrum to highlight the isotopic pattern of 
the singly charged desmethylPZN species. The ratio of intensities given in Figure 3.12 applies.  
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Figure 3.17 | Assessment of PZN antibiotic activity. (a) The minimum inhibitory concentration 
(MIC) of HPLC-purified PZN was measured against a panel of Gram-positive human pathogens. 
Values reported were the concentration of PZN that inhibited 99% of the bacteria growth in a 
microbroth dilution bioassay. *Due to separation difficulties, dihydroPZN was supplied as a 1:2:2 
mixture of non-, mono-, and dihydrolyzed species (m/z 1338, 1356, 1374). (b) PZN activity in an 
agar disk diffusion bioassay against B. anthracis Sterne. Upper left disk, 8 µg kanamycin control 
(positive); upper right, solvent control (negative); lower disk, 100 µg PZN (200 µg gave a similar 
inhibition diameter). (c) Visual appearance of live B. anthracis Sterne treated with a solvent 
control by DIC microscopy. (d) Same as (c) except cells were treated with 4 µg mL
-1
 PZN. Scale 
bar is the same for panel c.  
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Figure 3.18 | PZN biosynthetic gene clusters. (a) Open-reading frame diagram showing the 
genetic organization of PZN clusters, which form a subclass of TOMMs. Gene designations and 
predicted functions are color coded in the provided legend. (b) PZN precursor peptide alignment. 
Shown in purple are conserved residues within the N-terminal leader region. *Denotes the leader 
peptide cleavage site, which is known for BamA and BpumA but predicted for the others. Color-
coding indicates the posttranslational modifications of the BamA core region, which are 
extrapolated to the remaining precursor peptides: N
α
,N
α
-dimethylarginine (green), thiazoles (red), 
(methyl)oxazoles (blue), and methyloxazoline (brown). Abbrev.: Bam, Bacillus methylotrophicus 
FZB42; Bpum, Bacillus pumilus ATCC 7061; Cms, Clavibacter michiganensis subsp. 
sepedonicus; Cur, Corynebacterium urealyticum DSM 7109; Blin, Brevibacterium linens BL2.
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Figure 3.19 | Similarity/identity matrix of related (PZN-producing) biosynthetic proteins. 
Shown in yellow are amino acid identity scores obtained by pairwise alignment using ClustalW2, 
which includes the standard parameters for gap penalties. In blue are the corresponding amino 
acid percent similarity values, obtained by recording the ratio of similar amino acids to the full 
protein sequence after alignment (no gap penalties). PznJ, required biosynthetic protein of 
unknown function; PznCD, cyclodehydratase; PznB, FMN-dependent dehydrogenase; PznE, 
suspected leader peptidase; PznL, SAM-dependent methyltransferase. Abbreviations used are 
derived from the genus and species name for each organism. Bam, Bacillus methylotrophicus 
FZB42; Bpum, Bacillus pumilus ATCC 7061; Cms, Clavibacter michiganensis subsp. 
sepedonicus; Cur, Corynebacterium urealyticum DSM 7109; Blin, Brevibacterium linens BL2. 
Bam and Bpum are Firmicutes, while the other three species are Actinobacteria.
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Figure 3.20 (continued) | Demonstration of PZN production from Bacillus pumilus ATCC 
7061. Cells were grown in an identical fashion to B. methylotrophicus. (a) The cell surface 
metabolites were extracted with methanol, dried, concentrated, and separated on a preparative 
C18-HPLC column with UV monitoring at 266 nm (λmax for PZN). (b) The 22-min (top), 23-min 
(middle), and 24-min (bottom) fractions from HPLC purification were concentrated and spotted 
on to the MALDI target with sinapic acid. In the earliest fraction, m/z 1354 (hydrolyzed PZN is 
visible). In the latter two fractions, m/z 1336 (PZN) is readily identified, which was pooled for 
further analysis. (c) HPLC purified PZN from B. pumilus was subjected to high-resolution MS 
(LTQ-FT-MS), which verified the molecular formula to be consistent with PZN within the mass 
accuracy of the instrument (<5 ppm). (d) CID spectrum obtained upon isolation of the singly 
charged (m/z 1336) precursor ion. This data is analogous to Figure 3.1b (PZN from B. amylo. 
RSpMarA2). Figure 3.1b. (e) CID spectrum obtained upon isolation of the doubly charged (m/z 
668) precursor ion. This data is analogous to Figure 3.2b (PZN from B. amylo. RSpMarA2). 
However, different instrumental settings had to be employed to visualize the PZN ions, which 
were less abundant than from the B. amylo. overproducer (RSpMarA2) and required summing 
over many scans. An unidentified contaminant and instrumental noise account for the ions 
between m/z 750-1100.  
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Figure 3.21 | Plantazolicin (PZN) constitutes an entirely new class of highly discriminating 
antibiotic. PZN produced by Bacillus methylotrophicus FZB42 is biosynthesized from a 12 open 
reading frame biosynthetic gene cluster, which encodes a 41 amino acid precursor peptide and all 
necessary maturation machinery. One remarkable feature of PZN is the extensive incorporation of 
thiazole and (methyl)oxazol(in)e heterocycles, which are installed by PznBCD. The final 
processing steps are likely carried out by PznE (leader peptide cleavage) followed by PznL-
dependent dimethylation of the newly formed α-amine group of arginine. 
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For this chapter, I established the PZN bioactivity (Figures 4.2, 4.3, and Tables 4.1, 4.4, 4.13), 
performed the radioactivity work (Figure 4.7), RNA experiments and analysis (Figures 4.8, 4.9, 
Tables 4.5, 4.9, 4.6, and 4.12) (Rockhopper was run by J. Doroghazi), growth curve analysis 
(Figure 4.10A), isobolograms (Figures 4.11A and 4.18A) generated spontaneous mutants and 
assembled bacterial genomes (Figure 4.16 and Table 4.14), performed endospore studies (Table 
4.2), γ phage sensitivity (Table 4.3), and qualitative reverse transcriptase PCR (qRT-PCR, Table 
4.16). 
4.1 Abstract 
Plantazolicin (PZN) is a ribosomally synthesized and post-translationally modified 
natural product from Bacillus methylotrophicus FZB42 and Bacillus pumilus. Extensive tailoring 
to twelve of the fourteen amino acid residues in the mature natural product endows PZN with not 
only a rigid, polyheterocyclic structure, but also antibacterial activity. Here we report on the 
remarkably discriminatory activity of PZN toward Bacillus anthracis, which rivals a previously-
described B. anthracis-specific gamma (γ) phage lysis assay in distinguishing B. anthracis from 
other members of the Bacillus cereus group. We evaluate the underlying cause of this selective 
activity by measuring the RNA expression profile of PZN-treated B. anthracis, which, among 
other clues, revealed significant upregulation of genes within the cell envelope stress response. 
PZN depolarizes the B. anthracis membrane like other cell envelope-acting compounds but 
uniquely localizes to distinct ~200 nm wide foci within the envelope. Selection and whole-
genome sequencing of PZN-resistant mutants of B. anthracis implicate a relationship between the 
action of PZN and cardiolipin (CL) within the membrane. Exogenous CL increases the potency of 
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PZN in wild type B. anthracis and promotes the incorporation of fluorescently tagged PZN in the 
cell envelope. We propose that PZN localizes to and exacerbates structurally compromised 
regions of the bacterial membrane, which ultimately results in cell lysis.  
4.2 Introduction 
The current practice of employing broad-spectrum antibiotics to treat bacterial infections 
contributes to the rise of antibiotic resistance (de Man et al., 2000). As a countermeasure, species-
selective and narrow-spectrum antibacterial compounds are garnering increased attention in the 
medical community for their potential as therapeutics and diagnostics (Payne, 2008; Wilson et al., 
2005). Plantazolicin (PZN) is a polyheterocyclic, linear compound of the ribosomally synthesized 
and post-translationally modified peptide (RiPP) natural product family with narrow-spectrum 
antibiotic activity (Figure 4.1) (Scholz et al., 2011). More specifically, PZN is a member of the 
thiazole/oxazole-modified microcins (TOMMs), a recently grouped and rapidly expanding RiPP 
class with ~1,500 identified gene clusters (Arnison et al., 2013; Cox et al., 2015). Previously, 
PZN was described as an antibiotic compound that inhibits Gram-positive organisms closely 
related to its producing organism, Bacillus methylotrophicus FZB42 (Scholz et al., 2011). In 
2011, by screening a small panel of microorganisms, we described PZN as having potent activity 
towards Bacillus anthracis, but not other Gram-positive pathogens (Molohon et al., 2011). 
Several additional PZN-like gene clusters have been identified in six distinct bacterial genera 
(from three phyla) through genome mining, but experimental data on antibiotic specificity has so 
far been limited to PZN (Kalyon et al., 2011; Molohon et al., 2011; Scholz et al., 2011). 
Although PZN has been the subject of total synthesis (Banala et al., 2013; Wilson et al., 2015), 
heterologous expression (Deane et al., 2013), and enzymological studies (Hao et al., 2015; Lee et 
al., 2013; Sharma et al., 2013), insight into the mode of action (MOA) of PZN has not been 
reported in the seven years since the discovery of its biosynthetic gene cluster (Lee et al., 2008). 
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B. anthracis, the causative agent of anthrax and a category A priority pathogen, is a 
Gram-positive bacterium and is a member of the B. cereus sensu lato group, which includes B. 
cereus, B. anthracis, B. thuringiensis, and B. mycoides (Jensen et al., 2003; Rasko et al., 2005). 
Microbiologists have debated whether these organisms should be considered as one species, 
given that some strains share greater than 99% DNA sequence identity. Despite being grouped 
with other Bacillus species, B. anthracis harbors a number of features that set it apart from other 
members of the B. cereus group. Fully virulent B. anthracis contains two conserved plasmids, 
pXO1 and pXO2, which harbor the genes responsible for producing the anthrax toxin and poly-D-
glutamic acid capsule, respectively. However, homologous plasmids are also found in certain B. 
cereus strains (Kolsto et al., 2009). Beyond characteristic plasmid content, B. anthracis, unlike 
other members of the B. cereus group, harbors a nonsense mutation in plcR (phospholipase C 
regulator), rendering B. anthracis non-motile and non-hemolytic (Agaisse et al., 1999).   
Other defining features of B. anthracis that may facilitate species selectivity are exterior 
to the cell wall. B. anthracis displays a two-dimensional protein lattice called the surface layer (S-
layer). Decorated with surface-associated proteins in a csaB (cell surface attachment)-dependent 
manner (Mesnage et al., 2000), the S-layer is non-covalently attached to the secondary cell wall 
polysaccharide (SCWP) (Wang et al., 2013; Zheng et al., 2013), which is covalently tethered to 
the peptidoglycan. The B. anthracis SCWP is structurally unique (Choudhury et al., 2006; 
Weidenmaier and Peschel, 2008) and serves as the binding site for gamma (γ) phage (Ganguly et 
al., 2013; Schuch et al., 2013) and previously described B. anthracis typing antibodies (Ezzell et 
al., 1990). γ phage produce a peptidoglycan hydrolase, PlyG, which specifically recognizes the 
terminal galactoses of the B. anthracis SCWP and subsequently hydrolyzes the cell wall 
(Ganguly et al., 2013). Similarly, typing methods using monoclonal antibodies to the SCWP also 
exploit differences in the terminal sugar unit. However, there exist atypical B. anthracis strains 
that would constitute false-negatives in any diagnostic assay based on these methods (Abshire et 
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al., 2005; Ezzell et al., 1990). Wip1, another B. anthracis-specific phage, is even more selective 
than γ phage, yet certain B. cereus strains remain sensitive (Kan et al., 2013). Thus, the species 
specificity of PZN is intriguing not just from a MOA standpoint, but also as a means to 
distinguish B. anthracis from other B. cereus sensu lato members. 
Here we describe PZN as a remarkably selective small molecule antibiotic towards B. 
anthracis. The intriguing specificity was first examined by gene expression profiling, which 
yielded an expression signature distinct from broader spectrum antibiotics. We have identified 
and characterized a set of resistant mutants and evaluated their role in PZN resistance, which led 
to us to further investigate the bacterial membrane as the probable target of PZN. Using 
fluorescence-based approaches, we confirmed that PZN localizes to the cell envelope and rapidly 
causes membrane depolarization. Taken together with the observation that PZN interacts 
synergistically with the negatively charged phospholipid, cardiolipin (CL), we propose that PZN 
localizes to and aggravates transient weaknesses present in the B. anthracis cell membrane.  
4.3 Results 
4.3.1 Defining the species selectivity of PZN 
PZN was originally described as a Gram-positive antibiotic, inhibiting the growth of B. 
subtilis, B. cereus, and B. megaterium (Scholz et al., 2011). It is important to note, however, that 
the spot on lawn assay employed to reach this conclusion used an exorbitant amount of purified 
PZN (1 mg per spot). Using a microbroth dilution assay, the activity of PZN was later revealed to 
be considerably more selective, in that antibacterial activity was only detected toward B. 
anthracis upon screening a small panel of human pathogens (Molohon et al., 2011; Sterne and 
Proom, 1957). We continued to establish this unusually narrow-spectrum of activity by screening 
a larger panel of strains with varying degrees of genetic similarity (Table 4.1). PZN was found to 
be selective for vegetative B. anthracis, including fully virulent biosafety level 3 strains, with 
minimum inhibitory concentrations (MICs) between 1-16 μg/mL (0.75-12 µM). Endospores, the 
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dormant phase of the B. anthracis life cycle, were resistant to PZN until germination was initiated 
(Table 4.2). By microbroth dilution, B. subtilis and B. cereus were not susceptible to PZN at 
concentrations up to 64 μg/mL, which is in contrast to the previously reported spot on lawn assay 
(Scholz et al., 2011).  
To further investigate the selectivity of PZN towards B. anthracis, we conducted a head-
to-head comparison using the γ phage assay. Prior to modern genomic methods, γ phage 
sensitivity and other phenotype testing were popular methods for identifying B. anthracis 
(Abshire et al., 2005). Notwithstanding the reported 96% positive accuracy, non-B. anthracis 
strains that are sensitive to γ phage and true B. anthracis strains that are insensitive have been 
reported (Abshire et al., 2005; Hoffmaster et al., 2006; Schuch and Fischetti, 2006). We obtained 
a panel of atypical B. cereus strains that are sensitive to γ phage and tested them for PZN 
susceptibility (Table 4.3). B. cereus strains that generated a false positive in the γ phage assay 
were not susceptible to PZN (Kan et al., 2013; Marston et al., 2006; Schuch and Fischetti, 2006). 
In an attempt to further define the attributes giving rise to the species selectivity of PZN, 
we procured various bacterial strains that address key differences between B. anthracis and B. 
cereus. plcR, encoding the phospholipase C regulator, is nonfunctional in B. anthracis but is 
intact in B. cereus (Agaisse et al., 1999). Deletion of plcR in B. cereus did not increase its 
susceptibility to PZN (Table 4.1). Additionally, sortase-deficient strains of B. anthracis, which 
lack the ability to anchor various proteins to the cell wall, remain susceptible to PZN (Davison et 
al., 2005). Similarly, PZN activity was not dependent on the presence or composition of the B. 
anthracis S-layer, as strains deficient in S-layer assembly or decoration, namely those harboring 
mutations in csaB, sap, and eag, are equally susceptible to PZN (Mesnage et al., 2000). We 
further confirmed that susceptibility to PZN is plasmid-independent given that the susceptibility 
of a plasmid-deficient strain, B. anthracis LLNL A0517-1. (Table 4.1; Figure 4.2). Wip1 phage 
and antibody typing have also been used to discriminate B. cereus sensu lato strains, but also 
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have known exceptions to their specificity for B. anthracis (Ezzell et al., 1990; Kan et al., 2013). 
We obtained a “false-positive for B. anthracis” strain for each marker: B. cereus CDC32805 for 
Wip1 and B. cereus ATCC 7064 for antibody typing. We again observed no measurable PZN 
susceptibility for either strain (Table 4.1).  
After extensive susceptibility testing, the only notable exception to the B. anthracis 
selectivity of PZN was B. cereus G9241 (MIC of 8 µg/mL). B. cereus G9241 encodes the genes 
for an anthrax-like toxin on its pBCXO1 plasmid, which is named for its homology to the B. 
anthracis pXO1 plasmid (Hoffmaster et al., 2004). As B. cereus G9241 is encapsulated and 
toxigenic, it causes an anthrax-like disease but is undetectable in the γ phage assay (Hoffmaster et 
al., 2006). From a pathogen detection perspective, the action of PZN towards G9241 could be 
considered fortuitous if it were to be further developed as a diagnostic test. Together, these data 
not only highlight the species discrimination of PZN but also rule out plcR-related effects, 
sortase-mediated proteins, the SCWP, the S-layer, and plasmid-borne entities as targets of PZN. 
The spectrum of PZN activity calls into question whether bacteria are the naturally 
intended target. The canonical PZN-producing strain, B. methylotrophicus FZB42, has been 
described to have antifungal and nematicidal activity and is a prolific producer of other natural 
products (Burkett-Cadena et al., 2008; Chen et al., 2007). Liu et al. assigned a nematicidal 
activity to PZN, derived from experiments showing that PZN-deficient FZB42 strains exhibit 
reduced nematicidal activity against Caenorhabditis elegans (Liu et al., 2013). Since these 
experiments employed crude cellular extracts, we evaluated purified PZN in a similar manner, 
embedding the compound in agar (slow killing assay) or providing PZN in a liquid suspension 
(liquid fast killing assay). PZN was found to be no more toxic to C. elegans than a vehicle control 
and is clearly not nematicidal in its own right (Figure 4.3). Purified PZN was also not responsible 
for the antifungal activity of the native producer, leaving the ecological function of PZN 
unknown (Table 4.1). 
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After observing the specificity of PZN under one growth medium condition (Luria-
Bertani broth, LB), we re-assessed specificity against a smaller but representative panel of strains 
in two additional growth media (Mueller-Hinton and brain-heart infusion broths, Table 4.4). All 
tested strains of B. anthracis remained equally susceptible, but unexpectedly, some 
Staphylococcus aureus strains were susceptible to PZN under alternative growth media (MICs 
from 8 – 32 µg/mL). All other tested strains remained non-susceptible to PZN. 
4.3.2 Assessing potential macromolecules as the target of PZN 
In an attempt to identify the molecular target(s) of PZN, two biotinylated PZN probes 
were prepared for affinity purification, a standard technique for identifying targets of bioactive 
small molecules (Ziegler et al., 2013). First, an N-terminally biotinylated PZN was prepared from 
desmethylPZN, which is a biosynthetic intermediate obtainable by fermentation of an expression 
strain missing the PZN N-methyltransferase (Figure 4.1; Figure 4.4) (Molohon et al., 2011). 
Unfortunately, N-biotinylated PZN was devoid of antibiotic activity at the concentrations tested; 
however, C-terminally biotinylated PZN retained bioactivity, albeit with a 16-fold reduction in 
potency (Figure 4.1; Figure 4.5). For this reason, C-terminally labeled PZN-biotin was chosen for 
affinity-based target identification. Despite numerous attempts, we were unable to identify 
interactions unique to PZN-biotin compared to the control (data not shown). A photoaffinity 
tagged derivative of PZN was then prepared on the notion that PZN-biotin may weakly interact 
with its target, (Figure 4.1, Figure 4.6). To minimally perturb potential interactions, a minimalist, 
bifunctional analog containing a diazirine and alkyne was employed to enable crosslinking prior 
to biotinylation and enrichment (Li et al., 2013). Again, no binding partners were identified by 
either mass spectrometry or western blot.  
Because affinity purification-based strategies to identify small molecule targets is most 
successful when the interaction is proteinaceous and of high-affinity (Burdine and Kodadek, 
2004), we next considered the possibility that PZN interacted with a non-protein macromolecule. 
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We used radiolabeled precursors of the cell wall, fatty acids, and RNA (as well as protein), to 
assay for their biosynthesis in the presence of PZN. Similar to the nisin-like lanthipeptide Pep5, 
PZN extensively disrupted macromolecular biosynthesis (Sahl and Brandis, 1982) (Figure 4.7). 
Interestingly, PZN did not affect cell wall biosynthesis compared to the vancomycin control. 
4.3.3 The gene expression signature of PZN 
Sub-lethal antibiotic treatment stimulates rapid transcriptional responses in bacteria (Goh 
et al., 2002) and the induced/repressed genes may be indicative of MOA (Brazas and Hancock, 
2005). We thus performed RNA-Seq to evaluate the transcriptional response of B. anthracis 
following exposure to 0.25 µg/mL (0.25 × MIC) PZN for 10 min (Shaw and Morrow, 2003). A 
total of 74 genes were differentially regulated, including 63 upregulated and 11 downregulated 
genes, with an adjusted false discovery rate (q-value) of 0.01 (Figure 4.8; Table 4.5). The 
expression of a subset of these genes was validated by qRT-PCR (Table 4.6; Table 4.7). Fourteen 
of the upregulated genes were transporter subunits, a common stress response upon antibiotic 
treatment (Li and Nikaido, 2009). Conversely, PZN treatment led to the downregulation of genes 
associated with L-lactate metabolism, for which the implications remain unclear.  
The most highly upregulated B. anthracis genes upon PZN treatment were bas1344 and 
bas1345, which encode a hypothetical protein and a predicted member of the PspA/IM30 family, 
respectively (Table 4.6). These genes are homologous to the B. subtilis genes liaI and liaH (lipid 
II cycle interfering antibiotics), which are involved in the cell envelope stress response. Induction 
of these genes upon antibiotic treatment is well documented in B. subtilis, specifically to 
antibiotics interacting with lipid II in some capacity (e.g., nisin, vancomycin, and bacitracin) 
(Jordan et al., 2008). Induction of lia is also seen upon treatment of B. subtilis with daptomycin, 
despite the lack of direct interaction between daptomycin and lipid II (Wecke et al., 2009). PZN 
treatment also results in massive upregulation of bas5200 and bas5201, which are homologous to 
a B. subtilis thermosensor two-component system that regulates the lipid desaturase, desRK 
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(Martin and de Mendoza, 2013). To our knowledge, PZN is the first compound known to alter the 
expression of desRK, further suggestive of a unique MOA.  
Recently, we reported on the synthesis of a PZN derivative, Me2-Arg-Az5 (Figure 4.1) 
(Hao et al., 2015).  Chemically, Me2-Arg-Az5 represents the N-terminal half of PZN, but the 
activity spectrum of Me2-Arg-Az5 is broader and includes other Bacillus species as well as S. 
aureus (Table 4.8). To investigate their differing spectra of activity, we recorded the gene 
expression profile of B. anthracis treated with Me2-Arg-Az5 under otherwise identical conditions 
(0.25 × MIC, 10 min) by RNA-Seq. The two compounds shared a minor portion of their 
expression profiles, but each profile was largely independent (Figure 4.9; Tables 4.9-4.10). For 
example, sub-lethal Me2-Arg-Az5 treatment also induced the desRK two-component system, but 
expression of liaIH remained unchanged. Additionally, Me2-Arg-Az5 failed to induce B. 
anthracis lysis, in contrast to PZN (Figure 4.10). These data, together with strain susceptibility, 
suggest that PZN and Me2-Arg-Az5 pursue independent, but possibly related, targets.  
4.3.4 PZN depolarizes the B. anthracis membrane 
We examined the activity of PZN towards B. anthracis in the presence of the membrane 
disrupting agents nisin and daptomycin. Based on the resulting isobolograms, both compounds 
elicited strong synergistic activity with PZN (Figure 4.11) (Berenbaum, 1989). Both nisin and 
daptomycin disrupt membrane potential in Gram-positive organisms, and their synergism with 
PZN suggests that PZN might also depolarize the B. anthracis membrane (Ruhr and Sahl, 1985; 
Silverman et al., 2003). Thus, DiOC2(3) (3,3’-diethyloxacarbocyanine iodide) was used to 
measure the membrane potential of PZN-treated B. anthracis cells. As expected, PZN treatment, 
at both inhibitory and sub-inhibitory concentrations, correlated with a decrease in membrane 
potential, suggesting that PZN exerts its action by disrupting the integrity of the cell membrane 
(Figure 4.11). 
111 
4.3.5 Subcellular localization of PZN 
With mounting evidence that PZN targets the cell membrane, we aimed to determine the 
subcellular localization of PZN by confocal microscopy. Antibiotics derivatized with fluorescent 
probes have previously been used to shed light on their MOAs (Bindman and van der Donk, 
2013; Tiyanont et al., 2006). Localization of PZN was established by employing a Cy5-labeled 
PZN derivative (PZN-Cy5) (Figures 4.1, 4.12) that retained much of its anti-B. anthracis activity 
(MIC of 4 µg/mL, 2 μM). PZN-Cy5 localized to distinct ~200 nm wide foci in B. anthracis 
Sterne (Figure 4.13A). To confirm that PZN-Cy5 behaved in a matter identical to unlabeled PZN, 
we carried out a competition assay where and excess of PZN was applied to B. anthracis Sterne 
followed by addition of PZN-Cy5. Due to the extensive cell lysis elicited by PZN, we employed a 
later-described spontaneously PZN-resistant Sterne mutant (PR06) for this competition assay. 
Just as in B. anthracis Sterne, PZN-Cy5 localized to distinct foci in B. anthracis PR06 (Figure 
4.13B). PZN-Cy5 failed to label strain PR06 when an excess of unlabeled PZN was administered 
first, demonstrating that PZN and the PZN-Cy5 probe identically interact with B. anthracis 
(Figure 4.13C). Due to the photoswitching properties of Cy5, we were able to further investigate 
PZN-Cy5 localization using stochastic optical reconstruction microscopy (STORM, Figure 4.14) 
(Huang et al., 2008). Using this super-resolution imaging technique, B. anthracis Sterne cells 
were again confirmed to accumulate PZN-Cy5 at the foci described above. These foci were 
clearly localized to the surface of the cells, further implicating a component of the cell envelope 
as the target of PZN (Figure 4.15). B. anthracis cells contain 16 ± 2 foci per cell, each with a 
diameter of 181 ± 7 nm, as determined by analysis of 14 cells treated with PZN-Cy5 (Figure 
4.15). Notably, the labeling pattern of PZN-Cy5 is different from BODIPY-vancomycin, which 
has been shown to localize to bacterial septa at the site of peptidoglycan synthesis (Nguyen-Mau 
et al., 2012). If PZN were acting on the cell wall, sites of active PG synthesis or the entire cell 
wall would be labeled with PZN-Cy5. The non-septal, punctate labeling of PZN-Cy5 suggests 
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that the target of PZN is neither nascent nor existing peptidoglycan, which is congruent with the 
observation that PZN did not block cell wall biosynthesis (Figure 4.7).  
4.3.6 Isolation and characterization of PZN-resistant mutants 
An orthogonal strategy for obtaining antibiotic MOA information involves the selection 
and mapping of resistant mutant polymorphisms (Silver, 2011). The genes containing the 
resistance-conferring mutations can either be involved directly in the MOA of the antibiotic or in 
a target-unrelated mechanism of immunity. We isolated PZN-resistant B. anthracis by growing 
the Sterne strain on agar plates containing PZN at 4 × MIC. The resistance frequency was 
determined to be 2.3 × 10
-7
, and the resulting mutants exhibited MICs that were ≥32 μg/mL. 
Genomic DNA was isolated and sequenced for six independently-selected PZN-resistant strains 
(PR01 through PR06) and the parent Sterne strain. Comparison of PR01 through PR06 to the 
parent revealed that all six polymorphisms were confined to a 50-nucleotide section of a single 
gene, bas4114, which is annotated as an AcrR transcriptional repressor (Table 4.11) (Deng et al., 
2013). This particular AcrR protein is predicted to contain a single transmembrane domain near 
the C-terminus (Figure 4.16) (Viklund et al., 2008), which is precisely where the PZN-resistance 
conferring mutations were found, all resulting in premature stop codons. Directly downstream of 
bas4114 are two EmrE-type efflux pumps, encoded by bas4115-4116. We hypothesized that as 
an AcrR transcriptional repressor, BAS4114 would negatively regulate bas4115-4116, and 
mutations near the C-terminus of BAS4114 would result in regulator dysfunction and 
derepression of the efflux pumps. This in turn would increase resistance to PZN. Therefore, 
RNA-Seq was employed to compare the mRNA expression profiles of PR06 to the parent Sterne 
strain. This analysis revealed a significant upregulation of bas4114-4117 (Table 4.12). PR06 and 
the Sterne parent were equally susceptible to Me2-Arg-Az5 (Table 4.8), again underscoring 
differences between PZN and Me2-Arg-Az5. The susceptibility of PR06 to a panel of 
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mechanistically-diverse antibiotics, including daptomycin, was also assessed (Table 4.13). The 
PZN resistance-conferring mutation did not alter the susceptibility towards any tested antibiotic. 
Mutation of bas4114 is clearly the favored route for generating PZN-resistance in B. 
anthracis, as shown by the occurrence of multiple independent mutations within the same gene. 
In order to subvert this resistance mechanism, and to obtain more insightful information about 
PZN MOA, we deleted bas4114-4117 from the parental strain by homologous recombination 
(Figure 4.17) (Janes and Stibitz, 2006). B. anthracis Sterne Δbas4114-4117 thus became the new 
parental strain for isolating second-generation PZN-resistant mutants, as the removal of bas4114-
4117 rendered the strain resensitized to PZN at wild type levels (1 μg/mL). This time, two routes 
were pursued for obtaining PZN-resistant strains. First, we selected spontaneous PZN-resistant 
mutants by challenging with 4 × MIC. Isolation of the spontaneous mutants resulted in a mutation 
frequency an order of magnitude lower than before (1.3 × 10
-8
). Two independently-selected 
resistant strains (PR07 and PR08) were subjected to whole-genome sequencing, revealing single 
point mutations within ftsE (Table 4.14). FtsE is an ATP-binding protein that associates with its 
cognate permease FtsX, which together comprise an ABC transporter that functions during cell 
wall elongation and septum formation (Yang et al., 2011). 
In a second strategy to obtain PZN-resistant mutants, we cultured B. anthracis Sterne 
Δbas4114-4117 in the presence of a sub-lethal concentration of PZN. The concentration of PZN 
was gradually increased with the number of passages (Friedman et al., 2006). We isolated 
genomic DNA from a 1
st
 passage strain (PR09-1, MIC 16 μg/mL) in addition to two independent 
4
th
 passage strains (PR09-4, PR10-4, MICs ≥64 μg/mL) for whole genome sequencing. PR09-1 
contained a point mutation in bas1659, which is annotated as a CitB-like response regulator 
(Table 4.14). Downstream of bas1659 are genes encoding a predicted histidine kinase (bas1660), 
ABC transporter subunits (bas1661-1663), and a cardiolipin (CL) synthase gene (bas1664). 
PR09-4 is a descendent of PR09-1, and as such, PR09-4 contained the same bas1659 mutation as 
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PR09-1 in addition to another point mutation in bas1662 (the permease domain of a locally-
encoded ABC transporter). PR10-4 contained a similar mutation series (bas1663, a second 
permease gene for what is presumably a trimeric ABC transporter) but had an additional mutation 
in bas1842, which is implicated in petrobactin biosynthesis (Lee et al., 2007). However, deletion 
of the petrobactin biosynthetic gene cluster did not decrease susceptibility to PZN (Table 4.1). 
4.3.7 Cardiolipin increases sensitivity to PZN 
We hypothesized that the regulatory- and transport-related mutations upstream of the 
gene encoding CL synthase could alter CL concentrations and thus, CL may be playing a role in 
PZN’s activity. We first examined the effect of exogenous CL on the interaction of PZN with the 
B. anthracis cell membrane. B. anthracis cells were treated with PZN-Cy5 (1 nM) in the presence 
and absence of exogenous CL (up to 100 µg/mL). Cell-associated PZN was then quantified by 
flow cytometry. The extent of PZN-Cy5 binding to B. anthracis was significantly increased when 
cells were co-treated with CL (Figure 4.18). This result is in contrast to that with daptomycin, 
which acts on the bacterial membrane but exhibits an antagonistic relationship with CL (Zhang et 
al., 2014). As predicted, co-administration of CL did not increase the labeling efficiency of 
daptomycin-Cy5 on B. anthracis cells (Figures 4.1, 4.18, 4.19) (Zhang et al., 2014). Congruent 
with these data was the observation that CL potentiated the killing activity of PZN towards B. 
anthracis. Indeed, the strongly synergistic behavior with CL enhanced the potency of PZN 
upwards of 16-fold while CL alone had no antibiotic activity at the concentrations tested (Figure 
4.18). 
The proportion of CL in cell membranes has been reported to increase during growth in 
high osmolarity medium, especially for B. subtilis (Romantsov et al., 2009). We thus tested 
whether increasing the osmolarity of the B. subtilis medium (and thus the CL content) would 
induce susceptibility to PZN. When grown in standard LB supplemented with an additional 1.5 M 
NaCl (final 1.67 M NaCl), PZN was weakly growth-suppressive towards B. subtilis (Table 4.15). 
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By measuring CL from total lipid extractions, CL levels did increase compared to standard 
growth in LB (Table 4.15). However, exogenous cardiolipin alone does not induce PZN 
susceptibility in B. subtilis (data not shown). Unfortunately, members of B. cereus sensu lato, 
including B. anthracis, are not tolerant of high osmolarity media (Peters et al., 1991). Therefore, 
induced susceptibility to PZN under high osmolarity conditions could not be evaluated for these 
strains. 
As stated previously, the stepwise-selected PZN-resistant mutants accumulated mutations 
in genes upstream of the CL synthase gene. We next analyzed the transcriptional response within 
the cls locus, including the upstream regulators/transporters and observed a dramatic increase in 
the expression of several cls genes in PR09-1 and PR09-4, including CL synthase itself and the 
transporters, but not the predicted response regulator and histidine kinase genes (Table 4.16). In 
contrast, there was no differential expression of any tested gene in the PR10-4 strain. Upon CL 
quantification, we did not detect differences in CL content between B. anthracis and the 
Δbas4114-4117 strain; however, only mutant PR10-4 contained a proportionally increased level 
of CL (Table 4.15).  
4.3.8 PZN colocalizes with cardiolipin and regions of increased fluidity 
The genetic and functional association with CL implicates the membrane as the most 
probable target for PZN. The lipid dye 10-N-nonyl acridine orange (NAO) approximates regions 
of the cell membrane enriched in CL (Mileykovskaya and Dowhan, 2000; Petit et al., 1992). 
Alone, NAO staining yielded a patchy appearance on B. anthracis membranes (Figure 4.20). We 
equilibrated B. anthracis cells with PZN-Cy5 and NAO to investigate if PZN localized to CL-rich 
regions in the cell membrane. There existed a clear but imperfect colocalization of the two dyes, 
suggesting a possible interaction with CL in the bacterial membrane (Figure 4.20). Additionally, 
1,1’-Didodecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate, (DilC12(3)), is a dye reported 
to associate with regions of increased fluidity (RIF) within cell membranes, which may also be 
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indicative of CL localization (Strahl et al., 2014). We observed colocalization of DilC12(3) and 
PZN-Cy5, consistent with PZN and CL co-associating with B. anthracis RIFs (Figure 4.20). 
4.4 Summary and Outlook 
Due to genomic advances, B. anthracis, the causative agent of anthrax, can be 
distinguished from the other members of the B. cereus sensu lato group by whole genome 
sequencing, multi-locus sequence typing (Marston et al., 2006; Tourasse and Kolsto, 2008), the 
presence of chromosomal lambdoid prophages (Kolsto et al., 2009), and the presence of a 
characteristic nonsense mutation in plcR. An alternative approach to B. anthracis identification 
now includes susceptibility to PZN, which is a natural product exhibiting potent and specific 
activity for B. anthracis under standard laboratory conditions. Our data demonstrate that the 
species selectivity of PZN is even more discriminating than that of the reputedly selective γ phage 
(Abshire et al., 2005; Kan et al., 2013; Marston et al., 2006; Schuch and Fischetti, 2006).  
B. cereus G9241, which was inhibited by PZN at 8 μg/mL, is a fortuitous exception to 
PZN selectivity, as it was isolated from a patient exhibiting an anthrax-like disease (Hoffmaster et 
al., 2004). Upon treatment with high concentrations of PZN in other rich media, namely Mueller-
Hinton and brain-heart infusion broths, the spectrum of PZN activity is broadened to include 
strains of S. aureus, a phenomenon that convolutes the search for PZN’s precise MOA. Upon 
testing a panel of Gram-positive strains, no bacterium besides S. aureus showed media-dependent 
susceptibility to PZN. 
We were able to rule out certain B. anthracis-defining features, namely the SCWP/S-
layer, plasmid-borne entities, proteins tethered to the cell wall, and plcR-related components as 
targets of PZN by analyzing select B. anthracis strains. Additionally, despite preparing a 
biotinylated PZN derivative that retained antibacterial activity, no proteinaceous binding partners 
could be identified. Similarly, a photoaffinity PZN probe was employed in the event that the 
PZN-biotin probe had decreased affinity for the target, but this too was unsuccessful.  
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The gene expression profile of PZN suggested a target within the B. anthracis cell 
membrane. Sub-lethal concentrations of PZN resulted in the differential expression of 74 genes 
within B. anthracis. Two of the most upregulated genes in the PZN expression profile are 
homologs of liaI and liaH, which are part of a known cell envelope stress response. A number of 
cell wall- and cell membrane-acting antibiotics induce the lia system (e.g. bacitracin, nisin, 
daptomycin, and vancomycin) (Wecke and Mascher, 2011). However, PZN likely has a distinct 
MOA, given that we observed an overall expression profile different from those reported for 
other antibiotics. Of particular note is the overexpression of the lipid desaturase (des) two-
component regulatory system. Cell survival in conditions of increased osmolarity is dependent on 
membrane fluctuations with an increase in unsaturated fatty acid composition (Lopez et al., 
1998). We have demonstrated that by increasing the osmolarity of the growth medium, we can 
induce, to a modest extent, PZN susceptibility in B. subtilis. Increased CL levels are characteristic 
of osmotic stress in B. subtilis, Escherichia coli, and Lactococcus lactis, among others 
(Romantsov et al., 2009). Furthermore, excess CL within the membrane results in increased 
fluidity and lipid bilayer deformation (Unsay et al., 2013). Regulation of the lipid desaturase, 
Des, influences the composition of phospholipids within the membrane (Aguilar et al., 1998). 
Thus, PZN induces stress in the cell membrane, inducing the des two-component system and 
likely affecting membrane fluidity.   
To further illuminate the MOA of PZN, we deleted four adjacent genes (bas4114-4117) 
involved in endowing B. anthracis with spontaneous resistance to PZN. Serially passaging the 
resulting deletion strain for PZN-resistant mutants yielded an accumulation of point mutations 
within a regulator (bas1659) and transporters upstream (bas1662-1663) of a CL synthase gene 
(bas1664). As these are missense mutations, we would not necessarily expect loss of function in 
the protein products. We observed differential expression of the CL synthase and upstream 
transporters in the PZN-resistant mutants, but only the PZN-resistant mutant PR10-4 displayed 
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differential levels of CL in the cell membrane. Increased CL content in the PR10-4 mutant 
suggests that CL does play a role in the activity of PZN, although there is not a straightforward 
relationship between CL content composition and PZN susceptibility. Based on our findings, we 
expect that in addition to CL, other membrane-associated biomolecules contribute to the ability of 
PZN to destabilize B. anthracis cell membranes. 
Nonetheless, our results reveal that CL plays an important role in PZN susceptibility, in 
that CL dramatically increased the potency of PZN without being cytotoxic at the concentrations 
investigated here. Such synergy was not observed between daptomycin and CL, and according to 
the available literature, increased CL contributes to daptomycin resistance in Entercocci; thus, 
although PZN and daptomycin both disrupt membrane function, they exhibit differences in MOA 
(Palmer et al., 2011; Zhang et al., 2014). CL has the potential to dramatically alter membrane 
architecture and may contribute to the susceptibility of B. anthracis through localization to 
distinct foci throughout the cell. The link between PZN and CL is further supported by the 
colocalization of PZN-Cy5 with the quasi-CL-specific dye, NAO, in B. anthracis (Mileykovskaya 
and Dowhan, 2000; Petit et al., 1992). In B. subtilis, NAO organizes into distinct foci at the septa 
and the poles (Matsumoto et al., 2006; Mileykovskaya and Dowhan, 2009), but it appears that in 
B. anthracis Sterne, NAO labels distinct, ~200 nm foci throughout the entirety of the cell 
membrane. Thus, B. anthracis appears to have a unique distribution of CL that facilitates an 
interaction with PZN and leads to cell death, whereas CL within other species may not be 
accessible to PZN. In addition to colocalization with NAO, we report that PZN-Cy5 colocalizes 
with DilC12(3), which is a dye that recognizes regions of increased fluidity (RIFs) in the 
membrane of B. subtilis (Strahl et al., 2014). RIFs are transiently weakened regions within the 
bacterial membrane that affect lipid homeostasis and membrane fluidity.  
In an effort to further understand the remarkable selectivity of PZN susceptibility, we 
initiated a comparative analysis of PZN and Me2-Arg-Az5 activities. Just as the PZN substructure 
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Me2-Arg-Az5 partially resembles PZN, our investigation reveals some similarities but major 
differences in their activities. Me2-Arg-Az5 displayed a broader range of antibiotic activity, 
including S. aureus and multiple Bacillus species (Hao et al., 2015). Importantly, mutations 
conferring PZN resistance did not confer resistance to other antibiotics or to Me2-Arg-Az5. 
Additionally, Me2-Arg-Az5 shared a minor portion of its gene expression profile with PZN; 
together with the evidence that Me2-Arg-Az5 does not lyse B. anthracis cells, we hypothesize that 
Me2-Arg-Az5 and PZN have distinct MOAs. A possible explanation for the observed differences 
between PZN and Me2-Arg-Az5 is that the C-terminal portion of the molecule is responsible for 
the species selectivity of the mature molecule and the N-terminal portion harbors the antibiotic 
activity, although this remains to be more extensively investigated. Thus, while Me2-Arg-Az5 is 
not useful as a mimic for the full-length natural product, it may represent a way to broaden the 
spectrum of PZN activity.  
In this paper, we report a MOA for PZN bioactivity involving cell membrane 
depolarization in a CL-enhanced manner. Through extensive testing, we determined that the 
stringency of PZN for B. anthracis is relaxed only in alternative media conditions. Additionally, 
the compound on its own does not contribute to B. methylotrophicus FZB42 antifungal or 
nematicidal activity. B. anthracis is very similar to other members of the B. cereus sensu lato 
family as described, but strains of B. anthracis designed to analyze key genetic differences retain 
their respective susceptibility to PZN. By imaging with confocal and STORM microscopy, PZN-
Cy5 was found to localize to the cell envelope and colocalize with RIFs and CL. Gene expression 
analysis reveals that PZN operates by a different MOA than previously described cell envelope-
targeting antibiotics. Thus, we present a model for PZN activity wherein PZN takes advantage of 
a locally weakened cell membrane, whether due to RIFs, CL-dependent membrane deformation, 
or some combination thereof. PZN accumulates to such membrane defects, which results in 
membrane depolarization and eventual cell lysis.  
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4.5 Experimental 
4.5.1 Strain and growth conditions 
All strain references are displayed in Table 4.1. All strains were grown in Luria-Bertani 
(LB) broth unless otherwise described (10 g/L tryptone, 5 g/L yeast extract, 10 g/L (0.34 M) 
NaCl). Biosafety level 3 strains of B. anthracis were grown on Mueller-Hinton agar. Neisseria 
strains were grown in gonococcal medium base supplemented with Kellogg’s I and II (Kellogg et 
al., 1963). Streptomyces endospores were isolated on mannitol soybean flour agar (20 g/L 
mannitol, 20 g/L soybean flour, 1.5% agar) and used to determine PZN susceptibility in ISP2 (4 
g/L yeast extract, 10 g/L malt extract, 4 g/L dextrose). Yeast strains were grown in YPD medium 
(10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose). C. elegans was cultured on nematode 
growth medium with E. coli OP50. Cultures were supplemented with 1.25 mM CaCl2 when 
assaying daptomycin susceptibility. In cases where increased osmolarity was desired, the LB was 
supplemented with additional NaCl (final concentration of 1.84 M). 
4.5.2 PZN production 
Stationary phase cultures of RSpMarA2 (Δsfp, yczE, degU) (Kalyon et al., 2011) were 
grown in LB with 7 µg/mL kanamycin and 7 µg/mL chloramphenicol. Sterilized aluminum sheet 
cake pans were prepared with M9 agar medium supplemented with BME vitamin mix and ATCC 
trace mineral solution and the aforementioned antibiotics. Cake pans were inoculated with 1.5 mL 
stationary phase RSpMarA2 and incubated 48 h at 37 °C. Bacterial lawns were loosened from the 
agar and resuspended in Tris-buffered saline (TBS) (150 mL/pan). The bacteria were then 
harvested via centrifugation (11,000 x g, 20 min). The supernatant was decanted and the cell 
pellets were stored at -20 °C until extraction. 
4.5.3 PZN purification 
PZN was extracted from bacterial pellets by resuspending in 150 mL MeOH/tray of cells 
with intermittent vortexing for 15 min at 22 °C. The cells were harvested by centrifugation as 
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above. The supernatant was vacuum filtered using Whatman filter paper, rotary evaporated, and 
subsequently lyophilized to dryness. The dried, crude PZN was resuspended in MeOH (1 mL/tray 
of extract) and centrifuged to remove insoluble debris (4,000 × g, 10 min). The supernatant was 
then injected onto a RediSep Rf High Performance 15.5 g HP C18 cartridge (Teledyne Isco) and 
purified by MPLC using a Combiflash Rf 200 system (25-100% MeOH/10 mM aqueous 
NH4HCO3 over 120 column volumes). The fractions containing PZN were pooled, rotary 
evaporated, and lyophilized to dryness, yielding roughly 5 mg/tray. PZN was dissolved in DMSO 
at concentrations of 30-50 mg/mL and stored at -80 ˚C for later use. 
4.5.4 PZN bioactivity 
PZN and Me2-Arg-Az5 bioactivity was determined via microbroth dilution assay as 
described in the Clinical and Laboratory Standards Institute manual (2006). The optical density 
(OD600) of a stationary phase culture was adjusted to 0.01 and added to a microtiter plate 
containing serially diluted PZN. Wells were visually inspected for turbidity, and the minimum 
inhibitory concentration (MIC) was determined as the lowest compound concentration that 
incurred no growth after 16 h. MICs were determined in LB unless growth conditions required an 
alternative medium (see above). The S. aureus media-dependent PZN susceptibility was analyzed 
using LB, Brain-Heart Infusion (BHI, Bacto), and Mueller-Hinton (BBL) broths. When indicated, 
cardiolipin (CL) was added to the medium at 100 μg/mL. 
A B. anthracis growth curve was generated using Tecan Infinite M200 Pro. B. anthracis 
Sterne 7702 cultures were grown in LB to stationary phase at 37 ˚C. Cultures were diluted to 
OD600 of 0.05 with fresh LB and allowed to recover to an OD600 of 0.35. Cultures were aliquoted 
into 96-well plates containing PZN and incubated at 37 ˚C with orbital shaking. OD600 was 
measured every 2 min. Values were normalized to an initial OD600 of 0.35 and adjusted to a 1 cm 
path length.  Error bars represent standard deviation of two independent experiments. 
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A growth curve in the presence of Me2-Arg-Az5 was generated as described above with 
the following differences: B. anthracis Sterne 7702 and S. aureus USA300 cultures were grown 
in duplicate to OD600 1.0 and aliquoted into 96-well plates. Wells were treated with 1:1 dilutions 
of Me2-Arg-Az5 at a maximum concentration of 12 µM. The plate was incubated at 37 °C with 
orbital shaking and OD600 was measured every 2 min. Values were normalized to an initial OD600 
of 1.0, adjusted to a 1 cm path length, and averaged at each time point. 
4.5.5 Bacterial endospore preparation and susceptibility screening 
B. anthracis Sterne 7702 endospores were prepared as described previously (Stojkovic et 
al., 2008). Briefly, B. anthracis Sterne 7702 cells were incubated overnight in LB at 37 °C. Difco 
Sporulation Media agar plates (8 g Nutrient Broth, 1 g KCl, 0.25 g MgSO4 + 7H2O, and 17 g 
agar, per liter) was inoculated with 150 μL of the stationary phase culture and incubated at 30 °C 
for 5 days. Lawns were recovered by resuspension in sterile H2O and filtered using 3.1 and 1.2 
μm filters to remove vegetative cells and aggregated endospores. Endospore filtrate was 
incubated at 65 °C for 1 h to remove any remaining vegetative cells. Endospores were harvested 
by centrifugation at 8000 × g for 25 min at 4 °C. After decanting the supernatant, the endospores 
were washed 3 times with 40 mL of H2O, harvesting by centrifugation. Endospores were stored at 
4 °C in H2O and quantified by serial dilution. Endospores were screened for PZN activity by 
incubating 1 × 10
9
 endospores
 
with PZN (0-16 μg/mL) in H2O for 20 h at 37 °C. Endospores were 
subsequently incubated at 65 °C for 1 h to destroy any contaminating vegetative cells, and then 4 
°C for 4 h to recover, and followed by serial dilution onto LB agar plates to assess germination. 
Plate counts represent the average of two trials. 
4.5.6 Gamma (γ) phage sensitivity 
γ phage were propagated as described previously (Abshire et al., 2005) using B. anthracis 
Sterne 7702 cells on brain heart infusion (BHI) agar plates, with no visible loss in infectivity. 
Phage infectivity was tested against a panel of B. cereus and B. anthracis strains using a serial 
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dilution assay. Stationary phase cultures were adjusted to an OD600 of 0.1 and 100 µL was plated 
on BHI plates. 5 µL of phage stock (2.6 × 10
8 
plaque forming units/mL) was serially diluted (2-
fold) and spotted onto the plates and allowed to dry. After incubation at 37 °C for 16 h, plates 
were removed and visually inspected for plaques. 
4.5.7 C. elegans nematicidal assays 
Wild-type N2 C. elegans were cultured on E. coli OP50 using standard techniques 
(Brenner, 1974). Eggs were isolated from gravid hermaphrodites using standard bleaching 
protocols (Emmons et al., 1979) and incubated for 18 h at 20 °C to obtain synchronized L1 
larvae. Cultures were then transferred to new NGM plates seeded with OP50 E. coli and 
incubated for 48 h at 25 °C. Resulting L4 larvae were used for assays adapted from Liu et al (Liu 
et al., 2013).  
Slow killing assays were performed using 12-well cell culture dishes with wells 
containing 1 mL NGM agar amended with 64 μg/mL PZN dissolved in DMSO or an equivalent 
volume (2 μL) of DMSO alone. One half of the slow killing assay wells were also seeded with 10 
µL of OP50 E. coli. The effect of DMSO alone on mortality was also tested and found to be 
negligible. Subsequently, 40-60 L4 hermaphrodites were transferred to each well, incubated at 25 
°C and checked every 24 h for 3 days. Each treatment was performed with two biological 
replicates, each having three technical replicates.  Liquid fast killing assays were also performed 
using 12-well cell culture dishes with wells containing 1 mL M9 buffer combined with 64 μg/mL 
PZN dissolved in DMSO or DMSO alone. 40-60 L4 larvae were transferred into each well and 
incubated at 25 °C for 24 h. Fast killing assays were replicated similarly to the slow killing assay 
(two biological, three technical replicates). For the duplicate assay, an additional control of M9 
buffer was included. In both fast and slow killing assays, animals were scored according to 
criteria shown in Liu et al. Mortality rates were also calculated using identical ratios.  
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4.5.8 RNA isolation and transcriptional profiling of PZN-treated Sterne cells 
For the compound-treated samples, independent 3 mL cultures of B. anthracis Sterne 
7702 cells were grown to an OD600 of 0.4, and 0.25 × MIC of PZN, 0.25 × MIC Me2-Arg-Az5 
(Hao et al., 2015), or an equivalent volume of DMSO was added and allowed to incubate for 10 
min at 37 °C. Together with resistant mutant PR06, RNA was isolated and prepared as described 
previously (Scholz et al., 2011).  RNA-Seq libraries were created using the TruSeq Stranded 
RNA Sample Prep kit (Illumina, San Diego, CA) after rRNA depletion using the RiboZero 
Bacteria kit (Epicentre, Madison, WI). Sequencing was performed for 1 × 100 cycles on a HiSeq 
2000 with Version 3 Chemistry. Transcriptomic data was processed with the Rockhopper version 
1.30 pipeline (McClure et al., 2013) using B. anthracis Sterne and B. anthracis Ames Ancestor 
plasmid pXO1 (NC_007322.2) as references. Default values (allowed mismatches 0.15, minimum 
seed length 0.33, minimum expression of UTRs and ncRNAs 0.5) were used, with the exception 
that reverse complement reads were used for mapping. The RNA-Seq data discussed in this 
publication have been deposited in NCBI's Gene Expression Omnibus (Barrett et al., 2013) and is 
accessible through GEO Series accession number GSE73343 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73343).  
4.5.9 cDNA construction and qRT-PCR analysis 
cDNA was generated using the published protocol from the Promega Improm-II system, 
replacing the reverse transcriptase with Invitrogen m-MLV reverse transcriptase. qRT-PCR was 
performed with iTaq universal SYBR Green Supermix and following manufacturer’s instructions 
using a Roche Lightcycler 480 System. Fold changes upon PZN treatment were calculated as 
described previously (Schmittgen and Livak, 2008). 
4.5.10 Membrane depolarization 
Three independent stationary phase cultures of B. anthracis Sterne 7702 were used to 
inoculate fresh LB and grown to OD600 0.5 at 37 ˚C with shaking. Aliquots (10 µL) were diluted 
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to 1 mL in PBS containing 3 mM DiOC2(3) (3,3’-diethyloxacarbocyanine iodide) and compounds 
(DMSO - vehicle, 5 µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 3.0 µM 
daptomycin, 0.5 µM PZN, 1.0 µM PZN). Cells were mixed at 21 °C for 30 min prior to analysis 
by flow cytometry (BD LSR II Flow Cytometry Analyzer). Voltages for fluorescein 
isothiocyanate (FITC) and propidium iodide (PI) fluorescence were set so that average counts per 
cell were between 10
3
 and 10
4
. Geometric means for fluorescence ratios were normalized to the 
control DiOC2(3) samples.  
4.5.11 Compound preparation 
Me2-Arg-Az5. Me2-Arg-Az5 was synthesized as previously described (Sharma et al., 
2013).  
PZN-Cy5. PZN (500 µg, 3.74 x 10
-7
 mol) in 20 µL dimethylformamide (DMF) was 
mixed with 5 µL N,N’-diisopropylethylamine (DIPEA), 10 µL of a 190 mM solution of 1-
hydroxybenzotriazole (HOBt) in DMF, and 10 µL of a 190 mM solution of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) in DMF for 15 min at 21 °C. Then 29.3 µL of a 10 
µg/µL solution of Cy5 amine (Lumiprobe) in DMF was added. The reaction was protected from 
light and stirred at 22 °C for 24 h. The sample was dried by speed vacuum, redissolved in 5% 
MeOH, and purified on a Sep-Pak C18 cartridge (Waters) on a gradient from 0 – 100% MeOH. 
Fractions containing PZN-Cy5, as determined by MALDI-TOF mass spectrometry, were 
combined and their purity assessed by analytical HPLC (Thermo BetaSil C18 column [250 mm × 
4.6 mm], 40 – 95% MeOH). Concentration was determined using the extinction coefficient of 
Cy5 in DMSO (ε646 = 250,000 L cm
-1
 mol
-1
). 
Daptomycin-Cy5. A 1 mg/mL solution of daptomycin in DMSO was prepared and 33 µL 
was mixed with 2 µL of 10 mM Cy5 NHS ester (Lumiprobe) and stirred at 22 °C, protected from 
light, for 4 h. Labeled compound was purified by reverse-phase chromatography on a Perkin 
Elmer Flexar HPLC outfitted with a Thermo Scientific BetaSil C18 column (250 mm × 4.6 mm 
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I.D., 5 µm particle size) using 10 mM NH4HCO3 as the aqueous phase on a 45 min gradient from 
25 – 95% MeCN at a flow rate of 1 mL/min. Absorbance monitoring at 647 nm was used to 
identify the fraction containing daptomycin-Cy5, which was confirmed by MALDI mass 
spectrometry. Purity was determined by a second analytical HPLC run using the same solvents on 
a 30 min gradient from 40 – 95% MeOH. Concentration was determined using the extinction 
coefficient of Cy5 in DMSO. 
Biotin-PZN (N-terminal label). A 100 mM solution of EZ-link N-hydroxysuccinimide 
(NHS) Biotin (Thermo Scientific) in 80% MeCN, 10 mM MOPS (pH 8.0) was prepared. 
DesmethylPZN (200 µg, 1.53 × 10
-7
 mol) was dissolved in 24 µL of the same buffer and treated 
with 6 µL EZ-link NHS biotin solution for 4 h at 22 °C. The solvent was removed by speed 
vacuum and the sample was dissolved in MeOH for purification by HPLC (BetaSil C18 column, 
250 mm × 4.6 mm, 1 mL/min, 50 – 95% MeOH over 60 min, 10 mM NH4HCO3 aqueous phase, 
monitored at 254 nm). Fractions containing purified biotin-PZN were combined, dried, and 
redissolved in DMSO. B. anthracis Sterne 7702 susceptibility was determined to be >32 µg/mL 
using a standard microbroth dilution assay.  
PZN-Biotin (C-terminal label). PZN (500 µg, 3.74 × 10
-7
 mol) was dissolved in 10 µL 
DMF and 1 µL DIPEA was added to the sample. A solution of 2.0 mM EDC and 2.0 mM HOBt 
in DMF was prepared and 2 µL was added to the PZN. After 5 min stirring, 1.0 mg biotin 
cadaverine was added to the reaction and allowed to proceed at 22 °C for 30 h. The reaction was 
dried by speed vacuum, redissolved in MeOH, and purified by HPLC (BetaSil C18 column, 250 
mm × 4.6 mm, 1 mL/min, 50 – 95% MeOH over 60 min, 10 mM NH4HCO3 aqueous phase, 
monitored at 254 nm). Fractions containing purified PZN-biotin were combined, dried, and 
redissolved in DMSO. B. anthracis Sterne 7702 susceptibility was determined to be 32 µg/mL by 
a standard microbroth dilution assay. 
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PZN-diazirine-alkyne. PZN (6.68 mg, 5.0 × 10
-6
 mol) was dissolved in 75 µL DMF and 
1.4 µL Et3N was added with stirring. The sample was cooled in an ice bath to 0 ˚C. HOBt (0.95 
mg, 0.007 mmol) and EDC (1.1 mg, 0.007 mmol) were dissolved in 100 µL DMF and added to 
the PZN. 2-(2-azidoethyl)-2-(but-3-ynyl)-1,3-dioxolane (0.96 mg, 0.007 mmol) (Li et al., 2013) 
was dissolved in 200 µL DMF and 24 µL was added after 10 min at 0 ˚C with stirring, protected 
from light. The reaction was allowed to warm to 22 ˚C and allowed to proceed for 24 h. The 
solvent was removed by speed vacuum and the sample was redissolved in MeOH. The sample 
was purified by HPLC (BetaSil C18 column, 250 mm × 4.6 mm, 1 mL/min, 50 – 95% MeOH over 
60 min, 10 mM NH4HCO3 aqueous phase, monitored at 254 nm). Fractions containing purified 
PZN-diazirine-alkyne were combined, dried, and redissolved in DMSO. B. anthracis Sterne 7702 
susceptibility was determined to be 32 µg/mL using a standard microbroth dilution assay. 
4.5.12 Structural characterization of PZN derivatives 
Purified samples were dried by speed vacuum and dissolved in 50% MeCN supplemented 
with 1% (v/v) acetic acid. The diluted samples were directly infused using an Advion Nanomate 
100 to an LTQ-FT hybrid linear ion trap-FTMS system (ThermoFisher) operating at 11 T. The 
MS was calibrated weekly using calibration mixture following the manufacturer's instructions, 
and tuned daily with Pierce LTQ Velos ESI Positive Ion Calibration Solution (ThermoFisher). 
Spectra were collected in profile mode with a resolution of 100,000. The singly charged ions 
were targeted for CID using an isolation width of 5 m/z, a normalized collision energy of 35, an 
activation q value of 0.4, and an activation time of 30 ms. Data analysis was performed using 
Thermo Xcalibur software. 
4.5.13 Affinity purification using PZN-Biotin 
LB (200 mL) was inoculated with 10 mL stationary phase B. anthracis Sterne 7702. The 
culture was grown with shaking at 37 °C to OD600 0.5. The sample was divided into 100 mL 
aliquots, centrifuged, and individually resuspended in 1.5 mL lysis buffer (50 mM Tris, 500 mM 
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NaCl, 2.5% v/v glycerol, 0.1% v/v Triton X-100, pH 7.5) with 500 mU mutanolysin. After 
equilibrating for 30 min at 22 °C, the samples were sonicated (4 × 30 s, 50% amplitude) and 
harvested by centrifugation (17,000 × g, 10 min). The insoluble fractions were resuspended in 1.5 
mL 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% w/v CHAPS, pH 7.5) and sonicated (10 s, 50% amplitude). One 
sample was treated with 1.0 × 10
-7
 mol PZN-biotin and the other was treated with vehicle 
(DMSO). The samples were treated for 30 min at 22 °C before the addition of 100 µL 
streptavidin-agarose resin suspension (pre-equilibrated with Tris buffer, 50 mM Tris-HCl, 150 
mM NaCl, pH 7.5). After mixing for 3 h at 22 °C, samples were applied to Bio-Rad spin columns 
and the flow through was collected. The resin was washed (5 × 4 mL Tris buffer). The resin was 
then resuspended in 200 µL 1% SDS in PBS and boiled for 10 min. After cooling, the eluent was 
collected and analyzed by SDS-PAGE for the presence of unique bands in the sample containing 
PZN-biotin. Unique bands, as visualized by Coomassie and silver stain, were not found compared 
to the vehicle-treated sample (data not shown). Samples were also analyzed by Western blot 
using the following procedure: proteins were transferred by electroblot to a polyvinylidene 
fluoride (PVDF) transfer membrane (EMD Millipore). The membrane was blocked overnight at 4 
°C in TBS containing 0.1% (v/v) Tween-20 (TBST buffer), treated for 1 h at 4 °C with 1/3,000 
dilution of streptavidin-HRP in TBST, and then washed (2 × 30 s then 5 × 5 min) with TBST. 
After washing once in PBS (1 × 30 s), the membrane was treated with 1:1 hydrogen peroxide 
solution:luminol solution (Bio-Rad) for imaging. 
4.5.14 Photoaffinity purification using PZN-diazirine-alkyne 
The procedure used for photoaffinity purification studies was similar to that of affinity 
purification experiments, except that the samples were incubated with PZN-diazirine-alkyne or 
vehicle (DMSO) for 4 h at 4 °C, protected from light. The cells were then exposed to UV (4 W, 
365 nm) for 15 min at 22 °C to induce crosslinking. The samples were pelleted and resuspended 
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in PBS containing 1 mM CuSO4, 128 µM tris(3-hydroxypropyltriazolylmethyl)amine, 1.2 mM 
sodium ascorbate, and 50 µM biotin-azide for 1 h at 22 °C. The cells were then centrifuged 
(4,000 × g, 2 min), the supernatant was decanted, and the cells were resuspended in PBS treated 
with 200 U/mL mutanolysin. After incubation for 1 h at 37 °C, cells were sonicated as previously 
described. The insoluble fraction was separated by centrifugation and resuspended as previously 
described. Clarified lysates and insoluble fractions were all enriched with streptavidin-agarose 
resin as previously described, and eluents were compared by SDS-PAGE followed by Western 
blot and mass spectrometric analysis.  
4.5.15 Macromolecular synthesis assay 
Radiolabel incorporation into cellular macromolecules was carried out as previously 
described (Cotsonas King and Wu, 2009). Briefly, identical B. anthracis Sterne 7702 cultures 
were grown to an OD600 of 0.6 in Luria Broth and diluted to a final OD600 of 0.3. Radiolabelled 
precursor was added to a final concentration of 0.1 μCi, and compound (either PZN or control) 
was added to 1×, or 2× the MIC. Samples were taken at 60 min post-compound addition. OD600 at 
each time point was determined using identically treated cultures lacking radioactive compound. 
The macromolecules of the cultures treated with radiation were precipitated using trichloroacetic 
acid on glass filter disks and washed with dilute acid and ethanol successively. The filters were 
placed in scintillation vials with Ultima Gold scintillation cocktail. Radioactive counts were 
determined using a liquid scintillation analyzer (PerkinElmer Tri-Carb 2910 TR). The 
macromolecules, radiolabelled precursors, and their corresponding control antibiotics were as 
follows:  
cell wall: [1,6-
3
H (N)] N-acetyl-D-glucosamine (ARC, ART 0142), vancomycin control 
protein: [U-
14
C] L-amino acid mixture (MP, 1014750), chloramphenicol control  
 RNA: [
14
C(U)] uridine (ARC, ARC 0154), rifampicin control 
 fatty acid: acetic acid [1-
14
C] sodium salt (ARC, ARC 0101A), triclosan control 
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4.5.16 Confocal microscopy 
In general, cells were prepared by inoculating 5 mL LB with 200 µL of a stationary phase 
culture. After growing to an OD600 of 0.5 at 37 °C with shaking, 1 mL aliquots were centrifuged 
(3 min, 8000 × g), decanted, and resuspended in sterile PBS. Slides were prepared by mixing 1:1 
(v/v) cell suspensions in PBS and liquefied low gelling temperature agarose (Sigma-Aldrich, 2% 
w/v in water). All microscopy images were obtained using a Zeiss LSM 700 Confocal 
microscope with a 63×/1.4 Oil DIC objective and processed using Zen 2012 software. Laser 
intensity and gain were kept at a minimum and held constant for all experiments. Linear contrast 
was equally applied during image processing. To localize PZN, B. anthracis Sterne 7702 was 
treated in PBS with 0.2 µM PZN-Cy5 for 30 min at 22 °C. After washing in PBS (3 × 500 µL), 
cells were resuspended in a final volume of 250 µL PBS. Competition experiments were 
performed using PR06 (PZN-resistant) in PBS treated with DMSO (vehicle) or 1 µM PZN for 20 
min at 22 °C before the addition of 0.05 µM PZN-Cy5. After 20 min at 21 °C, the cells were 
washed in PBS (3 × 500 µL) and resuspended in a final volume of 250 µL PBS. Sterne underwent 
co-treatment in PBS with 0.2 µM PZN-Cy5 for 25 min before the addition of other fluorescent 
compounds. After 5 min additional treatment, cells were washed in PBS (5 × 500 µL) and 
resuspended in a final volume of 250 µL PBS. Concentrations used: NAO (Sigma-Aldrich), 1 
µM; Dil-C12, 1 µM; BODIPY-vancomycin, 1 µM; Bocillin-FL, 1 µM. For CL experiments, cells 
were treated with EtOH (vehicle), 10 µg/mL CL, or 100 µg/mL CL in addition to 0.2 µM PZN-
Cy5 for 30 min. 
4.5.17 Super-resolution microscopy (STORM) 
Cells for 3D super-resolution microscopy were grown and treated with PZN-Cy5 as 
described for confocal microscopy. The cells were immobilized on Nunc® Lab-Tek® 8-well 
chambered coverglass (Sigma-Aldrich) coated with 0.1% (w/v) poly-L-lysine (Sigma-Aldrich). 
After 10 min incubation, unattached cells were removed by washing chambers with sterile PBS. 
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Chambers were filled with 500 µL imaging buffer (10 mM NaCl, 50 mM Tris-HCl (pH 8.5), 10% 
w/v glucose). Immediately prior to imaging, cysteamine (Sigma-Aldrich, 10 mM final 
concentration), catalase (EMD Millipore, 909 U/mL), and pyranose oxidase (Sigma-Aldrich, 4.44 
U/mL) were added to the imaging buffer. 3D super-resolution microscopy was performed as 
described previously (Fei et al., 2015; Rust et al., 2006; Shashikanth et al., 2015). Briefly, 
samples were imaged using an Olympus IX-71 inverted microscope outfitted with a 100× NA 1.4 
SaPo oil objective. Mechanical shutters (LS6T2, Unibliz) were used to alternatively excite the 
sample with a red laser (DL640-100-AL-O, Crystalaser) and reactivate Cy5 with a violet laser 
(405 nm, 20 mW, Spectra Physics Excelsor). The lasers were expanded by 7.5×, reflected by a 
dichoroic mirror (Semrock FF408/504/581/667/762-Di01-25X36), and sent to the sample 
chamber with a focusing lens that also creates an incidental angle slightly smaller than the total 
internal reflection angle, reducing the background signal while allowing illumination of several 
hundred nm along the z-axis. The emission signal from the sample was passed through an 
emission filter (Semrock FF01-594/730-25) and two additional notch filters (Semrock NF01-
568/647-25X5.0 and NF01-568U-25), and was imaged on an EMCCD camera (DV887ECS-BV, 
Andor Tech). A cylindrical lens (SCX-50.8-1000.0-UV-SLMF-520-820, CVI Melles Griot, 2 m 
focal length) in the emission beam path induced astigmatism for 3D detection (Huang et al., 
2008).  ASI CRISP (Applied Scientific Instrumentation) and a piezo-objective (PI P-721.10) were 
used to compensate for vertical drift during data collection. The horizontal drift was corrected in 
the post data acquisition step by the analysis software utilizing the correlation function (Bates et 
al., 2007). The data analysis software was provided by Xiaowei Zhuang (Rust et al., 2006) and 
modified for 3D imaging.  
4.5.18 2D projection analysis 
2D projection analysis was used to determine spatial localization of PZN on B. anthracis 
cells. A total of 11 cells imaged by super-resolution microscopy were aligned lengthwise along 
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the y-axis, and then sectioned to remove poles and septa. Cells were projected onto the XZ plane 
and divided into units of 30 × 30 nm
2
. Within each unit, spot density was determined and color-
mapped. The probability of finding a dye molecule a certain distance R from the y-axis was 
calculated for radial windows with a 20 nm bin size and normalized to the area of the radial 
window.  
4.5.19 PZN-Cy5 cluster analysis 
A density-based clustering analysis algorithm, DBSCAN (Daszykowski et al., 2002), was 
used as previously reported (Fei et al., 2015; Shashikanth et al., 2015) to analyze super-resolution 
images of PZN-Cy5-treated B. anthracis. Briefly, spots in super-resolution images of 14 cells 
were grouped into clusters based on spatial density. The required Npts and Eps parameters were 
set to 19 and 40 nm, respectively, and used to identify core points in high density spots. 
Parameter values empirically set such that core points within a cluster were within Eps distance 
of each other and surrounded by at least Npts points. Cluster borders were defined by points 
located with Eps distance to any core point. Cluster size was calculated as twice the average 
distance between the cluster center and every point in the cluster.  
4.5.20 Selection of spontaneous PZN-resistant mutants 
Spontaneous PZN-resistant mutants were generated by plating 2 × 10
8 
B. anthracis Sterne 
7702 cells grown to stationary phase onto a PZN plate containing 4 × PZN MIC. Surviving 
colonies were tested for sustained PZN resistance via microbroth dilution as described above. 
Resistant mutants PR01, PR02, PR05, and PR06 were subjected to genomic DNA isolation as 
follows: 3 × 10 mL cultures of each strain were grown to stationary phase, harvested, and 
resuspended in 400 µL of water. Cells were lysed with 50 µL of 10% SDS and 5 µL of 20 mg/mL 
RNase solution at 22 °C for 5 min. DNA was isolated via 25:24:1 phenol/chloroform/isoamyl 
alcohol extraction, followed by addition of 24:1 chloroform/isoamyl alcohol. DNA precipitation 
via cold isopropyl alcohol and a subsequent 70% ethyl alcohol wash resulted in purified gDNA. 
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4.5.21 Whole genome sequencing and assembly 
Genomic libraries for resequencing were prepared using the TruSeq DNAseq Sample 
prep kit (Illumina, San Diego, CA). Sequencing was performed on a HiSeq 2000 with Version 3 
Chemistry for 1×100 cycles. SNP and DIP discovery was performed with two different methods. 
Regarding PR02, PR05, and PR06, CLC Genomics Workbench SNP and DIP discovery pipelines 
were employed using with the publicly available B. anthracis str. Sterne genome NC_005945.1 as 
a reference. PR01 required de novo assembly with IDBA UD version 1.0.9, followed by whole 
genome alignment and SNP discovery using Mauve version 2.3.1. Resistant mutants PR03 and 
PR04 were selected separately and underwent Sanger sequencing after PCR amplification of 
bas4114 and sequencing with the BamHI-BAS4114-f primer (Table 4.2). The WGS data 
discussed in this publication have been deposited in NCBI's GenBank and are accessible via 
BioProject accession number: PRJNA295544. Within this BioProject are individual accession 
numbers for each B. anthracis strain (taxId:1392) for which whole genome sequencing was 
performed: CP012720, PR01; CP012721, PR02; CP012722, PR05; CP012723, PR06; CP012724, 
PR07; CP012725, PR08; CP012726, PR09-1; CP012727, PR09-4; CP012728, PR10-4; 
CP012730, Parent1 (for PR01 through PR06); CP012729, Parent2 (for PR07 through PR10-4. 
4.5.22 Genetic deletion of bas4114-bas4117 
Markerless genetic deletions were created in B. anthracis Sterne 7702 following 
established protocols (Janes and Stibitz, 2006). The 500 base pairs upstream and downstream the 
bas4114-4117 gene cluster were cloned into the homologous recombination vector pBKJ236 
using Gibson cloning (New England Biolabs) with the BamHI and NotI restriction sites. The 
pBKJ236 constructs were transformed into the E. coli dam dcm strain SCS110. Overnight 
cultures of the vector-containing SCS110 strain grown in LB containing 500 µg/mL erythromycin 
were used for conjugation along with overnight cultures of the conjugation helper strain E. coli 
SS1827 grown in LB with 200 µg/mL ampicillin and B. anthracis Sterne 7702 grown in BHI. 
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From the stationary phase cultures, 400 µL were removed and washed twice by pelleting and 
suspending in 500 µL of LB to remove residual antibiotic. The pellets were resuspended in 200 
µL of LB, then mixed thoroughly in equal volumes, and 150 µL of the mixture was inoculated 
onto a BHI agar plate without spreading. The inoculum was allowed to dry and the plate was 
incubated at 22 °C for 24 h. The entire growth was then carefully removed from the plate, 
resuspended in 200 µL of LB, and spotted onto a BHI agar plate containing 5 µg/mL 
erythromycin and 60 U/mL polymyxin B (BHIep). The culture was allowed to dry and then 
subsequently plated to achieve single colonies. The plate was incubated at 22 °C until single 
colonies of B. anthracis Sterne 7702 were visible (~48 h). A single colony was used to inoculate 
a 2 mL culture of BHI containing 5 µg/mL erythromycin, and the culture was incubated with 
shaking at 22 °C overnight. The saturated culture was used to inoculate a fresh culture of BHI 
containing 5 µg/mL at a 1:1000 dilution. This culture was incubated at 37 °C with shaking until 
saturation (~8 h), then 150 µL of the culture was spotted onto a BHIep plate and allowed to dry. 
The spot was streaked for single colonies and the plate was incubated at 37 °C overnight. A 
single colony was picked and used to make competent cells as previously described (Quinn and 
Dancer, 1990). Briefly, a colony was used to inoculate a 1 mL culture of LB containing 0.1% 
glucose (LBG). The culture was incubated at 37 °C without shaking for 10 min, and then used to 
inoculate 25 mL of LBG in a 250 mL sealable Erlenmeyer flask. The culture was incubated with 
shaking at 100 rpm at 37 °C until it reached an OD600 of 0.20, at which point it was transferred to 
a 50 mL conical tube and pelleted at 4000 × g at 4 °C for 10 min. The spent media was discarded 
and the pellet was washed with ice cold electroporation buffer (EB; 10% w/v sucrose, 15% v/v 
glycerol, 2 mM potassium phosphate, pH 7.8) twice. The cells were resuspended in 400 µL of 
cold EB, transferred to a 0.4 cm gap electroporation cuvette (USA Scientific), and incubated on 
ice for 10 min. A plasmid encoding the I-SceI restriction enzyme, pSS4332 (Cybulski et al., 
2009), was added as 10 µL of a 500 ng/µL stock and the cells were pulsed one time at 2.5 kV, 25 
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µF, 200 Ω (mean time constant of 4.4 ms). The cells were then placed on ice for 10 min before 
being diluted with 600 µL LBG. The cells were recovered at 37 °C for 2 h and then plated on 
LBG agar plates containing 25 µg/mL kanamycin. Colonies were pooled and passaged repeatedly 
on BHI agar plates containing 25 µg/mL kanamycin until erythromycin sensitive colonies could 
be isolated. Sensitive colonies with the desired genes deleted were determined by PCR 
amplification with the cloning primers and were then repeatedly streaked on antibiotic free BHI 
agar plates until kanamycin sensitive colonies were isolated. Gene deletion was confirmed by 
PCR amplification with gene specific primers (Figure 4.17) and the strains were confirmed to be 
sensitive to both kanamycin and erythromycin by plating on the appropriate antibiotic containing 
BHI agar plates. 
After genetic deletion of bas4114-4117, a second round of spontaneously resistant 
mutants to PZN were selected and isolated as above. Serial-passage mutants were isolated as 
previously described (Friedman et al., 2006), starting with three independent cultures of an OD600 
of 0.1 B. anthracis Sterne 7702 Δbas4114-4117 in 0.25 μg/mL (0.25 × MIC) PZN LB. Cultures 
that grew were diluted to an OD600 of 0.1 and subjected to increased concentrations of PZN, until 
cultures were resistant to 64 µg/mL. Cultures were serially passaged onto PZN-free medium to 
confirm mutant stability. Genomic DNA was isolated as described above. All mutants derived 
from the Δbas4114-4117 deletion strain were sequenced as described and assembled via CLC 
Genomics Workbench and SNP analysis was performed with Mauve version 2.3.1. 
4.5.23 Effect of cardiolipin on fluorescence intensity 
Three independent stationary phase cultures of B. anthracis Sterne 7702 were used to 
inoculate fresh LB (200 µL into 5 mL LB) and the new cultures were grown to OD600 0.5 at 37 ˚C 
with shaking. Samples were prepared by diluting 10 µL aliquots of culture to 1 mL in PBS 
containing 1 nM PZN-Cy5 and vehicle (EtOH), 10 µg/mL CL (Sigma Aldrich), or 100 µg/mL 
CL. After mixing at 22 °C for 30 min, cells were analyzed by flow cytometry as described above 
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for differences in PZN-Cy5 fluorescence intensity. Geometric means were normalized to the 
control samples. 
4.5.24 Cardiolipin quantification from total lipid extracts 
Cultures of B. anthracis Sterne 7702, B. anthracis Δbas4114-4117, B. anthracis PR09-4, 
B. anthracis PR10-4, B. subtilis 168, E. faecium U503, and S. aureus USA300 (three independent 
10 mL cultures for each strain) were grown for 20 h at 37 ˚C. LB containing an additional 1.5 M 
NaCl was inoculated with 200 µL aliquots of stationary phase cultures of B. subtilis 168, E. 
faecium U503, and S. aureus USA300 (three independent 10 mL cultures for each strain) and 
grown for 40 h at 37 °C. The cells were harvested by centrifugation (4000 × g, 10 min, 4 °C) and 
resuspended in 5 mL 2:1 CHCl3:MeOH and 1.25 mL PBS, and then extracted for 1 h at 22 °C. 
The supernatant was removed after centrifugation (4000 × g, 10 min, 4 °C) and layers were 
washed with 1 mL CHCl3 and 1 mL PBS. The organic layer was removed and dried by speed 
vacuum. The crude lipids were redissolved in 200 µL CHCl3 and transferred to microfuge tubes, 
then dried again. The lipids were then dissolved in 20 µL CHCl3 and separated by preparative 
TLC (Analtech Silica Gel G) using 2:1 CHCl3:MeOH. The CL-containing spots were removed 
and extracted with 200 µL 2:1 CHCl3:MeOH for 15 min with shaking. The extracts were dried by 
speed vacuum and redissolved in 20 µL CHCl3. Each sample was spotted (0.5 µL) onto Merck 
Silica Gel 60 F254 analytical TLC plates and separated using 80:20:5 CHCl3:MeOH:AcOH. The 
plates were developed in iodine and imaged using a Bio-Rad ChemiDoc XRS+. ImageJ was used 
to subtract background and measure spot density to determine percent CL out of total lipid 
content. 
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4.7 Figures 
 
Figure 4.1 | Structures. Chemical structures of plantazolicin (PZN) (A), Me2-Arg-Az5 (B), 
Biotin-PZN (C), PZN-Biotin (D), PZN-photoaffinity probe (E), PZN-Cy5 (F), daptomycin (Dap)-
Cy5 (G) NAO, nonyl acridine orange (H), and DilC12(3) perchlorate (I). 
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Figure 4.2 | Confirmation of plasmid loss in B. anthracis 34F2 LLNL A0517-1. (Top) PCR of 
a conserved chromosomal gene, bas4114. (Bottom) pXO1 encoded gene lef is not present in 
A0517-1 or the select B. cereus strains. 
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Figure 4.3 | PZN is not toxic to Caenorhabditis elegans using two different experiments. PZN 
was subjected to purified PZN during both liquid fast killing (A) and slow killing assays (B-C). 
Animals were treated with 64 μg/mL PZN and analyzed by live/dead screening over the course of 
the experiments. P-values were generated using the Log-rank (Mantel-Cox) test. 
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Figure 4.4 | Mass spectrometry structural characterization of biotin-PZN. (A) Mass 
spectrum of the [M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) 
CID spectrum of the singly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to 
identified fragments of biotin-PZN, shown on the structure in panel (C). 
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Figure 4.5 | Mass spectrometry structural characterization of PZN-biotin. (A) Mass 
spectrum of the [M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) 
CID spectrum of the singly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to 
identified fragments of PZN-biotin, shown on the structure in panel (C). 
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Figure 4.6 | Mass spectrometry structural characterization of PZN-photoaffinity probe. (A) 
Mass spectrum of the [M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. 
(B) CID spectrum of the m/z 1427 species, corresponding to the loss of N2 from the original 
molecule. Labeled peaks correspond to identified fragments, shown on the structure in panel (C). 
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Figure 4.7 
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Figure 4.7 (continued) | PZN treatment results in the inhibition of three out of four analyzed 
macromolecular pathways. B. anthracis cells were treated with 1 × or 2 × MIC PZN and the 
appropriate radiolabelled precursor to the macromolecule of interest. After incubation for 1 h, 
macromolecules were precipitated and radiolabelled precursor incorporation into protein (A), 
fatty acid (B), peptidoglycan (C), or RNA (D) was measured. Each experiment included samples 
treated with a control compound that is known to affect a particular pathway (protein: 
chloramphenicol; fatty acid: triclosan; peptidoglycan: vancomycin; RNA: rifampicin. All 
compounds were added at 1 × or 2 × MIC, except rifampicin, which required significantly lower 
concentrations to achieve medial inhibition. Percent inhibition was determined by comparing 
radioactive incorporation between cells containing compound vs. vehicle. Error is reported as 
standard deviation with n = 3. 
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Figure 4.8 | B. anthracis gene expression profile when treated with PZN. A volcano plot 
represents the set of differentially regulated genes in response to treatment with 0.25 × MIC of 
PZN. Red (upregulated) and green (downregulated) points are genes with significantly altered 
expression in response to PZN treatment, while black genes did not meet the q-value (< 0.01) 
threshold. Genes where the q-value = 0 were given a value of 1 × 10
-105
. Abbreviations: # – 
hypothetical, * – transporter, ^ – transcriptional regulator, bdbD – B. subtilis hypothetical 
homolog, lldP-1 – L-lactate permease, ldh2/3 – L-lactate dehydrogenase, cydA-2 – cytochrome d 
ubiquinol oxidase, mmgD – citrate synthase 3, hutHIU – histidine utilization genes, gerN – 
germination protein, kamA – L-lysine 2,3-aminomutase, § – remaining upregulated genes. All 
differentially expressed genes are summarized in Table 4.5.  
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Figure 4.9 | The B. anthracis gene expression profile with Me2-Arg-Az5 differs from PZN 
treatment. (A) A volcano plot represents the set of differentially regulated genes in response to 
treatment with 0.25 × MIC of Me2-Arg-Az5. Red (upregulated) and green (downregulated) points 
are significantly expressed genes in response to Me2-Arg-Az5, while black genes did not meet 
the q-value (< 0.01) threshold. Genes where the q-value = 0 were given a value of E-155. 
Abbreviations: # – hypothetical, * – transporter, ^ – transcriptional regulator, atpI – ATP synthase 
protein I, hmp – nitric oxide dioxygenase, lldP-1 – L-lactate permease, ldh2/3 – L-lactate 
dehydrogenase, sugE-1 – EmrE protein (cationic drug membrane transporter), RR – response 
regulator, HK: histidine kinase , § – remaining upregulated. All genes are summarized in Table 
4.10. (B) Venn diagram demonstrating the commonality of the PZN and Me2-Arg-Az5 expression 
profiles. The compilation of common genes is located in Table 4.9. 
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Figure 4.10 | Growth curves of PZN and Me2-Arg-Az5 reveal different phenotypes. (A) B. 
anthracis cells treated with PZN undergo rapid decrease in optical density with concentrations 
above the minimum inhibitory concentration (MIC, determined from microbroth dilution assays). 
Time points were collected every two minutes and adjusted to a 1-cm path length. Error is 
reported as standard deviation with n = 3. (B) B. anthracis treated with Me2-Arg-Az5. Reduction 
in optical density is observed briefly at 4 × MIC. Both growth curves were measured in duplicate 
and normalized to OD600 0.35 (A) and 1.0 (B). 
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Figure 4.11 | PZN synergizes with cell envelope-acting antibiotics and depolarizes the B. 
anthracis membrane. (A) Isobolograms of the minimum inhibitory concentrations (μg/mL) of 
PZN with nisin (top) and daptomycin (bottom). Interactions taking place below the dotted line 
represent synergistic behavior. (B) Detection of membrane potential in B. anthracis. Red/green 
ratios were calculated using mean fluorescence intensities of cells treated for 30 min at RT with 
0.1 µM DiOC2(3) and the vehicle of DMSO (negative control), 0.1 µM DiOC2(3) and 5.0 µM 
CCCP (positive control), 0.1 µM DiOC2(3) and 0.5 µM PZN, and 0.1 µM DiOC2(3) and 1.0 µM 
PZN. Data were normalized to the positive control sample of DiOC2(3) and vehicle (DMSO). 
Error is given as standard deviation with n = 3. P-values are given relative to the DMSO control 
with * indicating < 0.0005 and ** indicating < 0.0001. Abbreviations: Dap, daptomycin; 
DiOC2(3), 3,3’-diethyloxacarbocyanine iodide; CCCP, carbonyl cyanide m-chlorophenyl 
hydrazone. 
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Figure 4.12 | Mass spectrometry characterization of PZN-Cy5. (A) Mass spectrum of the 
[M+H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of 
the singly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to identified 
fragments of PZN-Cy5, shown on the structure in panel (C). 
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Figure 4.13 | PZN-Cy5 localizes to distinct foci on B. anthracis. (A) Representative 
fluorescence microscopy images are shown for the Cy5, DIC, and merged channels of B. 
anthracis Sterne treated with 0.1 µM PZN-Cy5 (0.05 × MIC) for 30 min. Competition 
experiments in a PZN-resistant B. anthracis strain (PR06, vide infra) show (B) robust labeling 
with 0.05 µM PZN-Cy5 in the absence of unlabeled PZN and (C) significantly decreased labeling 
when cells are pretreated with 1 µM PZN (0.016 × MIC, resistant strain PR06) for 20 min. Scale 
bars, 2 µm.  
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Figure 4.14 | STORM images of PZN-Cy5 labeled B. anthracis. (A) 3-D super-resolution 
images of 12 representative B. anthracis treated with PZN-Cy5. (B) Two representative cells 
rotated about the z-axis show distinct, non-septal localization of PZN-Cy5. Green, blue, and 
yellow circles mark three individual foci in each rotated view. Scale bars, 1 µm. 
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Figure 4.15 | Cluster analysis of B. anthracis treated with PZN-Cy5 and imaged by super-
resolution microscopy. (A) Representation of cell alignment used in subsequent analyses. (B) 
PZN-Cy5 color density map of a representative cell projected onto the XZ plane. (C) Probability 
density of PZN-Cy5 increases as distance from the center of the cell (R) increases, reaching a 
maximum at the cell membrane. (D) Cluster analysis of two representative B. anthracis cells (top) 
shows identified clusters (bottom) used in subsequent size calculations. 
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Figure 4.16 | Hydropathy plot of BAS4114 reveals a single transmembrane helix. (A) The 
amino acid sequence of BAS4114 was analyzed using SPOCTOPUS, which predicted a 
transmembrane domain from residues 151-171. (B) Corresponding amino acids for each predicted 
membrane association. Green, inside the membrane; Red, transmembrane; Blue, outside the 
membrane. 
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Figure 4.17 | Confirmation of bas4114-4117 deletion in B. anthracis Sterne. Specific primers 
for each deleted gene were used to confirm their absence by PCR amplification. 1, bas4114 in 
wild type Sterne (WT); 2, bas4114 in deletion strain; 3, bas4115 in WT; 4, bas4115 in deletion 
strain; 5, bas4116 in WT; 6, bas4116 in deletion strain; 7, bas4117 in WT; 8, bas4117 in deletion 
strain. 
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Figure 4.18 | Cardiolipin increases PZN-Cy5 interaction with bacterial cells. (A) Mean 
fluorescence intensities of B. anthracis cell populations treated with daptomycin-Cy5 or PZN-
Cy5 in the presence or absence of exogenous CL were determined by flow cytometry and 
normalized to cells treated only with the Cy5-labeled compound and vehicle. Error is reported as 
standard deviation with n = 3. The PZN-Cy5 p-values are given relative to the 0 µg/mL control 
with * indicating <0.01 and ** indicating <0.001. The p-values for daptomycin-Cy5 were both 
>0.01. (B) Isobologram of the minimum inhibitory concentrations (μg/mL) of PZN and CL. 
Interactions taking place below the dotted line represent synergistic behavior. 
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Figure 4.19 | Mass spectrometry characterization of daptomycin-Cy5. (A) Mass spectrum of 
the [M+2H]
2+
 species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID 
spectrum of the doubly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to 
identified fragments of daptomycin-Cy5, shown on the structure in panel (C). 
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Figure 4.20 | PZN colocalizes with CL- and RIF-specific dyes. (A) From left to right, the 
channels for NAO, Cy5, DIC, and a merged image are shown to illustrate the co-localization of 
NAO (yellow) and PZN (red). (B) Same as panel A but with DilC12(3) replacing NAO. Scale 
bars, 2 µm. 
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4.8 Tables 
Table 4.1 | Minimum inhibitory concentrations reveal the species specificity of plantazolicin 
(PZN) 
Strain MIC (μg/mL) 
MIC 
(μM) 
Source 
B. cereus group 
   
B. anthracis Sterne 34F2 1 0.75 S. Blanke (UIUC) 
B. anthracis Sterne 7702 1 0.75 USDA 
B. anthracis Sterne 7702 Δbas4114-
4117 
1 0.75 This study 
B. anthracis Sterne 7SBON30 1 0.75 (Davison et al., 2005) 
B. anthracis Sterne 7SBON40 1 0.75 (Davison et al., 2005) 
B. anthracis Sterne 7SDG30 1 0.75 (Davison et al., 2005) 
B. anthracis Sterne 7SBTR30 1 0.75 (Davison et al., 2005) 
B. anthracis Sterne 7SBONTO 1 0.75 (Davison et al., 2005) 
B. anthracis Sterne 7SBTRTO 1 0.75 (Davison et al., 2005) 
B. anthracis Sterne 7SBTO30 1 0.75 (Davison et al., 2005) 
B. anthracis BSL3 strains 2 – 16 1.5 – 12 USAMRIID 
B. anthracis CDC 684 2 1.5 USAMRIID 
B. anthracis Sterne 34F2 A0517-1 1 0.75 BEI 
B. anthracis Sterne 34F2 A0517-2 2 1.5 BEI 
B. anthracis Sterne 34F2 ΔblsO 1 0.75 (Anderson et al., 2011) 
B. anthracis Sterne 34F2 ΔcsaB 1 0.75 (Kern et al., 2010) 
B. anthracis Sterne 34F2 Δsap 1 0.75 (Nguyen-Mau et al., 2012) 
B. anthracis Sterne 34F2 Δeag 1 0.75 (Nguyen-Mau et al., 2012) 
B. anthracis Sterne 34F2 Δanthrose 1 0.75 
C. Turnbough (U. 
Alabama Birmingham) 
B. anthracis Sterne 34F2 ΔbclA 1 0.75 
(Tan and Turnbough, 
2010) 
B. anthracis Sterne BA850 
(Δpetrobactin)  
1 0.75 (Carlson et al., 2010) 
B. anthracis Sterne BA781 1 0.75 BEI 
B. anthracis Weybridge 1 0.75 BEI 
B. cereus 14579 >64 >48 USDA 
B. cereus 541 (ΔplcR) >64 >48 (Pomerantsev et al., 2003) 
B. cereus ATCC 7064   >64 >48 ATCC 
B. cereus ATCC 13472   >64 >48 BGSC 
B. cereus BAG4x2-1 >64 >48 BEI 
B. cereus E33L >64 >48 BEI    
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Table 4.1 (continued)    
B. cereus G9241 8 6 BEI 
B. cereus GP7 >64 >48 BGSC 
B. cereus Rock3-44 64 48 NMRS 
B. cereus VD014 >64 >48 BEI 
B. cereus VD115 >64 >48 BEI 
B. mycoides 96/3308 >64 >48 BGSC 
B. samanii C1   >64 >48 BEI 
B. thuringiensis Konkukian 97-27   >64 >48 BEI 
B. thuringiensis israelensis ATCC 
35646 
  >64 >48 BEI 
B. thuringiensis subsp. thuringiensis >64 >48 BGSC 
Atypical gamma phage sensitivity 
   
B. cereus ATCC 4342   >64 >48 BEI 
B. cereus CDC 32805 >64 >48 
(Schuch and Fischetti, 
2006) 
B. cereus 2002013145 >64 >48 CDC 
B. cereus 2002013146 >64 >48 CDC 
B. cereus 2002013100 >64 >48 CDC 
B. cereus 2000031002 >64 >48 CDC 
Non B. cereus group 
   
B. methylotrophicus FZB42   >64 >48 BGSC 
B. amyloliquefaciens B-14393T   >64 >48 BGSC 
B. megaterium 899 32 24 BGSC 
B. pumilus SAFR-032   >64 >48 BGSC 
B. subtilis    
AKP4 (Δdes) >64 >48 
D. de Mendoza (U. 
Nacional de Rosario) 
AKP21 (ΔdesRK) >64 >48 
D. de Mendoza (U. 
Nacional de Rosario) 
BSU-LIKE1 (ΔliaIH) >64 >48 BGSC 
HB0042 >64 >48 Personal Collection 
HB0934 (ΔliaGFSR) >64 >48 J. Helmann (Cornell) 
HB5126 (ΔliaIH) >64 >48 J. Helmann (Cornell) 
str. 168 >64 >48 J. Wells (USCF) 
Brevibacillus formosus SS 86-3 >64 >48 BGSC 
Brevibacillus laterosporus ATCC 
9141 
>64 >48 BGSC 
Neisseria meningititis serotype C >64 >48 (Nassif et al., 1991) 
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Table 4.1 (continued)    
Neisseria sicca >64 >48 ATCC 
Staphylococcus aureus    
12608 >64 >48 P. Hergenrother (UIUC) 
29213 64 48 P. Hergenrother (UIUC) 
33591 64 48 P. Hergenrother (UIUC) 
USA300 >64 >48 P. Hergenrother (UIUC) 
Streptomyces coelicolor >64 >48 USDA 
Streptomyces lividans >64 >48 USDA 
Eukaryotic organisms 
   
Caenorhabditis elegans N2 >64 >48 CGC 
Saccharomyces cerevisiae  >64 >48 H. Zhao (UIUC) 
Talaromyces stipitatus >64 >48 H. Zhao (UIUC) 
    
 
a
n ≥ 3 replicates 
b
Highlighted strains were tested for gamma phage susceptibility and are displayed in the main 
text 
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Table 4.2 | PZN is not antibacterial against B. anthracis endospores 
[PZN] (μg/mL) CFU/mLa 
    Vehicle 9.8E+08 
    0.5 4.3E+08 
    1 8.3E+08 
    2 6.8E+08 
    4 3.4E+08 
    8 6.5E+08 
    16 3.5E+08 
    
      aColony forming units per mL of endospore suspension 
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Table 4.3 | γ phage sensitivity and PZN susceptibility of Bacillus strains 
Strain 
γ Phage 
Sensitivity
a
 PZN MIC
b
 Source
c
 
B. anthracis Sterne 7702 +++ 1 USDA 
B. anthracis Sterne 34F2 A0517-1
d
 +++ 2 BEI 
B. cereus 2002013145 +++ >64 CDC
e
 
B. cereus 2002013146 +++ >64 CDC
e
 
B. cereus 2002013100 ++ >64 CDC
e
 
B. cereus 2000031002 +++ >64 CDC
e
 
B. cereus ATCC 4342 + >64 ATCC 
B. cereus ATCC 7064 + >64 ATCC 
B. cereus CDC 32805 + >64 
(Schuch and 
Fischetti, 2006) 
B. cereus G9241 - 8 BEI 
B. megaterium 899 - 32 BGSC 
B. mycoides 96/3308 - >64 BGSC 
    
a 
Plus signs indicate the level of phage sensitivity, with +++ representing the most sensitive  
b MIC (minimum inhibitory concentration) as determined by microbroth dilution, units in μg/mL 
c 
Abbreviations: USDA, United States Department of Agriculture; BEI, Biodefense and Emerging 
Infections Research Resources Repository; CDC, United States Centers for Disease Control and 
Prevention; ATCC, American Type Culture Collection; BGSC, Bacillus Genetic Stock Center 
d 
LLNL A0517 was obtained from BEI as a mixture of two colony types. A0517_1 was confirmed 
to be devoid of pXO1 by PCR (Figure 4.2) 
e 
Strains identified by multilocus sequence typing analysis (Hoffmaster et al., 2006) 
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Table 4.4 | MICs of representative strains demonstrating PZN activity in various rich media 
 
MIC (μg/mL) 
 Strain LB
a
 MH BHI 
Bacillus anthracis Sterne 1 1 1 
Bacillus cereus CDC32805 >64 >64 >64 
Bacillus cereus ATCC 4242 >64 >64 >64 
Bacillus sp. Al Hakam >64 >64 >64 
Bacillus methylotrophicus FZB42 >64 >64 >64 
Bacillus subtilis strain 168 >64 >64 >64 
Enterococcus faecium U503 >64 >64 >64 
Listeria monocytogenes 4b >64 >64 >64 
Staphylococcus aureus ATCC 12608 >64 16 32 
Staphylococcus aureus ATCC 29213 64 8 16 
Staphylococcus aureus ATCC 33591 64 8 16 
Staphylococcus aureus USA300 >64 >64 >64 
     aLuria-Bertani (LB), Mueller-Hinton (MH), Brain Heart Infusion (BHI) 
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Table 4.5 | Complete RNA-Seq analysis of differentially expressed B. anthracis genes after 
PZN treatment 
Locus Tag Gene Description Fold Change q-value 
BAS1222 ywcJ
a
 
formate/nitrite transporter family 
protein -7 3.19E-38 
BAS0577 lldp-1 L-lactate permease -7 2.14E-24 
BAS4869 ldh3 L-lactate dehydrogenase -6 6.40E-27 
BAS0169 
 
hypothetical protein -6 1.30E-25 
BAS4146 
 
hypothetical protein -5 3.66E-19 
BAS4762 ldh2 L-lactate dehydrogenase -4 1.19E-13 
BAS1089 yjzC
a
 hypothetical protein -4 5.38E-16 
BAS1615 yfmQ
a
 hypothetical protein -3 1.49E-05 
BAS3917 
 
hypothetical protein -3 9.12E-04 
BAS4690 cydA-2 
cytochrome d ubiquinol oxidase 
subunit I -3 4.40E-04 
BAS0513 bdbD hypothetical protein -3 1.00E-03 
BAS1942 sdpI
a
 hypothetical protein 2 5.98E-03 
BAS3405 
 
ahpC/TSA family protein 2 6.00E-03 
BAS2363 
 
hypothetical protein 2 1.27E-03 
BAS2776 yetG
a
 hypothetical protein 2 9.17E-04 
BAS1163 
 
hypothetical protein 3 2.06E-03 
BAS0730 yfhC
a
 nitroreductase family protein 3 6.85E-03 
BAS4453 
 
hypothetical protein 3 4.90E-04 
BAS2568 
 
TetR family transcriptional regulator 3 1.43E-03 
BAS2566 kynB hypothetical protein 3 2.83E-03 
BAS0683 yqgI
a
 phosphate ABC transporter permease 3 7.44E-04 
BAS4452 
 
hypothetical protein 3 2.81E-05 
BAS2565 kynA 
tryptophan 2,3-dioxygenase family 
protein 3 3.85E-03 
BAS3439 hutG
a
 formimidoylglutamase 3 1.17E-03 
BAS3871 
 
hypothetical protein 3 1.35E-05 
BAS0214 lagB invasion protein LagB 3 2.21E-04 
BAS1691 fabH2 3-oxoacyl-ACP synthase 3 6.35E-04 
BAS4502 ytpI
a
 hypothetical protein 3 2.71E-06 
BAS1573 
 
hypothetical protein 3 8.18E-03 
BAS0849 
 
hypothetical protein 3 1.49E-06 
BAS1346 liaF
a
 hypothetical protein 3 1.77E-04 
BAS0525 yuaG
a
 hypothetical protein 3 6.06E-04 
166 
Table 4.5 (continued) 
BAS0610 rocE
a
 amino acid ABC transporter permease 3 1.77E-04 
BAS4777 sodC superoxide dismutase, Cu-Zn 3 6.63E-08 
BAS0524 yuaF
a
 hypothetical protein 4 2.77E-07 
BAS0848 yhaR
a
 enoyl-CoA hydratase 4 1.25E-07 
BAS4173 pstC phosphate ABC transporter permease 4 9.53E-06 
BAS4172 pstA phosphate ABC transporter permease 4 2.15E-07 
BAS4171 pstB 
phosphate transporter ATP-binding 
protein 4 7.63E-07 
BAS1307 ilvE1 
branched-chain amino acid 
aminotransferase 4 1.40E-08 
BAS4560 acsA acetyl-CoA synthetase 4 5.09E-06 
BAS3772 ylbP
a
 hypothetical protein 4 2.05E-05 
BAS0464 rocR-1 
arginine utilization regulatory protein 
RocR 4 1.01E-09 
BAS4877 fadN
a
 3-hydroxyacyl-CoA dehydrogenase 4 1.18E-09 
BAS0624 dppC
a
 
oligopeptide ABC transporter 
permease 4 7.90E-08 
BAS4174 phoX 
phosphate ABC transporter substrate-
binding protein 4 1.87E-08 
BAS5194 fadF
a
 ferredoxin, 4Fe-4S 4 1.32E-07 
BAS1894 dppE
a
 
oligopeptide ABC transporter 
substrate-binding protein 4 1.46E-08 
BAS1070 
 
hypothetical protein 4 1.73E-10 
BAS4778 
 
hypothetical protein 5 5.76E-14 
BAS0681 pstS
a
 
phosphate ABC transporter substrate-
binding protein 5 1.12E-16 
BAS4512 
 
hypothetical protein 5 1.76E-24 
BAS3440 hutI imidazolonepropionase 5 3.49E-21 
BAS2288 
 
hypothetical protein 6 7.47E-08 
BAS0625 
appB, 
oppB
a
 
oligopeptide ABC transporter 
permease 6 3.26E-20 
BAS2146 yokU
a
 hypothetical protein 6 5.30E-39 
BAS0626 
appF, 
oppF
a
 
oligopeptide ABC transporter ATP-
binding protein 6 2.29E-19 
BAS2145 kamA L-lysine 2,3-aminomutase 7 4.12E-35 
BAS3024 
 
arsR family transcriptional regulator 7 1.17E-52 
BAS2188 mmgD citrate synthase 3 8 2.67E-54 
BAS3441 hutU urocanate hydratase 8 5.49E-50 
BAS2649 
 
hypothetical protein 9 5.16E-42 
BAS2650 
 
hypothetical protein 9 2.30E-45 
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Table 4.5 (continued) 
BAS3442 hutH histidine ammonia-lyase 10 9.17E-104 
BAS0627 
appD, 
oppD
a
 
ABC transporter nucleotide-binding 
protein 11 1.62E-95 
BAS2287 yaaN
a
 hypothetical protein 13 4.38E-93 
BAS1521 gerN germination protein gerN 28 0 
BAS3456 
 
hypothetical protein 40 0 
BAS5200 
yvfU, 
desR
a
 DNA-binding response regulator 49 0 
BAS5201 
yvfT, 
desK
a
 sensor histidine kinase 56 0 
BAS5202 yvfS
a
 ABC transporter permease 130 0 
BAS5203 yvfR
a
 ABC transporter ATP-binding protein 135 0 
BAS1345 liaH
a
 PspA/IM30 family protein 1084 0 
BAS1344 liaI
a
 membrane protein 1407 0 
     aGenes are annotated by sequence homology to the corresponding Bacillus subtilis gene 
The q-value is an adjusted p-value, taking in to account the false discovery rate 
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Table 4.6 | RNA-Seq and qRT-PCR analysis of PZN-treated Bacillus anthracis 
 
  
Fold Change 
Locus Tag Gene Description RNA-Seq qRT-PCR
a
 
BAS0577 lldp-1 L-lactate permease -7  -7 ± 2 
BAS4869 ldh3 L-lactate dehydrogenase -6 -24 ± 14 
BAS4762 ldh2 L-lactate dehydrogenase -4 -3 ± 1 
BAS3439 hutG formimidoylglutamase 3  3 ± 1 
BAS3440 hutI imidazolonepropionase 5  4 ± 0 
BAS3441 hutU urocanate hydratase 8  3 ± 0 
BAS3442 hutH histidine ammonia-lyase 10  5 ± 2 
BAS0627 appD, oppD
b
 
ABC transporter nucleotide-binding 
protein 
11 6 ± 3 
BAS1521 gerN germination protein 28    14 ± 9 
BAS5200 yvfU, desR
b
 DNA-binding response regulator 49 37 ± 30 
BAS5201 yvfT, desK
b
 sensor histidine kinase 56 94 ± 36 
BAS1345 liaH
b
 PspA/IM30 family protein 1084  138 ± 10 
BAS1344 liaI
b
 membrane protein 1407 352 ± 191 
 
a Error is given as standard deviation with n ≥ 3 replicates 
b 
Gene annotations are derived from sequence homology to the given B. subtilis gene 
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Table 4.7 | Primers used in this study 
Confirmation of LLNL A0517_1 pXO1 plasmid loss 
pXO1_0172 lef RT-r GATGCGAAAGTAGTGCCAAAGA 
pXO1_0172 lef RT-r CCACAGCATGTCCAAATTCG 
Confirmation of spontaneous mutants 
BamHI-BAS4114-f AAAAGGATCCATGACAGCAAACCGCATTAAAG 
NotI-BAS4114-r AAAAGCGGCCGCTCAGTTTGAAAGGCCTCGC 
Generation and Confirmation of the bas4114-bas4115 deletion strain 
G236Tet-up-vec-f 
TGGAGCTCCACCGCGGTGGCAGGCGTTTGCTGATAC
AC 
G236Tet-up-down-r TAAAAAAGGACAGTTTCATCCCCTACCTACC 
G236Tet-down-up-f GGGGATGAAACTGTCCTTTTTTATATTCATTCAGAC 
G236Tet-down-vec-r 
TCGACCTGCAGCCAAGGACGCATCTGTCTTTGTTTC
AGTG 
TetR-f GCAAACCGCATTAAAGCTGTAGC 
TetR-r CAGTTTGAAAGGCCTCGCC 
SugE4115-f GGCATGGATTTATGTAATCTTAGCTGG 
SugE4115-r GCCTCCTTCGCTTCTTTTTCTTC 
SugE4116-f GGCTTGGGTATTTTTAATTCTAGCTGG 
SugE4116-r CTTAATAGTTTTAAGCCAACAGCGCC 
BAS4117-f GTGGAAAGAAAAAGGGAAGCAACTG 
BAS4117-r GTTCAGAAGAACTGTCCTTTTTAAATAACTTATTCC 
RT-qPCR 
 
Banth 16S qRT-f CGGAATTATTGGGCGTAAAG 
Banth 16S qRT-r TCTCCCAGTTTCCAATGACC 
BAS0577 lldp-1 qRT-f TGGTTCACTATTCGCACCAC 
BAS0577 lldp-1 qRT-r TTTGCTATTGTGCCACCAAC 
BAS0627 appD qRT-f ACGAATTATCTGGCGGAATG 
BAS0627 appD qRT-r AGCCGTTGTTGGCTCATC 
BAS1344 liaI qRT-f GGAGCAGGAGTTGTGTACTGG 
BAS1344 liaI qRT-r GATGGACAAGCCGATTAAACC 
BAS1345 liaH qRT-f ATCAAAGCAAGCGCTTATCG 
BAS1345 liaH qRT-r TTCTAATCGAGTTACTTGCCCTTC 
BAS1521 gerN qRT-f ACGAATGACTGGATTTGATGC 
BAS1521 gerN qRT-r GAAAGTCCTGTTCCTGCAATG 
BAS1659 CitB RR qRT-f AACGACGTTCGATGATGATG 
BAS1659 CitB RR qRT-r TTATCGCATCACGAATACGC 
BAS1660 Sensor HK qRT-f TGAAAGCATTCGGATTACATTG 
BAS1660 Sensor HK qRT-r TCATGCTTACTGGCAAATTCC 
BAS1661 ABC trans qRT-f TGCGAAGATGAATATTGGTGTC 
BAS1661 ABC trans qRT-r ACCCGTACAGTCCAGCAAAG 
BAS1662 ABC trans qRT-f CGGTTGTAATGACGACGATG 
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Table 4.7 (continued)  
BAS1662 ABC trans qRT-r TAGGCGCAGCAATAAGGTG 
BAS1663 ABC trans qRT-f TATGGGAATGTAGGGCAAGG 
BAS1663 ABC trans qRT-r AGAAATTTCACCGTATCATTTGC 
BAS1664 minor cls ClsB qRT-f TGGCACAACAAACTTTACTTCG 
BAS1664 minor cls ClsB qRT-r AACGCCTTATTAACTTGCCCTAC 
BAS1842 asbE qRT-f GGGTATTTGCTTTCTGGTCTTG 
BAS1842 asbE qRT-r TTTCACGGAAGTATGCAAAGG 
BAS1843 asbF qRT-f CAGATCCAGTTGACAGCTTCC 
BAS1843 asbF qRT-r CGGTTCGAACACATGTAAATAATC 
BAS3439 hutG qRT-f TAACGGGCTTTGCAAACAG 
BAS3439 hutG qRT-r CATTTGACGGACCACCATC 
BAS3440 hutI qRT-f TGACCCGCATACTCATCTTG 
BAS3440 hutI qRT-r AAGAATACCTCCGCCTTGTTC 
BAS3441 hutU qRT-f ATTTGTTGGCTTGGTTACGG 
BAS3441 hutU qRT-r CACGACCGATAACGATTGG 
BAS3442 hutH qRT-f TGCGATGGTTGCTCTTACAG 
BAS3442 hutH qRT-r AAAGAACTCCTTGCGCTGTC 
BAS4762 ldh2 qRT-f AATCGTTCGCGGTATTATGG 
BAS4762 ldh2 qRT-r TGGTAGACCAGATTCTTTCCAAG 
BAS4869 ldh3 qRT-f AATCATGAACGTGCAGTTGG 
BAS4869 ldh3 qRT-r TTGCAGTCTTCATAGCTTCCTG 
BAS5033 ftsX qRT-f CGGAAAGACGTTTGAGTTATTTG 
BAS5033 ftsX qRT-r TCGCAATTGTTGCTGTATCTG 
BAS5034 ABC ftsE qRT-f TCTTGAAGATCGTGCAGACG 
BAS5034 ABC ftsE qRT-r ATCGGCAATTACGACTTTCG 
BAS5200 desR qRT-f TTGAAGTAATTGGGCAAGCTG 
BAS5200 desR qRT-r TCTAACCCGCTTTGAATTGG 
BAS5201 desK qRT-f GCAGTGACGAATGTTGTAAAGC 
BAS5201 desK qRT-r CCAATTCCGTTATCTTCTACCG 
BAS5288 TetR reg qRT-f AAGATGAGGAATTGCTTGTTACG 
BAS5288 TetR reg qRT-r CTTGTATAACCGGAATCCTTGG 
BAS5289 transporter qRT-f CGGAGCTCTTGTTGCCTTAC 
BAS5289 transporter qRT-r AAGCACGATTGCGTTTGTTAC 
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Table 4.8 | Minimum inhibitory concentrations (μM) of Me2-Arg-Az5 reveal a broader 
spectrum of activity than PZN 
 
Strain MIC (μM)a 
Bacillus anthracis Sterne 7702 3 
Bacillus anthracis PR06 3 
Bacillus anthracis A0517-1 3 
Bacillus cereus ATCC 4342 6 
Bacillus megaterium 899 3 
Bacillus subtilis 168 6 
Escherichia coli DH5a >48 
Enterococcus faecium U503 48 
Listeria monocytogenes 4b >48 
Neisseria sicca ATCC 29256 >48 
Staphylococcus aureus USA300 3 
Streptococcus pyogenes M1 48 
Pseudomonas putida >48 
  a
Minimum inhibitory concentration, determined my 
microbroth dilution assay, measured in μM 
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Table 4.9 | Common differentially expressed genes after PZN and Me2-Arg-Az5 treatment 
   
Fold Change 
Locus Tag Gene Description PZN Me2-Arg-5Az 
BAS0169 
 
hypothetical protein -6 -4 
BAS0513 bdbD hypothetical protein -3 -2 
BAS0577 lldp-1 L-lactate permease -7 -7 
BAS1089 
 
hypothetical protein -4 -4 
BAS1222 ywcJ formate/nitrite transporter family protein -7 -7 
BAS1615 
 
hypothetical protein -3 -3 
BAS3917 
 
hypothetical protein -3 -2 
BAS4146 
 
hypothetical protein -5 -5 
BAS4690 cydA-2 cytochrome d ubiquinol oxidase subunit I -3 -2 
BAS4762 ldh2 L-lactate dehydrogenase -4 -4 
BAS4869 ldh3 L-lactate dehydrogenase -6 -4 
BAS5200 ycfU,desR DNA-binding response regulator 49 6 
BAS5201 yvfT, desK sensor histidine kinase 56 5 
BAS5202 yvfS ABC transporter permease 130 13 
BAS5203 yvfR ABC transporter ATP-binding protein 135 12 
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Table 4.10 | Complete RNA-Seq analysis of differentially expressed B. anthracis genes after 
Me2-Arg-Az5 treatment  
 
Locus Tag Gene Description Fold Change qValue 
BAS0577 lldp-1 L-lactate permease -7 5.95E-90 
BAS1222 ywcJ
a
 
formate/nitrite transporter family 
protein -7 1.30E-59 
BAS4134 
 
hypothetical protein -7 1.61E-116 
BAS4146 
 
hypothetical protein -5 6.09E-31 
BAS4711 
 
hypothetical protein -5 3.53E-31 
BAS0169 
 
hypothetical protein -4 9.57E-21 
BAS1089 yjzC
a
 hypothetical protein -4 2.76E-23 
BAS1357 hmp nitric oxide dioxygenase -4 6.57E-12 
BAS4762 ldh2 L-lactate dehydrogenase -4 1.24E-16 
BAS4869 ldh3 L-lactate dehydrogenase -4 3.46E-17 
BAS1023 
 
hypothetical protein -3 3.80E-06 
BAS1349 
 
hypothetical protein -3 1.12E-08 
BAS1615 yfmQ
a
 hypothetical protein -3 1.28E-06 
BAS4990 cggR 
gapA transcriptional regulator 
CggR -3 0.004179 
BAS0070 pabC 4-amino-4-deoxychorismate lyase -2 0.003344 
BAS0513 bdbD hypothetical protein -2 8.87E-04 
BAS0547 maeN
a
 
citrate cation symporter family 
protein -2 0.002003 
BAS0566 rapD, rapI
a
 transcriptional regulator -2 0.004179 
BAS0631 rbsR ribose operon repressor -2 6.17E-05 
BAS1024 
 
hypothetical protein -2 8.87E-04 
BAS1185 
 
hypothetical protein -2 0.007387 
BAS1273 
 
ABC transporter permease -2 8.71E-05 
BAS1666 gltT
a
 
proton/sodium-glutamate symport 
protein -2 5.37E-04 
BAS2706 
 
hypothetical protein -2 0.003549 
BAS2707 
 
ABC transporter ATP-binding 
protein -2 8.05E-04 
BAS3173 
 
transcriptional regulator -2 8.18E-07 
BAS3917 
 
hypothetical protein -2 8.14E-04 
BAS4414 
 
succinate dehydrogenase, 
cytochrome b558 subunit -2 0.003007 
BAS4690 cydA-2 
cytochrome d ubiquinol oxidase 
subunit I -2 0.004179 
BAS4922 nupC
a
 
NupC family nucleoside 
transporter -2 0.004085 
BAS5002 whiA hypothetical protein -2 0.007026 
BAS5316 yycI
a
 YycI protin -2 7.74E-04 
BAS0982 fadR, yvdT
a
 
TetR family transcriptional 
regulator 3 8.50E-04 
BAS4115 sugE-1 sugE protein 4 4.42E-10 
BAS5201 yvfT, desK
a
 sensor histidine kinase 5 2.03E-21 
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Table 4.10 (continued)   
BAS5200 yvfU, desR
a
 DNA-binding response regulator 6 4.21E-26 
BAS0375 yuxN, yfiR
a
 
TetR family transcriptional 
regulator 8 2.92E-37 
BAS0902 atpI
a
 ATP synthase protein I 8 2.99E-46 
BAS5203 yvfR
a
 
ABC transporter ATP-binding 
protein 12 1.66E-119 
BAS5202 yvfS
a
 ABC transporter permease 13 2.82E-151 
BAS0376 ykuC, yfiS
a
 
major facilitator family transporter 
protein 181 0 
     aGenes are annotated by sequence homology to the corresponding Bacillus subtilis gene 
The q-value is an adjusted p-value, taking in to account the false discovery rate 
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Table 4.11 | B. anthracis Sterne mutations conferring PZN-resistance accumulate in 
bas4114, an AcrR family transcriptional regulator 
Strain 
bas4114 
Mutation 
Consequence 
Sterne Wild type 
DALEAFLCLLDGLMVELLFAGLNRFETRLNASWQVFWR
GLSN
a
 
PR01
c
 457G→T DAL*b 
PR02 492^T DALEAFLCLLDGLMV* 
PR03 495^AG DALEAFLCLLDGLMVESYYSQV* 
PR04 504^C DALEAFLCLLDGLMVELLFRRFKSL* 
PR05 506^GC DALEAFLCLLDGLMVELLFAQV* 
PR06 507^ATTCGCA DALEAFLCLLDGLMVELLFAIRRFKSL* 
a 
Amino acids 150-191 of BAS4114. Bold residues represent the predicted transmembrane region, 
as defined by Spoctopus (Figure 4.16) (Viklund et al., 2008) 
b 
Asterisk (*) represents the termination of the protein sequence due to the nonsense mutation. 
c 
MICs for the PZN-resistant (PR) mutants are ≥ 32 μg/mL PZN, compared to 1 μg/mL for the 
wild type. 
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Table 4.12 | Upregulation of bas4114-4117 in PZN-resistant mutant, B. anthracis PR06 
Gene Annotation Fold change 
bas4114 acrR family transcriptional regulator 34 
bas4115 emrE drug efflux pump 152 
bas4116 emrE drug efflux pump 47 
bas4117 hypothetical protein 62 
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Table 4.13 | MICs (μg/mL) of selected antibiotics against PZN-resistant mutant, B. anthracis 
PR06 
Compound B. anthacis Sterne B. anthracis PR06 
Plantazolicin 1 64 
Tetracycline 0.125 0.125 
Vancomycin 1 1 
Triclosan 1 1 
Nisin 2 2 
Kanamycin 4 4 
Cerulenin 4 8 
Spectinomycin 8 4 
Chloramphenicol 8 4 
Daptomycin 8 8 
Ethidium Bromide 16 16 
 
  
178 
Table 4.14 | PZN-resistant mutants of B. anthracis Sterne Δbas4114-4117 
Strain Mutation Gene 
Amino Acid 
Consequence 
MIC
a
 
PR07 bas5034 A425G 
cell division ABC transporter, 
FtsE 
G142E 
8 
PR08 bas5034 G270T 
cell division ABC transporter, 
FtsE 
F90L 
32 
PR09-1 bas1659 G190C 
CitB RR
b
/luxR family 
transcriptional regulator 
V64L 
16 
PR09-4 bas1659 G190C 
CitB RR
b
/luxR family 
transcriptional regulator 
V64L 
>64 
 
bas1662 A638G ABC transporter permease H213R 
 
PR10-4 bas1659 C248T 
CitB RR
b
/luxR family 
transcriptional regulator 
T83M 
64 
 
bas1663 C1127T ABC transporter permease A376V 
 
 
bas1842 A43G petrobactin biosynthesis asbE S15G 
 
a MIC as determined by microbroth dilution, measured in μg/mL 
b 
Response regulator 
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Table 4.15 | Effect of B. anthracis Sterne mutations and B. subtilis growth conditions on 
PZN susceptibility and cardiolipin content of bacterial membranes 
 
Strain MIC (µg/mL) % CL
a 
B. anthracis Sterne 7702 1 4.6 ± 0.1 
B. anthracis Sterne 7702 Δbas4114-4117 1 3.6 ± 0.5 
B. anthracis PR09-4 >64 6.1 ± 2.5 
B. anthracis PR10-4 64 24.2 ± 1.6* 
B. subtilis 168 >128 27.5 ± 2.7 
B. subtilis 168
b 
32 37.0 ± 6.1 
 
a
 Error is given as standard deviation with n = 3. P-values were compared to either a parental 
strain (Δbas4114-4117 for PR10-4) or the same strain grown in a normal osmolarity medium with 
* indicating <0.0001 
b
 Luria-Bertani broth supplemented with 1.5 M NaCl  
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Table 4.16 | qRT-PCR of cls locus in evolved PZN-resistant mutants 
 
Fold change 
Gene PR09-1 PR09-4 PR10-4 
BAS1659  NS  NS  NS
a
 
BAS1660  NS  NS  NS 
BAS1661 21 ± 7 48 ± 26  NS 
BAS1662 23 ± 13  NS  NS 
BAS1663 24 ± 9 48 ± 26  NS 
BAS1664 (cls) 39 ± 7 74 ± 26  NS 
BAS1842 (asbE) - -  NS 
BAS1843 (asbF) - -  NS 
    aNS not significant 
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APPENDIX A: PLANTAZOLICIN PUBLICATION WITH MINOR CONTRIBUTIONS 
 
A.1 Engineering Unnatural Variants of Plantazolicin Through Codon Reprogramming 
This chapter was preprinted with permission from (Deane et al., 2013). 
Deane, C.D., Melby, J.O., Molohon, K.J., Susarrey, A.R., and Mitchell, D.A. (2013) ACS Chem 
Biol: 8, 1998-2008. doi: 10.1021/cb4003392. Copyright © 2013 American Chemical Society. 
I constructed the fosmid library and isolated the clone used for PZN production. 
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APPENDIX B: OTHER PUBLICATIONS WITH MINOR CONTRIBUTIONS 
 
B.1 HIV-1 Integrase Inhibitor-Inspired Antibacterials Targeting Isoprenoid Biosynthesis 
This chapter was reprinted with permission (Zhang et al., 2012). 
Zhang, Y., Fu-Yang, L., Li, K., Zhu, W., Liu, Y.L., Cao, R., Pang, R., Lee, E., Axelson, J., 
Hensler, M., Wang, K., Molohon, K.J., Wang, Y., Mitchell, D.A., Nizet, V., and Oldfield, E. 
(2012) ACS Med Chem Lett: 3, 402-406. doi: 10.1021/ml300038t. Copyright © (2012) American 
Chemical Society. 
 
I conducted the assays generating the minimum inhibitory concentrations for the compounds in 
this manuscript.  
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B.2 Antibacterial Drug Leads Targeting Isoprenoid Biosynthesis 
 
This chapter was reprinted with permission (Zhu et al., 2013). 
Zhu W, Zhang Y, Sinko W, Hensler ME, Olson J, Molohon KJ, Lindert S, Cao R, Li K, Wang K, 
Wang Y, Liu YL, Sankovsky A, de Oliveira CA, Mitchell DA, Nizet V, McCammon JA, Oldfield 
E. (2013) Proc Natl Acad Sci U S A: 110, 123-128. doi: 10.1073/pnas.1219899110. Copyright © 
(2013) American Chemical Society. 
 
I obtained the minimum inhibitory concentrations of the compounds in this manuscript, as well as 
reported the synergistic activity of cpd 17 with methicillin (Figure 7A).  
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B.3 Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases 
This chapter was reprinted with permission (Li et al., 2014). 
Li, K., Schurig-Briccio, L.A., Feng, X., Upadhyay, A., Pujari, V., Lechartier, B., Fontes, F.L., 
Yang, H., Rao, G., Zhu, W., Gulati, A., No, J.H., Cintra, G., Bogue, S., Liu, Y.L, Molohon, K.J., 
Orlean, P., Mitchell, D.A., Freitas-Junior, L., Ren, F., Sun, H., Jiang, T., Li, Y., Guo, R.T, Cole, 
S.T., Gennis, R.B., Crick, D.C., and Oldfield, E. (2014) J. Med. Chem: 57, 3126-3139. doi: 
10.1021/jm500131s. Copyright © (2014) American Chemical Society. 
 
I obtained the minimum inhibitory concentrations of the compounds against methicillin resistant 
Staphylococcus aureus USA300 (Table 1).  
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